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Abstract 
 
Genome-wide association studies, which examine millions of genetic variants in thousands of 
individuals, have identified many complex trait associated loci. As sample sizes increase, 
particularly through meta-analysis, the number of disease associated loci has increased rapidly. 
The objective of this dissertation is to demonstrate the advantages of combining data across 
studies using summary statistics and to demonstrate methods that use publicly available 
information, such as functional annotation of the genome, to gain further insight into the genetics 
of human disease. 
In the first project, we analyze data from 188,578 individuals using genome-wide and custom 
genotyping arrays to identify new loci and refine known loci for lipid traits low-density 
lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, and 
total cholesterol.  We identify and annotate 157 loci associated with lipid levels at P < 5x10-8, 
including 62 loci not previously associated with lipid levels in humans. Using dense genotyping 
in individuals of European, East Asian, South Asian, and African ancestry, we narrow 
association signals in 12 loci. We find that loci associated with blood lipids are often associated 
with cardiovascular and metabolic traits including coronary artery disease, type 2 diabetes, blood 
pressure, waist-hip ratio, and body mass index. Our results illustrate the value of genetic data 
from individuals of diverse ancestries and provide insights into biological mechanisms regulating 
blood lipids to guide future genetic, biological, and therapeutic research. 
In the second project, we propose that causal variants for a trait may share certain genomic 
features. Importantly, we show that when these genomic features can be identified, we can use 
 xv
them to help pinpoint likely causal variants among many trait associated variants. We develop a 
model that identifies genomic features enriched among the associated loci and uses this 
information to prioritize likely functional variants in each locus leading to narrower sets of 
variants for follow-up. Our models work for both quantitative and case-control data and can be 
used with summary statistics, making it convenient to incorporate in ongoing meta-analysis of 
genome-wide association studies that can include 100,000s of individuals. 
In the third project, we consider meta-analysis where studies may have overlapping sets of 
participants. In such scenarios, meta-analysis methods that do not account for overlap will 
perform poorly and have inflated Type I error. We propose a method to identify participant 
overlap between GWAS using only summary statistics, estimate the degree of overlap, and 
correctly meta-analyze studies taking into account the overlap. Our method builds upon and 
extends previous methods that allow meta-analysis of GWAS studies with known overlap 
proportions.  We illustrate our method using simulations and artificially created overlapping 
samples using real GWAS data. 
 
 
1 
 
Chapter 1: Introduction 
 
Conducting genome-wide association studies (GWAS) is an established way to identify 
genetic factors contributing to human traits and diseases. Typically, millions of single nucleotide 
polymorphisms (SNPs) are genotyped or imputed in large cohorts, and then each SNP is tested 
for association with the trait of interest (McCarthy et al. 2008; Hindorff et al. 2009). 
Developments in high throughput genotyping technology have led to decreases in the cost of 
conducting a GWAS, enabling increased sample sizes and the study of increasingly diverse 
traits. In recent years, GWAS have reproducibly identified thousands of variants associated with 
phenotypes as diverse as psychiatric diseases (Cross-Disorder Group of the Psychiatric 
Genomics Consortium 2013; Neale et al. 2010; Duncan et al. 2017), type 2 diabetes (Morris et al. 
2012), and food taste preferences (Pirastu et al. 2016), leading to discoveries about genes and 
pathways involved in common diseases and complex traits, providing new insights about their 
biology and disease etiology (Visscher et al. 2012). 
Contrary to early expectations, however, the variants identified by GWAS typically 
explain only a modest portion of risk for most complex diseases, as the genetic effects due to 
common alleles are typically quite small (Ioannidis et al 2006; Manolio et al 2009). Larger 
samples facilitate detection of small effect variants and have enabled gradual increases in the 
proportion of risk that can be explained (Moonesinghe et al. 2008; Burton et al. 2009; Chapman 
et al. 2011). A common strategy to enable these large sample sizes is to perform a meta-analysis 
– the statistical synthesis of information from multiple independent studies (Evangelou and 
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Ioannidis 2013). Currently, most meta-analyses are conducted using summary statistics of the 
association results on a per variant basis (see next section for details), which reduces logistical 
burdens of pooling data and mitigates risks associated with sharing individual level data 
(Solovieff et al. 2013). Most genetic risk variants discovered recently have come from large-
scale meta-analyses of GWAS (Zeggini and Ioannidis 2009; Panagiotou et al. 2013). 
With this increasing popularity of meta-analysis of GWAS, many consortia have been 
formed to investigate the genetics of various complex traits and diseases (Seminara et al. 2007) 
such as type 2 diabetes (DIAGRAM) (Morris et al. 2012), lipids (GLGC) (Global Lipids 
Genetics Consortium 2013), anthropomorphic traits like height and BMI (GIANT) (Wen et al. 
2012; Wood et al. 2014), and various psychiatric disorders (PGC) like ADHD and Schizophrenia 
(Demontis et al. 2017; Ripke et al. 2013). Many of these consortia make their summary statistics 
publicly available, so that newer studies can use their results in a meta-analysis, thus leveraging 
these large-scale efforts to power new discoveries or to refine known loci.  
An Overview of Meta-Analysis Methods for GWAS 
In a typical meta-analysis, individual level data are analyzed locally, and summary level 
results are shared with the coordinating meta-analysis team (Zeggini and Ioannidis 2009). The 
summary results may be odds ratios, standardized effect sizes or other metrics, with a measure of 
their uncertainty such as variance or p-values. Additionally, marker information such as alleles 
and allele frequencies are provided.  
Several models can be used for meta-analysis, and can be broadly categorized into three 
groupings: fixed effects, random effects, or Bayesian. Most models involve taking some 
weighted combination of estimators from individual studies. Fisher’s approach combines P-
values directly by taking the mean of −	log	() across studies, but fails to take the direction of 
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the effect into account. A similar approach is based on Z-scores, calculating the average Z-scores 
across studies, weighing them proportionally to the sample sizes (Stouffer et al. 1949). This 
approach does consider the direction of the effect and is useful in cases where only P-values are 
available (Cooper et al. 2009). 
Fixed effects meta-analysis assumes that the true effect of each risk allele is the same in 
all the datasets. A common method is to use inverse variance weighting for the effect sizes 
(Willer et al. 2010). This also requires that the trait be measured on the same scale for each 
study, with the same units and transformations so that the effect sizes are comparable across 
studies. This is the most powerful of the approaches; though there may be some questions 
regarding the assumption of fixed effects (Kavvoura and Ioannidis, 2008).  
In contrast, random effects models do not assume that the true effect sizes are constant 
across studies, which is a more realistic assumption especially if the samples are of mixed 
ancestry. While random effects models such as the DerSimonian and Laird estimator (1986) may 
be more appropriate, they generally have limited power and are not used in discovery efforts. 
Newer random effects models have been proposed that attempt to increase the power by making 
simplifying assumptions -- such as the assumption that there is no heterogeneity in genetic 
effects under the null hypothesis – and thus focusing analyses on the most interesting portions of 
the parameter space (Han and Eskin 2011). Another proposed alternative is to use a subset-based 
approach that uses a fixed effects model on a subset of the studies (Bhattacharjee et al. 2012). 
While these methods increase power when their specific assumptions are met, the fixed-effects 
model outperforms them when analyzing a single trait across homogeneous populations.  
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Bayesian methods have also been used for meta-analysis (Burton et al. 2007), but they 
are less common as they depend on assumptions made about the prior distributions of 
parameters, and can be computationally intensive to implement genome-wide. 
Regardless of which method is chosen, once the meta-analysis is conducted, the most 
significant variants are investigated. Generally, variants with P-values less than a genome-wide 
significant cut-off (typically p < 5 × 10) are flagged. Other secondary analyses such as 
conditional analysis may be conducted to gain insight into loci associated with the trait of 
interest. 
Prioritizing Variants for Follow-up 
Once a GWAS or meta-analysis is completed, it is important to sort through the flagged 
SNPs to examine interesting variants for follow-up studies or secondary analyses. Variants and 
genes can be prioritized for follow-up based on criteria such as literature review for biological 
plausibility (Minelli et al. 2013), evidence from other GWAS of the same or related traits, 
pathway analysis, regulation of mRNA expression levels, and presence of protein-altering 
variants. “Causal” variants are defined as the functional genetic variants that influence the risk 
for disease and explain the observed association. However, all variants in high linkage 
disequilibrium may show association with the trait or disease, and hence, it can be difficult to 
identify a specific causal variant. Fine mapping involves refining lists of potentially causal 
variants in regions with dense coverage where all the variants are genotyped or imputed with 
high quality genotypes. One of the goals of GWAS is to identify genes that are potentially causal 
for the trait of interest and thus fine mapping the associated loci is important for understanding 
the biological mechanisms involved in the trait under study. Variants in strong linkage 
disequilibrium with a causal SNP show strong association signals and thus the most significantly 
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associated variant is often not the causal one (Schaub et al. 2012; Faye et al. 2013). Fine 
mapping can be done through iterative conditional analysis or joint analysis at associated loci 
(Yang et al. 2012), ridge regression based methods (Malo et al. 2008), and Bayesian modeling 
(Maller et al. 2012; Hormozdiari et al. 2014). These methods focus on using the association 
results, that is, they do not consider biological plausibility, and generally require individual level 
data at the fine mapping loci. 
Large-scale initiatives such as The Encyclopedia of DNA Elements (ENCODE Project 
Consortium 2012) and the Roadmap Epigenomics Project (Bernstein et al. 2010) provide 
detailed maps of regulatory regions for more than 80% of the human genome. Functional 
annotations such as transcription factor binding sites and expression quantitative trait loci tend to 
be enriched in complex trait associated loci (Veyrieras et al. 2008; Gaffney et al. 2012; Trynka 
and Raychaudhuri 2013; Karczewski et al. 2013). A systematic investigation into the enrichment 
of these characteristics among associated loci can lend insight for future functional studies. 
With advances in sequencing technology, it is feasible to obtain the sequencing data or 
impute all common variants in associated regions with high quality. Thus, it is plausible to 
assume that the causal variant exists in the data (Chen et al. 2015) and attempt to narrow down a 
list of potentially causal variants by systematically modeling genomic features that they may 
share (Pickrell 2014; Kichaev et al. 2014). For example, a plausible assumption may be that 
causal variants for traits tend to be non-synonymous variants, which alter an amino acid in a 
protein-coding sequence, potentially resulting in a functionally impaired protein. There exist 
methods to integrate diverse annotations into one measure such as the CADD score which 
prioritizes functional, deleterious and pathogenic variants across many functional categories 
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(Kircher et al. 2014). Quantifying the enrichment of such genomic features can help 
systematically prioritize variants for follow-up.  
Overlapping Samples in Meta-Analysis Studies 
To date, more than 2,500 GWAS and meta-analyses have been published (MacArthur et 
al. 2017). For certain traits, several independent or partially overlapping consortia may exist 
(Evangelou and Ioannidis 2013), and meta-analyses combining data from the different consortia 
as well as using future studies can greatly increase the power to detect weak signals. However, a 
basic assumption in the meta-analysis methods discussed above is that the studies are 
independent; that is, the samples analyzed the studies are independent with no overlap of 
participants. If there is overlap between studies, using these methods may result in to inflated 
Type I error and, hence, increased false signals (Lin and Sullivan 2009).  
Moreover, due to GWAS requirements for large sample sizes, sometimes controls are 
shared among various studies. For example, many psychiatric GWAS have used controls 
ascertained and sampled by P.V. Gejman (Shi et al. 2009) and many case-control studies use 
publicly available genotype data for large sets of population-based controls such as WTCCC 
(Burton et al. 2007). Additionally, same cohorts may contribute to different meta-analysis 
efforts. For example, for Type 2 Diabetes (http://www.type2diabetesgenetics.org/), data from 
FUSION was used in both GoT2D GWAS (Fuchsberger et al. 2016) and 70KforT2D GWAS 
(Bonàs-Guarch et al. 2017). 
If studies have overlapping samples, covariance between studies needs to be accounted 
for when analyzing them together through meta-analysis. Methods exist for this purpose when 
individual level data are available, or if the number of overlapping samples is known (Lin and 
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Sullivan 2009). However, precise sample overlap numbers are not always known, and it is 
difficult to obtain individual level data to determine the overlap. 
Thesis Overview 
The scope of this dissertation is to show diverse uses of summary level genetic 
association data to gain insight into the genetics of diseases and complex traits. I first conduct a 
large-scale meta-analysis and demonstrate the challenges inherent in trying to interpret the 
results. I then show how publicly available data, such as genomic features, can be used to 
prioritize variants for follow-up using summary statistics from published GWAS or meta-
analyses. I finally develop a method to allow for meta-analysis when studies have potentially 
overlapping samples without requiring individual level data. 
In the second chapter, we conducted a large-scale meta-analysis of 188,578 individuals 
for the lipid traits of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein 
cholesterol (HDL-C), triglycerides and total cholesterol. We identified sixty-two novel loci in 
addition to the 95 loci already known in literature. There are 240 genes within 100 kb of the 62 
novel loci, which is a daunting challenge for future functional studies. We prioritized variants 
based on literature review, pathway analysis, protein altering variants and overlap with regulators 
of transcription in liver and tested enrichment using different tests including permutation based 
ones. We found lipid associated loci to be strongly associated with Coronary Artery Disease 
(CAD), Type 2 Diabetes (T2D), Body Mass Index (BMI) and blood pressure.  Additionally, we 
investigated fine mapped loci for different ancestries and identified several loci where the fine 
mapped signal was clearly different from the known GWAS signal.  
In the third chapter, I assume that causal variants are likely to share certain genomic 
features and model and estimate the enrichment of the genomic feature among trait associated 
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loci. If the enrichment parameter is found to be statistically significant, we use it to weight the 
association signals to generate posterior probabilities of each variant being causal. I make an 
assumption that every locus has at most one causal variant and propose two different approaches: 
(i) a Bayesian approach that divides the entire genome into loci with each locus having some 
probability of being causal and there being 0 or 1 causal variant at each locus, and (ii) assuming 
that variants outside the associated loci cannot be causal and thus considering only associated 
loci and assuming that there is exactly 1 causal variant at each locus. While the Bayesian 
approach may be more realistic, it requires summary level data across the whole genome 
whereas the second approach only requires summary level data for the associated loci and the 
number of variants with and without the genomic feature of interest outside the associated loci. 
The second approach is thus computationally faster. After testing the enrichment parameter for 
significance, we calculate the posterior probability of each variant being causal and use that to 
construct 95% credible sets of potentially causal variants. 
In the fourth chapter, I propose a method to use summary level data to estimate the 
overlap proportions between a pair of studies. While independent studies are likely to have 
positively correlated Z-scores due to trait associated loci showing similar effect sizes, truncating 
the Z-scores and estimating the correlation leads to accurate estimates of overlap proportion. 
Thus, my method identifies if there is overlap between a pair of studies, estimates it and corrects 
for it to conduct a meta-analysis where covariance due to overlap is accounted for. 
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Chapter 2 : Discovery and Refinement of Loci Associated with Lipid Levels1 
 
Introduction 
Blood lipids are heritable, modifiable, risk factors for coronary artery disease (CAD) 
(Kannel et al. 1961; Castelli et al. 1988), a leading cause of death (Lloyd-Jones et al. 1988). 
Human genetic studies of lipid levels can identify targets for new therapies for cholesterol 
management and prevention of heart disease, and can complement animal studies (Teslovich et 
al. 2010; Barter et al. 2012). Studies of naturally occurring genetic variation can proceed through 
large-scale association analyses focused on unrelated individuals or through investigation of 
Mendelian forms of dyslipidemia in families (Rahalkar et al. 2008). We previously identified 95 
loci associated with blood lipids, accounting for ~10-12% of the total trait variance (Teslovich et 
al. 2010) and showed that variants with small effects can point to pathways and therapeutic 
targets that enable clinically-important changes in blood lipids (Teslovich et al. 2010; Musunuru 
et al. 2010). 
Here, we report on studies of naturally occurring variation in 188,578 European-ancestry 
individuals and 7,898 non-European ancestry individuals. Our analyses identify 157 loci 
associated with lipid levels at P < 5x10-8, including 62 new loci. Thirty of the 62 loci do not 
include genes implicated in lipid biology by previous literature. We tested lipid-associated SNPs 
for association with mRNA expression levels, carried out pathway analyses to uncover 
                                                 
1
 This work was published in Nature Genetics as Discovery and Refinement of Loci Associated with Lipid Levels (2013) 45(11), 
pp.1274-1283. I was joint first author and contributed in performing the meta-analysis, bioinformatics analyses, preparing the 
tables, figures and supplementary information as well as discussing the analysis, results, interpretation and presentation of the 
results. The full list of authors is at the end of the chapter as well as in the supplementary information. 
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relationships between loci, and compared the locations of lipid-associated SNPs with those of 
genes and other functional elements in the genome. These results provide direction for biological 
and therapeutic research into risk factors for CAD. 
Results 
Novel loci associated with blood lipid levels 
We examined subjects of European ancestry, including 94,595 individuals from 23 
studies genotyped with GWAS arrays (Teslovich et al. 2010) and 93,982 individuals from 37 
studies genotyped with the Metabochip array (Voight et al. 2012) (Supplementary Table S2.1 
and Supplementary Fig. S2.1). The Metabochip includes variants representing promising loci 
from our previous GWAS (14,886 SNPs) and from GWAS of other CAD risk factors and related 
traits (50,459 SNPs), variants from the 1000 Genomes Project (2010) and focused resequencing 
(Sanna et al. 2011) efforts in 64 previously associated loci (28,923 SNPs), and fine-mapping 
variants in 181 loci associated with other traits (93,308 SNPs). In cases where Metabochip and 
GWAS array data were available for the same individuals, we used Metabochip data to ensure 
key variants were directly genotyped, rather than imputed. 
We excluded individuals known to be on lipid lowering medications and evaluated the 
additive effects of each SNP on blood lipid levels after adjusting for age and sex. Genomic 
control values (Devlin and Roeder, 1999) for the initial meta-analyses were 1.10 – 1.15, low for 
a sample of this size, indicating that population stratification should have only a minor impact on 
our results (Supplementary Fig. S2.2). After genomic control correction, 157 loci associated 
with blood lipid levels were identified (P < 5x10-8), including 62 new loci (Tables 2A-D, Figure 
2.1, Supplementary Tables S2.2 and S2.3).  Loci were >1 Mb apart and nearly independent (r2 
< 0.10). Of the 62 novel loci, 24 demonstrated the strongest evidence of association with HDL 
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cholesterol, 15 with LDL cholesterol, 8 with triglyceride levels, and 15 with total cholesterol 
(Supplementary Fig. S2.3). Several of these loci were validated by a similar extension based on 
GLGC GWAS results (Asselbergs et al. 2012). 
The effects of newly identified loci were generally smaller than in earlier GWAS 
(Supplementary Fig. S2.4).  For the 62 newly identified variants, trait variance explained in the 
Framingham offspring were 1.6% for HDL cholesterol, 2.1% for triglycerides, 2.4% for LDL 
cholesterol, and 2.6% for total cholesterol.   
Overlap of genetic discoveries and prior knowledge 
To investigate connections between our new loci and known lipid biology, we first 
catalogued genes within 100 kb of the peak associated SNPs and searched PubMed and OMIM 
for occurrences of these gene names and their aliases in the context of relevant keywords. After 
manual curation, we identified at least one strong candidate in 32 of the 62 loci (52%) 
(Supplementary Table S2.4). For the remaining 30 loci, we found no literature support for the 
role of a nearby gene on blood lipid levels. This search highlighted genes whose connections to 
lipid metabolism have been extensively documented in mouse models (such as VLDLR  and 
LRPAP1 (Welch et al. 1996)) and human cell lines (such as VIM (Sarria et al. 1992)), as well as 
candidates whose connection to lipid levels is more recent, such as VEGFA. For the latter, recent 
studies of VEGFB have suggested that vascular endothelial growth factors have an unexpected 
role in the targeting of lipids to peripheral tissues (Hagberg et al. 2010), which we corroborate by 
associating variants near VEGFA with blood triglyceride and HDL levels. 
Multiple types of evidence supported several literature candidates (Supplementary 
Table S2.2). For example, VLDLR is categorized by Gene Ontology (Ashburner et al. 2000) in 
the retinoid X nuclear receptor (RXR) activation pathway, which also includes genes (APOB, 
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APOE, CYP7A1, APOA1, HNF1A, HNF4A) in previously implicated loci (Teslovich et al. 2010). 
However, since these additional sources of evidence build on overlapping knowledge they are 
not truly independent.   
To estimate the probability of finding ≥32 literature supported candidates after automated 
search and manual review of results, we repeated our text-mining literature search using 100 
permutations of SNPs matched for allele frequency, distance to the nearest gene, and number of 
linkage disequilibrium proxies.  To approximate hand-curation of the text-mining results, we 
focused on genes implicated by 3 or more publications (25 in observed data, 8.7 on average in 
control SNP sets, P = 8x10-8). 
Pathway analyses 
We performed a gene-set enrichment analysis, using MAGENTA (Segre et al. 2010), to 
evaluate over-representation of biological pathways among associated loci. Across the 157 loci, 
MAGENTA identified 71 enriched pathways. These pathways included at least one gene in 20 of 
our newly identified loci (Supplementary Table S2.5). Examples include DAGLB (connected to 
previously associated loci by genes in the triglyceride lipase activity pathway), INSIG2 
(connected by the cholesterol and steroid metabolic process pathways), AKR1C4 (connected by 
the steroid metabolic process and bile acid biosynthesis pathways), VLDLR (connected by the 
retinoic X receptor activation and lipid transport pathways, among others), PPARA, ABCB11, 
and UGT1A1 (three genes assigned to pathways implicated in activation of nuclear hormone 
receptors, which play an important role in lipid metabolism through the transcriptional regulation 
of genes in sterol metabolic pathways (Fitzgerald et al. 2001)). Among the 16 loci where 
literature review and pathway analysis both suggested a candidate, the predictions overlapped 14 
times (Supplementary Table S2.2; by chance, we expect 6.6 overlapping predictions, 
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 P = 1x10-5). 
Protein-protein interactions 
We assessed evidence for physical interactions between proteins encoded near our 
associated SNPs using DAPPLE (Rossin et al. 2011).  We found an excess of direct protein-
protein interactions for genes in loci associated with LDL (10 interactions, P = 0.0002), HDL (8 
interactions, P = 0.002), and total cholesterol (6 interactions, P = 0.017), but not for triglycerides 
(2 interactions, P = 0.27) (Supplementary Fig. S2.5). Most of the interactions involved genes at 
known loci (such as the interaction network connecting PLTP, APOE, APOB, and LIPC) or 
highlighted the same genes as literature and pathway analyses (such as those connecting VLDLR, 
APOE, APOB, CETP, and LPL). Among novel loci, we identified a link between AKT1 and 
GSK3B. GSK3B has been shown to play a role in energy metabolism (Plyte et al. 1992) and its 
activity is regulated by AKT1 through phosphorylation (Toker and Cantley 1997). Literature 
review also supported a role in blood lipid levels for these two genes. 
Regulation of gene expression by associated variants 
Many complex trait associated variants act through the regulation of gene expression. We 
examined whether our 62 novel variants were associated with expression levels of nearby genes 
in liver, omental fat, or subcutaneous fat. Fifteen were associated with expression of a nearby 
transcript with P < 5x10-8 (Supplementary Table S2.6) and, in seven, the lipid-associated 
variant was in strong disequilibrium with the strongest expression-quantitative trait locus (eQTL) 
for the region (r2 > 0.8). In three of these loci, literature search also prioritized candidate genes. 
In all three, eQTL analysis and literature review identified the same candidate (DAGLB, 
SPTLC3, and PXK, P = 0.05). For the remaining four loci (near RBM5, ADH5, TMEM176A, and 
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GPR146), analysis of expression levels identified candidates that were not supported by 
literature or pathway analyses. 
Coding variation 
In some loci where previous coding variant association studies were inconclusive, we 
now find convincing evidence of association, demonstrating the benefits of the large sample 
sizes achievable by collaboration. For example, in the APOH locus (Kaprio et al. 1991), our most 
strongly associated variant is rs1801689 (APOH C325G, P = 1x10-11 for LDL cholesterol). 
Overall, at 15 of the 62 new loci, there is at least one nonsynonymous variant within 100kb and 
in strong (r2>0.8) linkage disequilibrium with the index SNP (Supplementary Table S2.7) (18 
loci with no restrictions on distance). This ~30% overlap between associated loci and coding 
variation is similar to that in other complex traits (The 1000 Genomes Project 2010). 
Unexpectedly, in the 11 loci where a candidate was suggested by literature review and by coding 
variation, the two coincided seven times (P = 0.03 compared to expected chance overlap of 3.8 
times); thus, agreement between literature and coding variation was less significant than for 
eQTL and pathway analysis or protein-protein interactions. 
Overlap between association signals and regulators of transcription in liver 
Despite our efforts, 18 of the 62 new loci remain without prioritized candidate genes. The 
liver is an important hub of lipid biosynthesis and there is evidence that lipid loci might be 
associated with changes in gene regulation in liver cells (Ernst et al. 2011). Using ENCODE data 
(Ernst et al. 2011), we evaluated whether associated SNPs overlapped experimentally annotated 
functional elements identified in HepG2 cells, a commonly used model of human hepatocytes.  
To determine significance, we generated 100,000 lists of permuted SNPs, matched for minor 
allele frequency, distance to the nearest gene, and number of SNPs in r2 > 0.8 (described in 
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Methods). In HepG2 cells, lipid-associated SNPs were enriched in eight of the 15 functional 
chromatin states defined by Ernst et al. (The ENCODE Project Consortium 2011) (P < 1x10-5; 
Supplementary Table S2.8).  The strongest enrichment was in regions with “strong enhancer 
activity” (3.7-fold enrichment, P = 2x10-25; Supplementary Table S2.9). In the other eight cell 
types examined by Ernst et al., no more than three functional chromatin states showed evidence 
for enrichment (and, when present, enrichment was weaker). 
We proceeded to investigate the overlap between lipid loci and functional marks in 
HepG2 cells in more detail (Supplementary Table S2.9). Notable regulatory elements showing 
significant overlap with lipid loci included histone marks associated with active regulatory 
regions (H3K27ac, P = 3x10-20; H3K9ac, P = 3x10-22), promoters (H3K4me3, P = 2x10-15, 
H3K4me2, P = 8x10-12), transcribed regions (H3K36me3, P = 4x10-14), indicators of open 
chromatin (FAIRE, P = 5x10-9; DNase, P = 2x10-4), and regions that interact with transcription 
factors HNF4A (P = 6x10-10) and CEBP/B (P = 1x10-5). Overall, 56 of our 62 new loci contained 
at least one SNP that overlaps a functional mark (The ENCODE Project Consortium 2011) 
and/or chromatin state (Ernst et al. 2011) highlighted in Supplementary Table S2.9, including 
all but 3 of the loci where no candidates were suggested by literature review or analyses of 
pathways, coding variation, or gene expression (Supplementary Table S2.10).   
Initial fine-mapping of 65 lipid-associated loci 
Previous fine-mapping of five LDL-associated lipid loci found that variants showing the 
strongest association were often substantially different in frequency and effect size from those 
identified in GWAS (Sanna et al. 2011). Metabochip genotypes enabled us to carry out an initial 
fine-mapping analysis for 65 loci: 60 selected for fine-mapping based on our previous study4 and 
5 nominated for fine-mapping because of association to other traits.  
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For each of these loci, we identified the most strongly associated Metabochip variant and 
evaluated whether it (a) reached genome-wide significant evidence for association (to avoid 
chance fluctuations in regions where the signal was relatively weak) and (b) was different from 
the GWAS index SNP in terms of frequency and effect size (operationalized to r2 < 0.8 with the 
GWAS index SNP). In the European samples, fine-mapping identified eight loci where the fine-
mapping signal was clearly different from the GWAS signal (Supplementary Table S2.11). The 
two largest differences were at the loci near PCSK9 (top GWAS variant with minor allele 
frequency f = 0.24 and P = 9x10-24; fine-mapping variant with f = 0.03, P = 2x10-136) and APOE 
(GWAS variant f = 0.20, P = 3x10-44, fine-mapping variant f = 0.07, P = 3x10-651), consistent 
with Sanna et al (2011). Large differences were also observed near LRP4 (GWAS f = 0.17, P = 
8x10-14; fine-mapping f = 0.35, P = 1x10-26), IGF2R (GWAS f = 0.16, P = 7x10-9; fine-mapping 
f = 0.37, P = 2x10-13), NPC1L1 (GWAS f = 0.27, P = 2x10-5; fine-mapping f = 0.24, P = 1x10-
12), ST3GAL4 (GWAS f = 0.26, P = 2x10-6; fine-mapping f = 0.07, P = 6x10-11), MED1 (GWAS 
f = 0.37, P = 3x10-5; fine-mapping f = 0.24, P = 2x10-10), and COBLL1 (GWAS f = 0.12, P = 
2x10-6; fine-mapping f = 0.11, P = 6x10-9). Thus, although the large changes observed by Sanna 
et al (2011) after fine-mapping are by no means unique, they are not typical. Except for the 
R46L variant in PCSK9, the variants showing strongest association in fine-mapped loci all had 
minor allele frequency > .05.  
We also attempted fine-mapping in African (N=3,263), East Asian (N=1,771), and South 
Asian (N=4,901) ancestry samples. Despite comparatively small samples, ancestry-specific 
analyses identified SNPs clearly distinct from the original GWAS variant in five loci 
(Supplementary Table S2.11). These were: APOE, consistent with European ancestry analyses 
above; three loci where differences in linkage disequilibrium between populations enabled fine-
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mapping in African (SORT1, LDLR) or East Asian (APOA5) ancestry samples; and CETP, where 
an African-specific variant was present. For CETP, SORT1, and APOA5, results are consistent 
with other fine-mapping and functional studies (Musunuru et al. 2010; Buyske et al. 2012; 
Palmen et al. 2012).  
Association of lipid loci with metabolic and cardiovascular traits 
To evaluate the role of the 157 loci identified here on related traits, we evaluated the most 
strongly associated SNPs for each locus in genetic studies of coronary artery disease (CAD, 
N=114,590 including 37,653 cases) (Schunkert et al. 2011; The Coronary Artery Disease (C4D) 
Consortium 2010), type 2 diabetes (T2D, N=47,117 including 8,130 cases) (Voight et al. 2010), 
body mass index (BMI, N=123,865 individuals) (Speliotes et al. 2010) and waist-hip ratio 
(WHR, N=77,167 individuals) (Heid et al. 2010), systolic and diastolic blood pressure (SBP and 
DBP, N=69,395 individuals) (International Consortium for Blood Pressure Genome-Wide 
Association Studies 2011), and fasting glucose (N=46,186 non-diabetics) (Dupuis et al. 2010). 
We observed an excess of SNPs nominally associated (P < 0.05) with all these traits: a 5.1 fold 
excess for CAD (40 nominally significant loci, P = 2x10-19), a 4.1 fold excess for BMI (32 loci, 
P = 1x10-11), 3.7 fold excesses for DBP (29 loci, P = 1x10-9), a 3.4 fold excess for WHR (27 loci, 
P = 1x10-9), a 2.5 fold excess for SBP (20 loci, P = 1x10-4), a 2.3 fold excess for T2D (18 loci, P 
= 0.001), and a 2.2 fold excess for fasting glucose (17 loci, P = 3x10-3) (Supplementary Table 
S2.12). Interestingly, among the novel loci, we observed greater overlap with BMI, SBP, and 
DBP (9 overlapping loci each) than with CAD (8 overlapping loci). Among new loci, the two 
SNPs showing strongest association to CAD map near RBM5 (rs2013208, PHDL = 9x10-12, PCAD 
= 7x10-5) and CMTM6 (rs7640978, PLDL = 1x10-8, PCAD = 4x10-4). 
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We tested whether the LDL-, total cholesterol- or triglyceride- increasing allele, or HDL-
decreasing allele was associated with increased risk of cardiovascular disease or related 
metabolic outcomes; the direction of effect of each locus was categorized according to the 
primary association signal at the locus, as in Tables 2A-D.  We observed association with 
increased CAD risk (104/149, P = 1x10-6), SBP (96/155, P = 2.7x10-3) and WHR adjusted for 
BMI (92/154, P = 0.019). There were many instances where a single locus was associated with 
many traits. These included variants near FTO, consistent with previous reports (Freathy et al. 
2008); near VEGFA (associated with triglyceride levels, CAD, T2D, SBP, and DBP), near 
SLC39A8 (associated with HDL cholesterol, BMI, SBP, and DBP), and near MIR581 (associated 
with HDL cholesterol, BMI, T2D, and DBP). In some cases, like FTO, a strong association with 
BMI or another phenotype generates weaker association signals for other metabolic traits 
(Freathy et al. 2008). In other cases, like SORT1, a primary effect on lipid levels may mediate 
secondary association with other traits, like CAD (Musunuru et al. 2010).  
Association of individual lipids with coronary artery disease 
Epidemiological studies consistently show high total cholesterol and LDL cholesterol 
levels are associated with increased risk of CAD, whereas high HDL cholesterol levels are 
associated with reduced risk of CAD (Clarke et al. 2007). In genetic studies, the connection 
between LDL cholesterol and CAD is clear, whereas the results for HDL cholesterol levels are 
more equivocal (Willer et al. 2008; Voight et al. 2012; Frikke-Schmidt et al. 2008). In our data, 
trait increasing alleles at the loci showing strongest association with LDL cholesterol (31 loci), 
triglycerides (30 loci), or total cholesterol (38 loci) were associated with increased risk of CAD 
(P = 2x10-12, P = 2x10-16, and P = 0.006). Conversely, trait decreasing alleles at loci showing the 
strongest association with HDL cholesterol (64 loci), were associated with increased CAD risk 
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with P = 0.02. When we focused on loci uniquely associated with LDL cholesterol (12 loci 
where P > .05 for other lipids), triglycerides (6 loci), or HDL cholesterol (14 loci), only the LDL 
association remained significant (P = 0.03).  
To better explore how associations with individual lipid levels related to CAD risk, we 
used linear regression to test whether association with lipid levels could predict impact on CAD 
risk. In this analysis, the effect on CAD of 149 lipid loci (CAD results were not available for 8 
SNPs) was correlated with LDL (Pearson r=0.74, P = 7x10-6) and triglyceride (Pearson r=0.46, P 
= 0.02) effect sizes, but not HDL effect sizes (Pearson r=-9x10-4, P = 0.99; Supplementary Fig. 
S2.6). Since most variants affect multiple lipid fractions (Figure 2.1), dissecting the relationship 
between lipid level and CAD effects requires multivariate analysis. In a companion manuscript, 
we use multivariate analysis and detailed examination of triglyceride associated loci to show that 
increased LDL and triglyceride levels, but not HDL, appear causally related to CAD risk.  
Evidence for additional loci, not yet reaching genome-wide significance 
To evaluate evidence for loci not yet reaching genome-wide significance, we compared 
direction of effect in GWAS and Metabochip analyses of non-overlapping samples, outside the 
157 genome-wide significant loci. Among independent variants (r2 < 0.1) with P < 0.1 in the 
GWAS-only analysis, a significant excess were concordant in direction of effect for HDL 
(62.9% in 1,847 SNPs, P < 10-16), LDL (58.6% of 1,730 SNPs, P < 10-16), triglyceride levels 
(59.1% of 1,783 SNPs, P < 10-16), and total cholesterol (61.0% of 1,904 SNPs, P < 10-16), 
suggesting many additional loci to be discovered in future studies. 
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Discussion 
Molecular understanding of the genes and pathways that modify blood lipid levels in 
humans will facilitate the design of new therapies for cardiovascular and metabolic disease. This 
understanding can be gained from studies of model organisms, in vitro experiments, 
bioinformatic analyses, and human genetic studies. Here, we demonstrate association between 
blood lipid levels and 62 new loci, bringing the total number of lipid-associated loci to 157 (See 
Tables 2A-D and Figure 2.1). All but one of the loci identified here include protein-coding 
genes within 100 kb of the SNP showing strongest association. While 38 of the 62 new loci 
include genes whose role in blood lipid levels is supported by literature review or analysis of 
curated pathway databases, the remainder includes only genes whose role on blood lipid levels 
has not been documented. 
In total, there are 240 genes within 100 kb of one of our 62 new lipid-associated loci – 
providing a daunting challenge for future functional studies. Prioritizing on the basis of literature 
review, pathway analysis, regulation of mRNA expression levels, and protein altering variants 
suggests that 70 genes in 44 of the 62 new loci might be the focus of the first round of functional 
studies (summarized in Supplementary Table S2.2). While we found significant overlap, 
different sources of prioritization sometimes disagreed. This result suggests that truly 
understanding causality will be very challenging.  The Supplementary Note includes an 
interpreted digest of genes highlighted by our study. Clearly, a range of approaches will be 
needed to follow-up these findings. To illustrate possibilities, consider U. S. Patent Application 
#20,090,036,394 disclosing that, in the mouse, knockout of Gpr146 modifies blood lipid levels. 
Here, we show that variants near the human homologue of this gene, GPR146, are associated 
with levels of total cholesterol – providing an added incentive for studies of GPR146 inhibitors 
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in humans. GPR146 encodes a G-protein coupled receptor – an attractive pharmaceutical target – 
so it is tempting to speculate that, one day, pharmaceutical inhibition of GPR146 may modify 
cholesterol levels and reduce risk of heart disease. 
Each locus typically includes many strongly associated (and potentially causal) variants. 
Our fine-mapping results illustrate how genetic analysis of large samples and individuals of 
diverse ancestry can help focus the search for causal variants. In our fine-mapping analysis of 65 
lipid-associated loci, we were able to separate the strongest signal in a region from the prior 
GWAS signal in 12 instances. In three of these 12 instances, fine-mapping was enabled by 
analysis of a few thousand African or East Asian ancestry individuals, whereas in the remaining 
instances, fine-mapping was possible through examination of nearly 100,000 European ancestry 
samples. A more detailed fine-mapping exercise, including imputation of variants from emerging 
very large reference panels, may help refine the location of additional signals. 
Lipid-associated loci were strongly associated with CAD, T2D, BMI, SBP, and DBP. In 
univariate analyses, we found that impact on LDL and triglycerides all predicted association with 
CAD, but HDL did not.  In a more detailed multivariate investigation, a companion manuscript 
shows that our data is consistent with the hypothesis that both LDL and triglycerides, but not 
HDL, are causally related to CAD risk. HDL, LDL, and triglycerides levels summarize aggregate 
levels of different lipid particles, each with potentially distinct consequences for CAD risk. We 
evaluated association of our loci with lipid subfractions in 2,900 individuals from the 
Framingham Heart Study (Supplementary Table S2.13, Supplementary Fig. S2.7) and with 
sphingolipids, which are components of lipid membranes in cells, in 4,034 individuals from five 
samples of European ancestry (Demirkan et al. 2012) (Supplementary Table S2.14). The results 
suggest HDL-associated variants can have a markedly different impact on these sub-phenotypes. 
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For example, among HDL loci, variants near LIPC were strongly associated with plasmalogen 
levels (P < 10-40), variants near ABCA1 were associated with sphingomyelin levels (P < 10-5), 
and variants near CETP – which show the strongest association with HDL cholesterol overall – 
were associated with neither of these. Detailed genetic dissection of these sub-phenotypes in 
larger samples, could lead to functional groupings of HDL-associated variants that reconcile the 
results of genetic studies (which show no clear connection between HDL cholesterol-associated 
variants and CAD risk) and epidemiologic studies (which show clear association between plasma 
HDL levels and CAD risk). 
In summary, we report the largest genetic association study of blood lipid levels yet 
conducted. The large number of loci identified, the many candidate genes they contain, and the 
diverse proteins they encode generate new leads and insights into lipid biology. It is our hope 
that the next round of genetic studies will build on these results, using new sequencing, 
genotyping, and imputation technologies to examine rare loss-of-function alleles and other 
variants of clear functional impact to accelerate the translation of these leads into mechanistic 
insights and improved treatments for CAD. 
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URLs 
Summary results for our studies are available. We hope that they will facilitate continued 
research into the genetics of blood lipid levels and, eventually, help identify improved treatments 
for CAD. To browse the full result set, go to http:/www.sph.umich.edu/csg/abecasis/lipids2013/  
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Figure 2.1 Overlap between loci associated with different lipid traits 
This Venn diagram illustrates the number of loci that show association with multiple lipid traits.  The number of loci 
primarily associated with only one trait is listed in parentheses after the trait name and the locus name is listed below 
in italics.  Loci that show association with two or more traits are shown in the appropriate section. 
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Table 2-A Novel Loci Primarily Associated with HDL Cholesterol Obtained from Joint GWAS and Metabochip Meta-analysis  
 
Locus MarkerName Chr 
hg19  
Position (Mb) Associated trait(s) MAF 
Minor/major 
Allele Effect of A1 
Joint N 
(in 1000s) Joint P-value 
PIGV-NR0B2 rs12748152 1 27.14 HDL, LDL, TG .09 T/C -.051/.050/.037 187/173/178 1x10-15/3x10-12/1x10-9 
HDGF-PMVK rs12145743 1 156.70 HDL .34 G/T .020 181 2x10-8 
ANGPTL1 rs4650994 1 178.52 HDL .49 G/A .021 187 7x10-9 
CPS1 rs1047891 2 211.54 HDL .33 A/C -.027 182 9x10-10 
ATG7 rs2606736 3 11.40 HDL .39 C/T .025 129 5x10-8 
SETD2 rs2290547 3 47.06 HDL .20 A/G -.030 187 4x10-9 
RBM5 rs2013208 3 50.13 HDL .50 T/C .025 170 9x10-12 
STAB1 rs13326165 3 52.53 HDL .21 A/G .029 187 9x10-11 
GSK3B rs6805251 3 119.56 HDL .39 T/C .020 186 1x10-8 
C4orf52 rs10019888 4 26.06 HDL .18 G/A -.027 187 5x10-8 
FAM13A rs3822072 4 89.74 HDL .46 A/G -.025 187 4x10-12 
ADH5 rs2602836 4 100.01 HDL .44 A/G .019 187 5x10-8 
RSPO3 rs1936800 6 127.44 HDL, TGa .49 C/T .020/-.020 187/168 3x10-10/3x10-8 
DAGLB rs702485 7 6.45 HDL .45 G/A .024 187 7x10-12 
SNX13 rs4142995 7 17.92 HDL .38 T/G -.026 165 9x10-12 
IKZF1 rs4917014 7 50.31 HDL .32 G/T .022 187 1x10-8 
TMEM176A rs17173637 7 150.53 HDL .12 C/T -.036 184 2x10-8 
MARCH8-ALOX5 rs970548 10 46.01 HDL, TC .26 C/A .026/-.026 187/187 2x10-10/8x10-9 
OR4C46 rs11246602 11 51.51 HDL .15 C/T .034 176 2x10-10 
KAT5 rs12801636 11 65.39 HDL .23 A/G .024 187 3x10-8 
MOGAT2-DGAT2 rs499974 11 75.46 HDL .19 A/C -.026 187 1x10-8 
ZBTB42-AKT1 rs4983559 14 105.28 HDL .40 G/A .020 184 1x10-8 
FTO rs1121980 16 53.81 HDL, TG .43 A/G -.020/-.021 186/155 7x10-9/3x10-8 
HAS1 rs17695224 19 52.32 HDL .26 A/G -.029 185 2x10-13 
 
Chr, chromosome; MAF, minor allele frequency; A1, minor allele; A2, major allele. Effect sizes are given with respect to the minor allele (A1) in SD units.  For loci associated 
with two or more traits at genome-wide significance, the trait corresponding to the strongest P-value is listed first.  At one locus, the secondary trait was most strongly associated 
with a different SNP: ars719726 (within 1Mb of rs1936800, r2 = 0.74).  
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Table 2-B Novel Loci Primarily Associated with LDL Cholesterol Obtained from Joint GWAS and Metabochip Meta-analysis 
 
Locus MarkerName Chr 
hg19  
Position 
(Mb) 
Associated 
trait(s) MAF 
Minor/major 
Allele Effect of A1 
Joint N 
(in 1000s) Joint P-value 
ANXA9-CERS2 rs267733 1 150.96 LDL .16 G/A -.033 165 5x10-9 
EHBP1 rs2710642 2 63.15 LDL .35 G/A -.024 173 6x10-9 
INSIG2 rs10490626 2 118.84 LDL, TCb .08 A/G -.051/.042 173/184 2x10-12/6x10-9 
LOC84931 rs2030746 2 121.31 LDL, TC .40 T/C .021/.020 173/187 9x10-9/4x10-8 
FN1 rs1250229 2 216.30 LDL .27 T/C -.024 173 3x10-8 
CMTM6 rs7640978 3 32.53 LDL, TC .09 T/C -.039/-.038 172/186 1x10-8 
ACAD11 rs17404153 3 132.16 LDL, HDLc .14 T/G -.034/.028 172/187 2x10-9/5x10-9 
CSNK1G3 rs4530754 5 122.86 LDL, TC .46 G/A -.028/-.023 173/187 4x10-12/2x10-9 
MIR148A rs4722551 7 25.99 LDL, TGd, TC .20 C/T .039/.029/.023 173/187/178 4x10-14/9x10-11/7.0x10-9 
SOX17 rs10102164 8 55.42 LDL, TC .21 A/G .032/.030 173/187 4x10-11/5x10-11 
BRCA2 rs4942486 13 32.95 LDL .48 T/C .024 172 2x10-11 
APOH-PRXCA rs1801689 17 64.21 LDL .04 C/A .103 111 1x10-11 
SPTLC3 rs364585 20 12.96 LDL .38 A/G -.025 172 4x10-10 
SNX5 rs2328223 20 17.85 LDL .21 C/A .03 171 6x10-9 
MTMR3 rs5763662 22 30.38 LDL .04 T/C .077 163 1x10-8 
 
Chr, chromosome; MAF, minor allele frequency; A1, minor allele; A2, major allele. Effect sizes are given with respect to the minor allele (A1) in SD units.  For loci associated with two or more traits 
at genome-wide significance, the trait corresponding to the strongest P-value is listed first.  At three loci, secondary traits were most strongly associated with different SNPs. 
b
rs17526895 (within 
1Mb of rs10490626, r
2
 = 0.98); 
c
rs13076253 (within 1Mb of rs17404153, r
2
 = 0.00); 
d
rs4719841 (within 1Mb of rs4722551, r
2
 = 0.10).  
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Table 2-C Novel Loci Primarily Associated with Total Cholesterol Obtained from Joint GWAS and Metabochip Meta-analysis 
 
 
Locus MarkerName Chr 
hg19  
Position 
(Mb) 
Associated 
trait(s) MAF 
Minor/major 
Allele Effect of A1 
Joint N 
(in 1000s) Joint P-value 
ASAP3 rs1077514 1 23.77 TC .15 C/T -0.03 184 6x10-9 
ABCB11 rs2287623 2 169.83 TC .41 G/A 0.027 184 4x10-12 
FAM117B rs11694172 2 203.53 TC .25 G/A 0.028 187 2x10-9 
UGT1A1 rs11563251 2 234.68 TC, LDL .12 T/C 0.037/0.034 187/173 1x10-9/5x10-8 
PXK rs13315871 3 58.38 TC .10 A/G -0.036 187 4x10-8 
KCNK17 rs2758886 6 39.25 TC .30 A/G 0.023 187 3x10-8 
HBS1L rs9376090 6 135.41 TC .28 T/C -0.025 187 3x10-9 
GPR146 rs1997243 7 1.08 TC .16 G/A 0.033 183 3x10-10 
VLDLR rs3780181 9 2.64 TC, LDL .08 G/A -0.044/-0.044 186/172 7x10-10/2x10-9 
VIM-CUBN rs10904908 10 17.26 TC .43 G/A 0.025 187 3x10-11 
PHLDB1 rs11603023 11 118.49 TC .42 T/C 0.022 187 1x10-8 
PHC1-A2ML1 rs4883201 12 9.08 TC .12 G/A -0.035 187 2x10-9 
DLG4 rs314253 17 7.09 TC, LDL .37 C/T -0.023/-0.024 184/170 3x10-10/3x10-10 
TOM1 rs138777 22 35.71 TC .36 A/G 0.021 185 5x10-8 
PPARA rs4253772 22 46.63 TC, LDLe .11 T/C 0.032/-0.031 185/171 1x10-8/3x10-8 
 
Chr, chromosome; MAF, minor allele frequency; A1, minor allele; A2, major allele. Effect sizes are given with respect to the minor allele (A1) in SD units.  For loci associated with two or more traits 
at genome-wide significance, the trait corresponding to the strongest P-value is listed first.  At one locus, the secondary trait was most strongly associated with a different SNP: 
e
rs4253776 (within 
1Mb of rs4253772, r
2
 = 0.95). 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
 
 
Table 2-D Novel Loci Primarily Associated with Triglycerides Obtained from Joint GWAS and Metabochip Meta-analysis 
 
Locus MarkerName Chr 
hg19  
Position 
(Mb) 
Associated 
trait(s) MAF 
Minor/major 
Allele Effect of A1 
Joint N 
(in 1000s) Joint P-value 
LRPAP1 rs6831256 4 3.47 TG, TCf,LDLf .42 G/A 0.026/-0.022/-
0.025 
177/173/187 2x10-12/1x10-10/2x10-8 
VEGFA rs998584 6 43.76 TG, HDL .49 A/C 0.029/-0.026 175/184 3x10-15/2x10-11 
MET rs38855 7 116.36 TG .47 G/A -0.019 178 2x10-8 
AKR1C4 rs1832007 10 5.25 TG .18 G/A -0.033 178 2x10-12 
PDXDC1 rs3198697 16 15.13 TG .43 T/C -0.020 176 2x10-8 
MPP3 rs8077889 17 41.88 TG .22 C/A 0.025 176 1x10-8 
INSR rs7248104 19 7.22 TG .42 A/G -0.022 176 5x10-10 
PEPD rs731839 19 33.90 TG, HDL .35 G/A 0.022/-0.022 176/185 3x10-9/3x10-9 
 
Chr, chromosome; MAF, minor allele frequency; A1, minor allele; A2, major allele. Effect sizes are given with respect to the minor allele (A1) in SD units.  For loci associated with two or more traits 
at genome-wide significance, the trait corresponding to the strongest P-value is listed first.  At one locus, secondary traits were most strongly associated with a different SNP: 
f
rs6818397 (within 1 
Mb of rs6831256, r
2
 = 0.18).  
 
 29
Online Methods 
Samples studied: We collected summary statistics for Metabochip SNPs from 45 studies. Among 
these, 37 studies consisted primarily of individuals of European ancestry (see Supplementary 
Table 1 and Supplementary Note for details), including both population-based studies and 
case-control studies of CAD and T2D. Another 8 studies consisted primarily of individuals with 
non-European ancestry: two studies of South Asian descent,  AIDHS/SDS (N=1,516) and 
PROMIS (N=3,385); two studies of East Asian descent, CLHNS (N=1,771) and TAI-CHI 
(N=7044); and five studies of recent African ancestry, MRC/UVRI GPC (N=1,687) from 
Uganda, SEY (N=426) from the Caribbean, and FBPP (N=1,614, TG results unavailable), GXE 
(N=397), and SPT (N=838) from the United States (more details in Supplementary Table 1 and 
Supplementary Note). 
Genotyping:  We genotyped 196,710 genetic variants prioritized on the basis of prior GWAS for 
cardiovascular and metabolic phenotypes using the Illumina iSelect Metabochip (Voight et al. 
2012) genotyping array. To design the Metabochip, we used our previous GWAS of ~100,000 
individuals (Teslovich et al. 2010) to prioritize 5,023 SNPs for HDL cholesterol, 5,055 for LDL 
cholesterol, 5,056 for triglycerides, and 938 for total cholesterol. These independent SNPs 
represent most loci with P < .005 in our original GWAS for HDL cholesterol, LDL cholesterol 
and triglycerides and with P < .0005 for total cholesterol. An additional 28,923 SNPs were 
selected for fine-mapping of 65 previously identified lipid loci. The Metabochip also included 
50,459 SNPs prioritized based on GWAS of non-lipid traits and 93,308 SNPs selected for fine-
mapping of loci associated with non-lipid traits (5 of these loci were associated with blood lipids 
by the analyses described here). 
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Phenotypes:  Blood lipid levels were typically measured after > 8 hours of fasting. Individuals 
known to be on lipid-lowering medication were excluded when possible. LDL cholesterol levels 
were directly measured in 10 studies (24% of total study individuals) and estimated using the 
Friedewald formula (Friedewald et al. 1972) in the remaining studies. Trait residuals within each 
study cohort were adjusted for age, age2, and sex, and then quantile normalized. Explicit 
adjustments for population structure using principal component (Price et al. 2006) or mixed 
model approaches (Kang et al. 2010) were carried out in 24 studies (35% of individuals); all 
studies were adjusted using genomic control prior to meta-analysis (Devlin and Roeder 2012). In 
studies ascertained on diabetes or CVD status, cases and controls were analyzed separately 
(Supplementary Table 1). All meta-analyses were limited to a single ancestral group (e.g. 
European only). 
Primary statistical analysis:  Individual SNP association tests were performed using linear 
regression with the inverse normal transformed trait values as the dependent variable and the 
expected allele count for each individual as the independent variable. These analyses were 
performed using PLINK (26 samples, 53% of the total number of individuals), SNPTEST (4 
samples, 20% of individuals), EMMAX (9 samples, 14% of individuals), Merlin (4 samples, 9% 
of individuals), GENABEL (1 sample, 3% of individuals), and MMAP (1 sample, 1% of 
individuals) (Supplementary Table 1). 
Meta-analysis:  Meta-analysis was performed using the Stouffer method (Stouffer et al. 1949; 
Willer et al. 2010), with weights proportional to the square root of the sample size for each 
sample. To correct for inflated test statistics due to potential population stratification, we first 
applied genomic control to each sample and then repeated the procedure with initial meta-
analysis results. For GWAS samples, we used all available SNPs when estimating the median 
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test statistic and inflation factor λ. For Metabochip samples, we used a subset of SNPs (N = 
7,168) that had P-values > 0.50 for all lipid traits in the original GWAS, expecting that the 
majority of these would not be associated with lipids and would behave as null variants in the 
Metabochip samples. Signals were considered to be novel if they reached a P-value < 5x10-8 in 
the combined GWAS and Metabochip meta-analysis and were >1 Mb away from the nearest 
previously described lipid locus and other novel loci. We used only European samples for the 
discovery of novel genome-wide significant loci. The non-European samples were meta-
analyzed and examined only for fine-mapping analyses.  
Quality control: To flag potentially erroneous analyses, we carried out a series of quality control 
steps. Average standard errors for association statistics from each study were plotted against 
study sample size to identify outlier studies. We inspected allele frequencies to ensure all 
analyses used the same strand assignment of alleles. We evaluated whether reported statistics and 
allelic effects were consistent with published findings for known loci. Genomic control values 
for study specific analyses were inspected, and all were <1.20. Finally, within each study, we 
excluded variants for which the minor allele was observed <7 times. 
Proportion of trait variance explained: We estimated the increase in trait variance explained by 
novel loci in the Framingham cohort (N=7,132) using three models for each trait-residual: 1) 
lead and secondary SNPs from the previously published loci (Teslovich et al. 2010) and 2) 
previously published lipid loci plus newly reported loci; and 3) newly reported loci.  We 
regressed lipid residuals on these sets of SNPs using the lme kinship package in R. 
Initial automated review of the published literature: An initial list of candidates within each 
locus was generated with Snipper (http://csg.sph.umich.edu/boehnke/snipper/) and then 
subjected to manual review. For each locus, Snipper first generates a list of nearby genes and 
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then checks for the co-occurrence of the corresponding gene names and selected search terms 
(“cholesterol”, “lipids”, “HDL”, “LDL”, or “triglycerides”) in published literature and OMIM.  
We supplemented this approach with traditional literature searches using PubMed and Google. 
Generating permuted sets of non-associated SNPs: To estimate the expected chance overlap 
between literature searches and our loci, we generated lists of permuted SNPs.  To generate these 
lists, we first identified all non-associated lipid SNPs (P > 0.10 for any of the 4 lipid traits) and 
created bins based on 3 statistics: minor allele frequency, distance to the nearest gene, and 
number of SNPs with r2 > 0.8.  For each index SNP, we identified 500 non lipid-associated SNPs 
that fell within the same 3 bins and randomly selected one SNP for each permuted list. 
Pathway analyses: To investigate if lipid-associated variants overlapped previously annotated 
pathways, we used gene set enrichment analysis (GSEA), as implemented in MAGENTA (Segre 
et al. 2010) using the meta-analysis of all studies, including GWAS and Metabochip SNPs. 
Briefly, MAGENTA first assigns SNPs to a given gene when within 110 kb upstream or 40 kb 
downstream of transcript boundaries. The most significant SNP P-value within this interval is 
then adjusted for confounders (gene size, marker density, LD) to create a gene association score. 
When the same SNP is assigned to multiple genes, only the gene with the lowest score is kept for 
downstream analyses. Subsequently, MAGENTA attaches pathway terms to each gene using 
several annotation resources, including GO, PANTHER, Ingenuity, and KEGG. Finally, the 
genes are ranked on their gene association score, and a modified GSEA test is used to test the 
null hypothesis that all gene score ranks above a given rank cutoff are randomly distributed with 
regard to a given pathway term (and compared to multiple randomly sampled gene sets of 
identical size). We evaluated enrichment by using a rank cutoff of 5% of the total number of 
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genes. A minimum of 10,000 gene set permutations were performed, and up to 1,000,000 
permutations for GSEA P-values below 1x10-4.   
We used the Disease Association Protein–Protein Link Evaluator package (DAPPLE; 
http://www.broadinstitute.org/mpg/dapple/dapple.php) to examine evidence for protein-protein 
interaction networks connecting genes across different lipid loci.  This analysis included the 62 
novel loci as well as the 95 previously known loci; we focus our discussion on pathways that 
included one or more genes from novel loci.   
Cis-expression quantitative trait locus analysis: To determine whether lipid-associated SNPs 
might act as cis-regulators of nearby genes, we examined association with expression levels of 
39,280 transcripts in 960 human liver samples, 741 human omental fat samples, and 609 human 
subcutaneous fat samples. Tissue samples were collected postmortem or during surgical 
resection from donors; tissue collection, DNA and RNA isolation, expression profiling, and 
genotyping were performed as described (Keating et al. 2008). MACH was used to obtain 
imputed genotypes for ~2.6 million SNPs in the HapMap release 22 for each of the samples. We 
examined the correlation between each of the 62 new index SNPs and all transcripts within 500 
kb of the SNP position, performing association analyses as previously described (Schadt et al. 
2008).  
Functional annotation of associated variants:  We attempted to identify lipid-associated SNPs 
that fall in important regulatory domains. We initially created a list of all potentially causal 
variants by selecting index SNPs at loci identified in this study or in Teslovich et al (2010). We 
then selected any variant in strong linkage disequilibrium (r2 > 0.8 from 1000 Genomes or 
HapMap) with each index SNP. We compared the position of the index SNPs and their proxies 
to previously described functional marks (Ernst et al. 2011; The ENCODE Project Consortium 
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2011). To assess the expected overlap with functional marks, we created 100,000 permuted sets 
of non-associated SNPs (see above) and evaluated permuted SNP lists for overlap with 
functional domains.  We estimated a P-value for each functional domain as the proportion of 
permuted sets with an equal or greater number of loci overlapping functional domains (for large 
P-values).  For small P-values we used a normal approximation to the empirical overlap 
distribution to estimate P-values. 
Association with lipid subfractions: Lipoprotein fractions for Women’s Genome Health Study 
(WGHS) samples (N = 23170) were measured using the LipoProtein-II assay (Liposcience Inc. 
Raleigh, NC) and Framingham Heart Study Offspring samples (N = 2900) were measured with 
the LipoProtein-I assay (Liposcience Inc. Raleigh, NC) (Chasman et al. 2009). Additional 
information on sub-fraction measurements can be found in Supplementary Fig. 7.  Log 
transformations were used for non-normalized traits.  All models were adjusted for age, sex, and 
PCs.  The genetic association analysis of WGHS used SNP genotypes imputed from the HapMap 
r22 CEU reference panel using MACH.  16,730 out of 23,170 WGHS participants were fasting 
for 8 hours prior to blood draw (72.2%). 
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Supplementary Tables 
Supplementary Table S2.1: Phenotypic Summary of Samples with Metabochip Genotype Results 
Short study name N 
% 
Female 
Mean age  
(SD) 
Mean 
HDL 
(SD) 
mg/dL 
Mean LDL 
(SD) mg/dL 
Mean TC 
(SD) mg/dL 
Mean TG 
(SD) mg/dL 
Excluded  
individuals  
on  
lipid-
lowering 
medication 
LDL-C 
estimated 
using 
Friedewald 
(F)  
or measured 
(M) 
Fasting > 8 hrs 
(F)  
or non-fasting  
(NF)  
blood draw 
Adjustment  
for 
population 
structure 
with PCA 
Analysis 
software  
used 
Study 
Reference 
(PMID) 
ADVANCE 505 40.6 65.7 (2.9) 54.6 (16.5) 128.3 (29.9) 209.7 (34.5) 137.7 (87.6) Yes F F Yes PLINK 18443000 
AIDHS/SDS a 1516 47.2 53.0 (12.1) 38.8 (13.8) 108.9 (38.7) 181.5 (49.2) 181.5 (116.7) Yes F F Yes PLINK 18598350 
AMC-PAS 304 25.0 43.0 (5.4) 44.2 (14.8) 148.9 (46) 234.2 (59.9) 167.1 (112.9) Yes F F No PLINK 19164808 
AMISH 1081 50.0 46.7 (15.1) 54.2 (11.6) 135.5 (38.7) 209 (42.6) 74.4 (44.3) Yes F F No MMAP 17261661 
BC58 2136 57.8 45.0 (0) 60 (15.1) 134.7 (35.6) 230.3 (41.8) 185.2 (130.2) Yes M NF No SNPTest 16155052 
CLHNS a 1771 47.3 21.5 (0.3) 42.3 (11.2) 94 (29.2) 157.2 (36.6) 105.5 (65.6) Yes F F Yes PLINK 20507864 
D2D 2007 (T2D) 287 43.6 62.3 (7.8) 50.8 (12.4) 132.4 (34.5) 213.2 (41.2) 151.1 (90.8) Yes F F Yes EMMAX 20459722 
D2D 2007 (controls) 1821 56.3 58.3 (8.3) 57.4 (13.4) 138 (31.3) 218 (35.9) 114.6 (70.6) Yes F F Yes EMMAX 20459722 
deCODE 15612 62.8 60.9 (17.1) 56 (17.9) 135.2 (39.9) 217.3 (43.8) 134.7 (81.8) Yes F F No SNPTEST 17478679 
DIAGEN (T2D) 439 50.3 66.0 (11.9) 47.5 (16) 114 (38.4) 198.7 (48.2) 199.6 (176.4) No F F Yes EMMAX 16801592 
DIAGEN (controls) 1093 56.7 62.4 (15.2) 59.3 (17.9) 127.7 (38.4) 207.2 (46.4) 135 (170.3) No F F Yes EMMAX 16801592 
DILGOM 3738 58.1 51.6 (13.5) 56.1 (13.5) 122.3 (32.1) 202 (36.8) 104.5 (62.9) Yes M F No PLINK 19959603 
DPS (T2D) 85 63.5 55.1 (6.4) 44 (11.7) 134.4 (32.8) 212.2 (37.7) 172.3 (85.5) Yes F F Yes EMMAX 11333990 
DPS (controls) 362 69.6 55.2 (7.3) 47.9 (11.1) 141.5 (31.2) 218.3 (34.2) 147.2 (61.8) Yes F F Yes EMMAX 11333990 
DRAGON (TAICHI) a 1052 41.7 62.9 (14.6) 43.3 (16.3) 101.9 (40.6) 174.5 (47.8) 146.6 (100.1) Yes F F Yes PLINK 18632180 
DR'S EXTRA (T2D) 121 50.4 68.7 (5.8) 58.3 (17.4) 112.1 (33.6) 181.1 (36.4) 142.6 (73.3) No M F Yes EMMAX 21186108 
DR'S EXTRA 
(controls) 1174 53.8 66.4 (5.3) 66.8 (18.6) 125.6 (32.2) 198.7 (35.9) 115.5 (58.9) No M F Yes EMMAX 21186108 
EAS 733 53.0 64.4 (5.7) 55.7 (13.2) 206.7 (47.2) 274.4 (51.1) 461.6 (152.4) Yes F F Yes PLINK 1917239 
EGCUT 1240 53.5 64.2 (10.9) 53.8 (27.9) 136.6 (44.1) 211.3 (46.8) 161.3 (111.6) Yes M F Yes SNPTest 19424496 
Ely 1602 53.6 61.1 (9.2) 56.5 (15.5) 135.5 (36.8) 215.6 (41) 128.5 (74.4) No F F No PLINK 7712700 
EPIC-CAD cases 
(EPIC-Norfolk CAD 
set) 1529 35.1 65.2 (7.9) 49.9 (14.3) 164.1 (40.2) 250.8 (46.4) 192.3 (108.1) No F NF No PLINK 10466767 
EPIC-T2D cases 
(EPIC-Norfolk T2D 
set) 700 40.3 62.2 (8.3) 46.4 (12.8) 153.3 (40.2) 245.4 (48.4) 243.7 (140.9) No F NF No PLINK 14693662 
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EPIC-T2D controls 
(EPIC-Norfolk T2D 
set) 994 56.8 59.4 (9.4) 55 (16.3) 154 (38.3) 239.2 (43) 156.8 (89.5) No F NF No PLINK 14693662 
FBPP a 1614 64.0 43.9 (12.5) 53.6 (15.8) 118.4 (37.8) 193.2 (43.5) NA Yes F F No Merlin 11799070 
Fenland 3186 53.3 46.9 (7.1) 58.8 (15.1) 129.3 (34.8) 207 (39.5) 103.7 (71.8) No F F No PLINK  
FINCAVAS 1201 44.4 58.5 (12.6) 54.6 (17.8) 113 (33.3) 191.2 (38.7) 119.6 (65.6) Yes F F Yes SNPTest 16515696 
FRISCII 2963 30.6 66.2 (9.7) 46.7 (15.2) 145.7 (38.2) 228.1 (43.1) 185.7 (119.5) Yes F F No GenABEL 10892758 
FUSION2 (T2D) 843 43.3 59.5 (8.5) 51.1 (14.8) 123.1 (36.2) 217.6 (47.3) 163.3 (92.8) Yes F F Yes EMMAX 17463248 
FUSION2 (controls) 1880 44.7 56.2 (8.2) 58.1 (15.8) 137.9 (34.9) 225.7 (42.5) 114.8 (68.5) Yes F F Yes EMMAX 17463248 
GLACIER 5764b 61.4 b 54.2 (8.0) b 56.3 (13.4) 173 (45.3) 232.5 (47.4) 142.6 (47.4) Yes F F Yes PLINK 20870969 
Go-DARTs 6759 46.1 57.8 (10.3) 55 (17) 120.7 (35.2) 216.7 (46.8) 177.2 (126.7) No F F No PLINK 17429603 
GXE a 397 76.8 39.8 (8.2) 50.9 (12) 146.1 (41.6) 204.3 (43.7) 84.7 (50.1) Yes F F Yes PLINK 21347282 
HALST (TAICHI) a 2375 49.4 68.9 (8.3) 52.6 (13.5) 120.0 (31.8) 197.7 (36.8) 123.1 (76.2) Yes F F Yes PLINK  
HUNT (T2D) 588 49.5 69.3 (11.3) 45.8 (14.6) 151.9 (42) 241.7 (51.8) 238.7 (163.4) No F NF Yes EMMAX 22879362 
HUNT (controls) 784 49.0 66.3 (14.4) 50.9 (14.3) 163.4 (44.1) 249.7 (48.3) 183.8 (101.1) No F NF Yes EMMAX 22879362 
IMPROVE 1769 50.0 64.4 (5.3) 48.8 (14.7) 148.6 (36.4) 224.1 (42.2) 139.1 (96.6) Yes F F Yes PLINK 19952003 
KORA F3 2816 52.1 56.3 (12.8) 59.2 (18.2) 129.6 (32.1) 220.2 (39.5) 163.9 (124.9) Yes M NF No PLINK 16032514 
KORA F4 2678 53.1 54.5 (13.1) 56.5 (14.7) 138.5 (34.8) 218.3 (39.5) 122.3 (86.8) Yes M F No PLINK 16032514 
MRC/UVRIGPCad 1687 56.7 35.0 (19.1) 39.9 (14.3) 78.6 (29) 138.9 (36.8) 104.5 (55.8) No M NF No EMMAX  
LURIC (cases) 983 26.4 64.9 (9.7) 38.5 (10.7) 124.5 (33.4) 201.2 (37.3) 170 (99.9) Yes M F No PLINK 11258203 
LURIC (controls) 523 46.1 57.9 (12.5) 42.8 (11.5) 121.2 (29.4) 198.8 (35) 154.5 (100.9) Yes M F No PLINK 11258203 
MDC 2125 51.3 57.4 (6.0) 53.9 (13.9) 160 (36.6) 235.5 (40.2) 109.2 (50.5) No F F Yes PLINK 8429286 
METSIM (T2D) 634 0.0 59.7 (6.8) 52.1 (16.1) 134.6 (36.2) 212.8 (44.4) 167 (111.8) Yes M F Yes EMMAX 19223598 
METSIM (controls) 829 0.0 53.7 (5) 57.3 (14.7) 138.4 (29.9) 215.3 (34) 120.1 (76.2) Yes M F Yes EMMAX 19223598 
NFBC86 4164 52.0 16.0 (0.4) 54.6 (11.2) 87.1 (22.4) 164.9 (30.2) 73.5 (36.3) No F F No PLINK  
NSHD 941 52.8 53.0 63.5 (19.7) 136.2 (38.3) 237.2 (43) 206.4 (154.2) No F NF No PLINK 16204333 
PIVUS 854 51.0 70.0 (0.2) 58.1 (15.5) 135.5 (31) 216.7 (38.7) 106.3 (44.3) Yes F F Yes PLINK 18489581 
PROMIS a 3385 18.0 52.5 (9.9) 35.5 (9.9) 122.3 (43.7) 192.7 (50.7) 210.2 (128.8) No M NF Yes PLINK 19404752 
SAPPHIRe (TAICHI) a 251 49.4 54.6 (10.5) 44.2 (12.6) 127.1 (38.2) 200.4 (43.4) 143.0 (80.0) Yes F F Yes PLINK 22839215 
SardiNIA 5378 56.8 43.2 (17.4) 64.3 (14.9) 127.1 (35.5) 208.4 (42.6) 86.9 (68.3) Yes F F No Merlin 16934002 
SCARFSHEEP 2973 0.3 58.3 (7.2) 45.7 (13.9) 156.3 (37.5) 230.7 (42.2) 148 (101) Yes F F No PLINK  
SEY a 426 54.7 48.7 (14.1) 48.3 (13.1) 141.4 (44.1) 213.3 (49.1) 117.8 (80.1) Yes F F No Merlin 15610228 
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SPT a 838c 61.8c 46.7 (0.5)c 48.8 (13) 133.7 (41.3) 192.8 (42.1) 89.1 (53.8) Yes F F Yes PLINK 9103091 
STR 2543 57.0 75.0 (10.2) 54.2 (15.5) 150.9 (42.6) 243.8 (50.3) 150.6 (79.7) Yes F F No Merlin 19606474 
TACT (TAICHI) a 173 31.2 64.1 (10.7) 34.3 (8.0) 103.5 (24.3) 180.1 (36.8) 130.0 (74.2) Yes F F Yes PLINK 19050055 
TCAD (TAICHI) a 2284 23.3 65.8 (11.7) 44.0 (12.5) 112.3 (40.7) 182.6 (42.4) 133.2 (84.7) Yes F F Yes PLINK 17967444 
TCAGEN (TAICHI) a 383 34.7 64.3 (13.3) 45.5 (17.7) 112.1 (37.0) 185.5 (44.6) 166.9 (131.6) Yes F F Yes PLINK 21184753 
THISEAS 929 50.7 58.6 (13.5) 52.7 (15.7) 134.5 (38.1) 211.9 (42.6) 127.1 (77.9) Yes F F No PLINK 20167083 
TROMSO (T2D) 710 50.4 60.0 (12.5) 51.2 (14.8) 168.4 (42.2) 260.5 (46.9) 223.3 (141.5) No F NF Yes EMMAX 21422063 
TROMSO (controls) 711 50.2 60.0 (12.5) 59.5 (16.4) 166.9 (43.7) 254.9 (48.3) 145.3 (89.9) No F NF Yes EMMAX 21422063 
TUDR (TAICHI) a 669 45.7 64.6 (12.1) 42.0 (15.0) 105.5 (40.5) 178.2 (52.7) 151.5 (97.6) Yes F F Yes PLINK 18632180 
ULSAM 1113 0.0 71.0 (0.6) 50.3 (11.6) 150.9 (34.8) 224.5 (38.7) 124 (70.9) Yes F F Yes PLINK 16030278 
WHII 3212 23.0 48.9 (6.0) 53.4 (28.3) 160.2 (78.6) 249.2 (43.3) 129.4 (101.9) Yes F F No PLINK 15576467  
 
a
 Studies of non-European ancestry
 
b
 GLACIER sample sizes differ by trait: TC 5,764, HDL 3,052, LDL 2,034, TG 3,365; %Female: TC 61.1, HDL 61.4, LDL 59.4, TG 59.6; mean age (SD): TC 49.5 (8.7), HDL 53.3 (8.4), LDL 54.2 (8.0), TG 50.9 (8.5) 
c
 SPT sample sizes differ by trait: TC 826, HDL 757, LDL 691, TG 838; % Female: TC 60.7, HDL 61.8, LDL 60.9, TG 61.3; mean age (SD): TC 46.7 (0.5), HDL 46.4 (0.5), LDL 46.5 (0.5), TG 46.7 (0.5) 
d
MRC/UVRI GPC is a GWAS cohort from which ~19,800 Metabochipfine-mapping SNPs were used in analysis 
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Supplementary Table S2.2: Biological Candidate Genes at Novel Loci based on Literature Search, Nonsynonymous Variants, Gene Expression Levels (eQTLs) 
and Pathway Analysis 
Locus Lead SNP Chr 
hg19 
Position 
(Mb) Traits GWS 
 
 
Nearest 
Gene 
Nearest  
Gene (kb) 
No. of Genes 
within 100kb 
Literature 
Candidate 
Gene with 
Nonsynonymous SNP 
(r
2
>0.8) 
eQTL Gene 
(P<5x10
-8
)  
Pathway 
Analysis 
 
Loci Primarily Associated with HDL Cholesterol 
PIGV-NR0B2 rs12748152 1 27.14 HDL, LDL, TG PIGV 13.5 7 PIGV, NR0B2 NUDC*, C1orf172*, 
NR0B2 
 NR0B2  
HDGF-PMVK* rs12145743 1 156.70 HDL RRNAD1 0 10 HDGF, CRABP2 HDGF     
ANGPTL1* rs4650994 1 178.52 HDL C1orf220 0 3      
CPS1 rs1047891 2 211.54 HDL CPS1 0 2  CPS1  CPS1 
ATG7 rs2606736 3 11.40 HDL ATG7 0 2       
SETD2 rs2290547 3 47.06 HDL SETD2 0 4  NBEAL2     
RBM5 rs2013208 3 50.13 HDL RBM5 0 4  MST1R* RBM5   
STAB1 rs13326165 3 52.53 HDL STAB1 0 10 STAB1, NISCH NISCH    
GSK3B rs6805251 3 119.56 HDL GSK3B 0 3 GSK3B, NR1I2     GSK3B 
C4orf52* rs10019888 4 26.06 HDL C4orf52* 131.5 0        
FAM13A rs3822072 4 89.74 HDL FAM13A 0 2        
ADH5 rs2602836 4 100.01 HDL ADH5 4.9 4   ADH5   
RSPO3 rs1936800 6 127.44 HDL, TG RSPO3 4 1        
DAGLB rs702485 7 6.42 HDL DAGLB 0 5 DAGLB  DAGLB DAGLB 
SNX13 rs4142995 7 17.92 HDL SNX13 0 1 SNX13      
IKZF1 rs4917014 7 50.31 HDL IKZF1 0 1 IKZF1      
TMEM176A rs17173637 7 150.53 HDL ABP1 20.1 5    TMEM176A   
MARCH8-ALOX5 rs970548 10 46.01 HDL, TC MARCH8 0 3 ALOX5 MARCH8     
OR4C46 rs11246602 11 51.51 HDL OR4C46 3.2 2   OR5W2*, OR5D13*, 
OR5AS1* 
    
KAT5 rs12801636 11 65.39 HDL PCNXL3 0 12 KAT5      
MOGAT2-DGAT2 rs499974 11 75.46 HDL MOGAT2 12.7 4 MOGAT2, 
DGAT2 
    
ZBTB42-AKT1 rs4983559 14 105.28 HDL ZBTB42 6.2 7 AKT1     AKT1 
FTO rs1121980 16 53.81 HDL, TG FTO 0 2       
HAS1 rs17695224 19 52.32 HDL FPR3 0 6 HAS1      
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Supplementary Table S2.2 (continued) 
Locus Lead SNP Chr 
hg19 
Position 
(Mb) Traits GWS 
 
 
Nearest 
Gene 
Nearest  
Gene (kb) 
No. of Genes 
within 100kb 
Literature 
Candidate 
Gene with 
Nonsynonymous SNP 
(r
2
>0.8) 
eQTL Gene 
(P<5x10
-8
)  
Pathway 
Analysis 
Loci Primarily Associated with LDL Cholesterol 
ANXA9-CERS2 rs267733 1 150.96 LDL ANXA9 0 10 CERS2 ANXA9    ANXA9 
EHBP1 rs2710642 2 63.15 LDL EHBP1 0 1 EHBP1     
INSIG2 rs10490626 2 118.84 LDL, TC INSIG2 10.2 2 INSIG2 CCDC93   INSIG2 
LOC84931 rs2030746 2 121.31 LDL, TC LOC84931 85.6 1        
FN1 rs1250229 2 216.30 LDL FN1 3.6 2 FN1 FN1     
CMTM6 rs7640978 3 32.53 LDL, TC CMTM6 0 3   DYNC1LI1     
ACAD11 rs17404153 3 132.16 LDL, HDL DNAJC13 0 2  ACAD11*     
CSNK1G3 rs4530754 5 122.86 LDL, TC CSNK1G3 0 2        
MIR148A rs4722551 7 25.99 LDL, TC, TG MIR148A 2.2 1        
SOX17 rs10102164 8 55.42 LDL, TC SOX17 48.2 1        
BRCA2 rs4942486 13 32.95 LDL BRCA2 0 5     BRCA2 
APOH-PRXCA rs1801689 17 64.21 LDL APOH 0 3 APOH, PRKCA APOH    APOH 
SPTLC3 rs364585 20 12.96 LDL SPTLC3 26.9 1 SPTLC3  SPTLC3   
SNX5 rs2328223 20 17.85 LDL SNX5 76.3 2 SNX5      
MTMR3 rs5763662 22 30.38 LDL MTMR3 0 2       
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Supplementary Table S2.2 (continued) 
Locus Lead SNP Chr 
hg19 
Position 
(Mb) Traits GWS 
 
 
Nearest 
Gene 
Nearest  
Gene (kb) 
No. of Genes 
within 100kb 
Literature 
Candidate 
Gene with 
Nonsynonymous SNP 
(r
2
>0.8) 
eQTL Gene 
(P<5x10
-8
)  
Pathway 
Analysis 
Loci Primarily Associated with Total Cholesterol 
ASAP3 rs1077514 1 23.77 TC ASAP3 0 6      
ABCB11 rs2287623 2 169.83 TC ABCB11 0 4 ABCB11 ABCB11   ABCB11 
FAM117B rs11694172 2 203.53 TC FAM117B 0 2      
UGT1A1 rs11563251 2 234.68 TC, LDL UGT1A1 0 12 UGT1A1/3/4/5 
UGT1A6/7/8/9 
   UGT1A1 
PXK rs13315871 3 58.38 TC PXK 0 4 PXK  PXK   
KCNK17 rs2758886 6 39.25 TC KCNK17 15.9 4       
HBS1L rs9376090 6 135.41 TC HBS1L 35.2 2        
GPR146 rs1997243 7 1.08 TC C7orf50 0 7  GPR146 GPR146   
VLDLR rs3780181 9 2.64 TC, LDL VLDLR 0 3 VLDLR    VLDLR 
VIM-CUBN rs10904908 10 17.26 TC VIM 10.0 3 VIM, CUBN     CUBN 
PHLDB1 rs11603023 11 118.49 TC PHLDB1 0 7       
PHC1-A2ML1 rs4883201 12 9.08 TC PHC1 0 4 A2ML1     
DLG4 rs314253 17 7.09 TC, LDL DLG4 1.6 13 ACADVL, 
CTDNEP1, 
SLC2A4 
   DLG4  
TOM1 rs138777 22 35.71 TC TOM1 0 4 HMOX1 HMGXB4     
PPARA rs4253772 22 46.63 TC, LDL PPARA 0 6 PPARA    PPARA 
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Supplementary Table S2.2 (continued) 
Locus Lead SNP Chr 
hg19 
Position 
(Mb) Traits GWS 
 
 
Nearest 
Gene 
Nearest  
Gene (kb) 
No. of Genes 
within 100kb 
Literature 
Candidate 
Gene with 
Nonsynonymous SNP 
(r
2
>0.8) 
eQTL Gene 
(P<5x10
-8
)  
Pathway 
Analysis 
Loci Primarily Associated with Triglycerides 
LRPAP1 rs6831256 4 3.47 TG, LDL, TC DOK7 0 4 LRPAP1    LRPAP1 
VEGFA rs998584 6 43.76 TG, HDL VEGFA 3.7 1 VEGFA    VEGFA 
MET rs38855 7 116.36 TG MET 0 1       
AKR1C4 rs1832007 10 5.25 TG AKR1C4 0 2 AKR1C4 AKR1C4   AKR1C4 
PDXDC1 rs3198697 16 15.13 TG PDXDC1 0 4       
MPP3 rs8077889 17 41.88 TG MPP3 0 6      MPP3 
INSR rs7248104 19 7.22 TG INSR 0 1     INSR 
PEPD rs731839 19 33.90 TG, HDL PEPD 0 2 CEBPG     
 
Supplementary Table S2.2 summarizes results of our search for candidates at each locus. The locus label includes a gene used to refer to the locus 
throughout the text. Except for loci labeled * (PMVK, ANGPTL1 and C4orf52) the locus label always refers to a gene within 100kb of the SNP with 
strongest association; in these three cases, the gene selected as the locus label was judged to be an especially worthy candidate >100kb or no genes within 
100kb of the lead SNP were available. The columns labeled literature candidate, non-synonymous SNP, eQTL and pathway analysis candidate indicate 
genes flagged in our various searches for candidate genes, further detailed in the text and in supplementary tables. Genes with a non-synonymous SNP in 
disequilibrium with the lead SNP for the locus but more than 100kb away are also labeled *. 
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Supplementary Table S2.3: Summary of Joint Meta-Analysis Association Results for 95 Previously Discovered Lipid Loci 
 
 
 
Nearest gene 
 
 
 
MarkerName 
 
 
 
Chr 
 
hg19 
Position 
(Mb) 
Primary 
trait, 
Secondary  
trait(s) 
 
 
MAF 
 
Alleles  
minor/ 
major 
 
 
 
Effect 
 
 
Joint N 
(in 1000s) 
 
 
 
Joint P-value 
Loci Primarily Associated with HDL Cholesterol 
PABPC4 rs4660293 1 40.03 HDL .24 G/A -.035 187 3x10-18 
ZNF648 rs1689800 1 182.17 HDL .35 G/A -.034 187 5x10-20 
GALNT2 rs4846914 1 230.30 HDL,TG .41 G/A -.048/.040 187/178 4x10-41/7x10-31 
COBLL1 rs12328675 2 165.54 HDL .13 C/T .045 187 2x10-15 
IRS1 rs2972146 2 227.10 HDL,TG .37 G/T .032/-.028 184/175 2x10-17/3x10-15 
SLC39A8 rs13107325 4 103.19 HDL .08 T/C -.071 179 1x10-15 
ARL15 rs6450176 5 53.30 HDL .26 A/G -.025 187 7x10-10 
CITED2 rs605066 6 139.83 HDL .42 C/T -.028 94 3x10-8 
KLF14 rs4731702 7 130.43 HDL .49 T/C .029 187 5x10-17 
PPP1R3B rs9987289 8 9.18 HDL,TC,LDL .10 A/G -.082/-
.084/-.071 
169/174/160 2x10-41/2x10-36/9x10-24 
TRPS1 rs2293889 8 116.60 HDL .41 T/G -.031 180102 4x10-17 
TTC39B rs581080 9 15.31 HDL,TC .21 G/C -.042/-.038 187/187 1x10-19/1x10-13 
ABCA1 rs1883025 9 107.66 HDL,TC .25 T/C -.07/-.067 186/187 2x10-65/6x10-53 
AMPD3 rs2923084 11 10.39 HDL .18 G/A -.026 187 5x10-8 
LRP4 rs3136441 11 46.74 HDL .18 C/T .054 187 7x10-29 
PDE3A rs7134375 12 20.47 HDL .43 A/C .021 187 1x10-8 
MVK rs7134594 12 110.00 HDL .48 C/T -.035 94 2x10-13 
SBNO1 rs4759375 12 123.80 HDL .08 T/C .056 94 3x10-8 
ZNF664 rs4765127 12 124.46 HDL .35 T/G .032/-.029 94/91 8x10-10/2x10-8 
SCARB1 rs838880 12 125.26 HDL .34 C/T .048 173 6x10-32 
LIPC rs1532085 15 58.68 HDL,TC,TG .40 A/G .107/.054/.
031 
185/186/176 1x10-188/7x10-47/2x10-18 
LACTB rs2652834 15 63.40 HDL .21 A/G -.028 186 4x10-11 
CETP rs3764261 16 56.99 HDL,LDL,TC,TG .32 A/C .241/-
.053/.050/-
.040 
178/165/177/169 1x10-769/2x10-34/4x10-31/2x10-25 
LCAT rs16942887 16 67.93 HDL .14 A/G .083 186 8x10-54 
CMIP rs2925979 16 81.53 HDL .31 T/C -.035 186 1x10-19 
STARD3 rs11869286 17 37.81 HDL .35 G/C -.032 178 3x10-17 
ABCA8 rs4148008 17 66.88 HDL .33 G/C -.028 166 1x10-12 
PGS1 rs4129767 17 76.40 HDL .48 G/A -.024 185 2x10-11 
LIPG rs7241918 18 47.16 HDL,TC .19 G/T -.09/-.058 93/93 1x10-44/4x10-18 
MC4R rs12967135 18 57.85 HDL .25 A/G -.026 154 4x10-8 
ANGPTL4 rs7255436 19 8.43 HDL .47 C/A -.032 93 2x10-8 
ANGPTL8 rs737337 19 11.35 HDL .11 C/T -.056 185 5x10-17 
LILRA3 rs386000 19 54.79 HDL .26 C/G .048 165 3x10-23 
HNF4A rs1800961 20 43.04 HDL,TC .05 T/C -.127/-.106 158/156 2x10-34/1x10-24 
PLTP rs6065906 20 44.55 HDL,TG .19 C/T -.059/.053 186/176 5x10-40/2x10-34 
UBE2L3 rs181362 22 21.93 HDL .23 T/C -.038 178 4x10-18 
 43
Supplementary Table S2.3 (continued) 
Loci Primarily Associated with LDL Cholesterol 
PCSK9 rs2479409 1 55.50 LDL,TC .32 G/A .064/.054 173/187 3x10-50/2x10-39 
SORT1 rs629301 1 109.82 LDL,TC .24 G/T -.167/-.134 143/156 5x10-241/2x10-170 
APOB rs1367117 2 21.26 LDL,TC .32 A/G .119/.100 173/187 1x10-182/3x10-139 
ABCG5/8 rs4299376 2 44.07 LDL,TC .31 G/T .081/.079 145/158 4x10-72/3x10-73 
MYLIP rs3757354 6 16.13 LDL,TC .24 T/C -.038/-.035 173/187 2x10-17/2x10-15 
HFE rs1800562 6 26.09 LDL,TC .07 A/G -.062/-.056 171/185 8x10-14/2x10-12 
LPA rs1564348 6 160.58 LDL,TC .18 C/T .048/.049 173/187 3x10-21/3x10-23 
PLEC1 rs11136341 8 145.04 LDL,TC .40 G/A .045/.038 83/87 7x10-12/6x10-9 
ABO rs9411489 9 136.155 LDL,TC .21 T/C .077/.069 119/130 2x10-41/3x10-35 
ST3GAL4 rs11220462 11 126.24 LDL,TC .14 A/G .059/.047 145/157 7x10-21/6x10-15 
NYNRIN rs8017377 14 24.88 LDL .46 A/G .030 173 3x10-15 
OSBPL7 rs7206971 17 45.43 LDL,TC .49 A/G .029/.030 81/85 3x10-7/1x10-7 
LDLR rs6511720 19 11.20 LDL,TC .12 T/G -.221/-.185 171/185 4x10-262/5x10-202 
APOE rs4420638 19 45.42 LDL,TC,HDL .19 G/A .225/.197/-.067 93/104/100 2x10-178/1x10-149/2x10-21 
TOP1 rs6029526 20 39.67 LDL,TC .47 A/T .044/.040 88/93 5x10-18/1x10-16 
Loci Primarily Associated with Total Cholesterol 
LDLRAP1 rs12027135 1 25.78 TC,LDL .46 A/T -.027/-.030 178/165 5x10-12/2x10-14 
EVI5 rs7515577 1 93.01 TC .23 C/A -.037 95 2x10-8 
MOSC1 rs2642442 1 220.97 TC,LDL .33 C/T -.035/-.036 111/102 3x10-11/5x10-11 
IRF2BP2 rs514230 1 234.86 TC,LDL .48 A/T -.039/-.036 95/90 5x10-14/9x10-12 
RAB3GAP1 rs7570971 2 135.84 TC .35 A/C .030 185 1x10-13 
RAF1 rs2290159 3 12.63 TC .23 C/G -.037 94 2x10-9 
HMGCR rs12916 5 74.66 TC,LDL .40 C/T .068/.073 183/168 5x10-74/8x10-78 
TIMD4 rs6882076 5 156.39 TC,TG,LDL .36 T/C -.051/-.029/-.046 187/178/173 5x10-41/2x10-15/3x10-31 
HLA rs3177928 6 32.41 TC,LDL .17 A/G .048/.045 180/166 1x10-21/3x10-17 
C6orf106 rs2814982 6 34.55 TC .12 T/C -.044 187 4x10-15 
FRK rs9488822 6 116.31 TC,LDL .36 T/A .034/.031 95/90 1x10-9/2x10-7 
DNAH11 rs12670798 7 21.61 TC,LDL .25 C/T .036/.034 187/173 1x10-16/5x10-14 
NPC1L1 rs2072183 7 44.58 TC,LDL .29 C/G .036/.039 184/170 4x10-15/7x10-16 
CYP7A1 rs2081687 8 59.39 TC,LDL .36 T/C .038/.031 95/90 9x10-12/1x10-7 
GPAM rs2255141 10 113.93 TC,LDL .30 A/G .031/.030 187/173 7x10-16/1x10-13 
SPTY2D1 rs10128711 11 18.63 TC .30 T/C -.031 157 1x10-11 
UBASH3B rs7941030 11 122.52 TC,HDL .39 C/T .028/.027 187/187 2x10-14/1x10-14 
BRAP rs11065987 12 112.07 TC,LDL .41 G/A -.031/-.027 187/173 2x10-16/1x10-11 
HNF1A rs1169288 12 121.42 TC,LDL .34 C/A .032/.038 176/163 4x10-17/6x10-21 
HPR rs2000999 16 72.11 TC,LDL .20 A/G .062/.065 186/172 7x10-41/4x10-41 
CILP2 rs10401969 19 19.41 TC,TG,LDL .09 C/T -.137/-.121/-.118 186/176/171 4x10-77/1x10-69/3x10-54 
FLJ36070 rs492602 19 49.21 TC .47 G/A .031 184 1x10-16 
ERGIC3 rs2277862 20 34.15 TC .15 T/C -.035 186 5x10-11 
MAFB rs2902940 20 39.09 TC,LDL .30 G/A -.024/-.027 186/172 9x10-10/2x10-11 
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Supplementary Table S2.3 (continued) 
Loci Primarily Associated with Triglycerides 
ANGPTL3 rs2131925 1 63.03 TG,LDL,TC .34 G/T -.066/-.049/-.075 178/173/187 3x10-74/3x10-32/4x10-80 
GCKR rs1260326 2 27.73 TG,TC .39 T/C .115/.051 178/187 2x10-239/3x10-42 
MSL2L1 rs645040 3 135.93 TG .23 G/T -.029 178 2x10-12 
KLHL8 rs442177 4 88.03 TG .42 G/T -.031 178 1x10-18 
MAP3K1 rs9686661 5 55.86 TG .20 T/C .038 177 3x10-16 
TYW1B rs13238203 7 72.13 TG .04 T/C -.059 102 3x10-6 
MLXIPL rs17145738 7 72.98 TG,HDL .13 T/C -.115/.041 176/185 9x10-99/5x10-13 
PINX1 rs11776767 8 10.68 TG .37 C/G .022 177 3x10-11 
NAT2 rs1495741 8 18.27 TG,TC .26 G/A .040/.032 88/92 3x10-12/3x10-8 
LPL rs12678919 8 19.84 TG,HDL .13 G/A -.170/.155 178/187 2x10-199/1x10-149 
TRIB1 rs2954029 8 126.49 TG,TC,LDL,HDL .47 T/A -.076/-.062/-.056/.040 178/187/173/187 1x10-107/2x10-65/2x10-50/3x10-29 
JMJD1C rs10761731 10 65.03 TG .44 T/A -.031 91 8x10-12 
CYP26A1 rs2068888 10 94.84 TG .45 A/G -.024 178 2x10-11 
FADS1-2-3 rs174546 11 61.57 TG,LDL,TC,HDL .36 T/C .045/-.051/-.048/-.039 178/173/187/187 7x10-38/2x10-39/3x10-37/8x10-28 
APOA1 rs964184 11 116.65 TG,TC,HDL,LDL .84 C/G -.234/-.121/.106/-.086 91/95/94/90 7x10-224/3x10-55/6x10-48/2x10-26 
LRP1 rs11613352 12 57.79 TG,HDL .26 T/C -.028/.028 178/187 9x10-14/2x10-13 
CAPN3 rs2412710 15 42.68 TG .04 A/G .099 154 2x10-11 
FRMD5 rs2929282 15 44.25 TG .07 T/A .072 84 2x10-9 
CTF1 rs11649653 16 30.92 TG .40 G/C -.027 90 2x10-7 
PLA2G6 rs5756931 22 38.55 TG .40 C/T -.020 174 3x10-8 
 
 
 
 
 
 
 
 
 
 
 
 45
Supplementary Table S2.4: Overlap of Novel Loci and Literature 
 
 
 
Locus 
 
 
 
Lead SNP 
 
 
 
Chr 
 
hg19 
Position 
(Mb) 
 
 
 
Traits GWS 
 
 
 
Literature 
Candidate 
 
 
 
Complete Gene Name 
 
 
 
Reference 
Loci Primarily Associated with HDL Cholesterol 
PIGV-NR0B2 rs12748152 1 27.14 HDL, LDL, TG PIGV phosphatidylinositol glycan anchor biosynthesis, class V PMID 20802478 
PMID 15623507 
PIGV-NR0B2 rs12748152 1 27.14 HDL, LDL, TG NR0B2 nuclear receptor subfamily 0, group B, member 2 PMID 22577560 
PMID 20375098 
HDGF-PMVK rs12145743 1 156.70 HDL HDGF hepatoma-derived growth factor PMID 14635185 
HDGF-PMVK rs12145743 1 156.70 HDL CRABP2 cellular retinoic acid binding protein 2 PMID 17484622  
ANGPTL1 rs4650994 1 178.52 HDL    
CPS1 rs1047891 2 211.54 HDL    
ATG7 rs2606736 3 11.40 HDL    
SETD2 rs2290547 3 47.06 HDL    
RBM5 rs2013208 3 50.13 HDL    
STAB1 rs13326165 3 52.53 HDL STAB1 stabilin 1 PMID 21480214 
PMID 19726632 
PMID 21030611 
STAB1 rs13326165 3 52.53 HDL NISCH nischarin PMID 21484668  
GSK3B rs6805251 3 119.56 HDL GSK3B glycogen synthase kinase 3 beta PMID 21334395 
PMID 21328461 
GSK3B rs6805251 3 119.56 HDL NR1I2 nuclear receptor subfamily 1, group I, member 2 PMID 21295138 
C4orf52 rs10019888 4 26.06 HDL    
FAM13A rs3822072 4 89.74 HDL    
ADH5 rs2602836 4 100.01 HDL    
RSPO3 rs1936800 6 127.44 HDL, TG    
DAGLB rs702485 7 6.45 HDL DAGLB diacylglycerol lipase, beta PMID 21949825  
SNX13 rs4142995 7 17.92 HDL SNX13 sorting nexin 13 PMID 12461558 
IKZF1 rs4917014 7 50.31 HDL IKZF1 IKAROS family zinc finger 1 (Ikaros) PMID 18483254 
TMEM176A rs17173637 7 150.53 HDL    
MARCH8-ALOX5 rs970548 10 46.01 HDL, TC ALOX5 arachidonate 5-lipoxygenase PMID 22293202 
OR4C46 rs11246602 11 51.51 HDL    
KAT5 rs12801636 11 65.39 HDL KAT5 K(lysine) acetyltransferase 5 PMID 18096664  
PMID 17996965 
MOGAT2-DGAT2 rs499974 11 75.46 HDL MOGAT2 monoacylglycerol O-acyltransferase 2 PMID 21734185 
PMID 14966132 
 46
Supplementary Table S2.4 (continued)       
 
MOGAT2-DGAT2 rs499974 11 75.46 HDL DGAT2 diacylglycerol O-acyltransferase 2 PMID 22493088 
PMID 21317108 
PMID 22155452 
ZBTB42-AKT1 rs4983559 14 105.28 HDL  AKT1 v-akt murine thymoma viral oncogene homolog 1 PMID 18054314  
PMID 20054340 
FTO rs1121980 16 53.81 HDL, TG    
HAS1 rs17695224 19 52.32 HDL HAS1 hyaluronan synthase 1 PMID 9933623 
Loci Primarily Associated with LDL Cholesterol 
ANXA9-CERS2 rs267733 1 150.96 LDL CERS2 ceramide synthase 2 PMID 20940143 
PMID 20110363 
PMID 19801672 
EHBP1 rs2710642 2 63.15 LDL EHBP1 EH domain binding protein 1 PMID 21332221 
INSIG2 rs10490626 2 118.84 LDL, TC INSIG2 insulin induced gene 2 PMID 22143767 
PMID 20817058 
PMID 20090767 
LOC84931 rs2030746 2 121.31 LDL, TC    
FN1 rs1250229 2 216.30 LDL FN1 fibronectin 1 PMID 16150826 
CMTM6 rs7640978 3 32.53 LDL, TC    
ACAD11 rs17404153 3 132.16 LDL, HDL    
CSNK1G3 rs4530754 5 122.86 LDL, TC    
MIR148A rs4722551 7 25.99 LDL, TC, TG    
SOX17 rs10102164 8 55.42 LDL, TC    
BRCA2 rs4942486 13 32.95 LDL    
APOH-PRXCA rs1801689 17 64.21 LDL APOH apolipoprotein H PMID 12740481 
APOH-PRXCA rs1801689 17 64.21 LDL PRKCA protein kinase C, alpha PMID 20692055 
PMID 12952980 
SPTLC3 rs364585 20 12.96 LDL SPTLC3 serine palmitoyltransferase, long chain base subunit 3 PMID 19648650 
SNX5 rs2328223 20 17.85 LDL SNX5 sorting nexin 5 PMID 15561769 
MTMR3 rs5763662 22 30.38 LDL    
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Supplementary Table S2.4 (continued) 
 
Loci Primarily Associated with Total Cholesterol 
ASAP3 rs1077514 1 23.77 TC    
ABCB11 rs2287623 2 169.83 TC ABCB11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 PMID 21726512 
PMID 19228692 
FAM117B rs11694172 2 203.53 TC    
UGT1A1 rs11563251 2 234.68 TC, LDL UGT1A1/3/4/5/6/7/8/9/20 UDP glucuronosyltransferase 1 family, polypeptide A1 PMID 17908920 
PXK rs13315871 3 58.38 TC PXK PX domain containing serine/threonine kinase PMID 20086096 
PMID 17178602 
KCNK17 rs2758886 6 39.25 TC    
HBS1L rs9376090 6 135.41 TC    
GPR146 rs1997243 7 1.08 TC    
VLDLR rs3780181 9 2.64 TC, LDL VLDLR very low density lipoprotein receptor PMID 8827514 
VIM-CUBN rs10904908 10 17.26 TC VIM vimentin PMID 22535769 
PMID 7706405 
PMID 1527066 
VIM-CUBN rs10904908 10 17.26 TC CUBN cubilin PMID 10371504 
PHLDB1 rs11603023 11 118.49 TC    
PHC1-A2ML1 rs4883201 12 9.08 TC A2ML1 alpha-2-macroglobulin-like 1 PMID 18648652 
DLG4 rs314253 17 7.09 TC, LDL ACADVL acyl-CoA dehydrogenase, very long chain PMID 19889959 
DLG4 rs314253 17 7.09 TC, LDL CTDNEP1 CTD nuclear envelope phosphatase 1 PMID 22134922 
DLG4 rs314253 17 7.09 TC, LDL SLC2A4 solute carrier family 2, member 4 PMID 16096283  
TOM1 rs138777 22 35.71 TC HMOX1 hemeoxygenase (decycling) 1 PMID 22004613 
PPARA rs4253772 22 46.63 TC, LDL PPARA peroxisome proliferator-activated receptor alpha PMID 21540177 
PMID 21487230 
Loci Primarily Associated with Triglycerides 
LRPAP1 rs6831256 4 3.47 TG, LDL, TC LRPAP1 low density lipoprotein receptor-related protein associated protein 1 PMID 16973241 
VEGFA rs998584 6 43.76 TG, HDL VEGFA vascular endothelial growth factor A PMID 21348596 
PMID 18789802 
MET rs38855 7 116.36 TG    
AKR1C4 rs1832007 10 5.25 TG AKR1C4 aldo-ketoreductase family 1, member C4 PMID 18024509 
PDXDC1 rs3198697 16 15.13 TG    
MPP3 rs8077889 17 41.88 TG    
INSR rs7248104 19 7.22 TG    
PEPD rs731839 19 33.90 TG, HDL CEBPG CCAAT/enhancer binding protein (C/EBP), gamma PMID 12177065 
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Supplementary Table S2.5: Pathways that Show Enrichment of Genes at Novel Loci by MAGENTA analysis 
 
Supplementary Tables 5A-D.Database and Gene Set define the source of the gene set with evidence for enrichment;  Effective Gene Set Size, the 
number of genes in a pathway independently assigned a score, after clustering nearby genes and excluding genes in regions with no SNP data; 
Expected Number of Hits, the number of genes expected to have a score in the top 5% of all scores given the gene set size; Observed Number of Hits, 
the number of genes observed in the top 5% of all gene scores; FDR P-value, the false discovery rate incurred by rejecting the null for this gene set 
and all others with more extreme enrichment using all GWAS+Metabochip results; Genome-wide Significant Genes, genes in the pathway labeled as 
hits by MAGENTA (Known and Novel refer to association evidence reported by this study); Other Enriched Genes, genes with scores in the top 5% 
of all gene scores but that do not reach genome-wide significance. We show here significant pathways (FDR p< .05) which contain at least one gene 
from one of the 62 Novel loci. 
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Supplementary Table S2.5-A: Pathways that Show Enrichment of Genes at Novel HDL Associated Loci by MAGENTA analysis 
Database Gene Set 
Effective 
Gene Set 
Size 
No. of 
Expected 
Genes 
(>95% 
Cutoff) 
No. of 
Observe
d Genes 
(>95% 
Cutoff) 
FDR  
P-value 
Genome-wide Significant Genes 
Novel Known Other Enriched Genes 
HDL Cholesterol 
Ingenuity FXR RXR activation 54 3 13 6.0x10-4 NR0B2 
SCARB1,LIPC,HNF4A,PLTP, 
APOB,APOE,MLXIPL,APOA1 APOC3,NR1H3,APOC2,NR1I2 
GOTERM Cholesterol metabolic process 52 3 11 1.3x10-2 NR0B2 
CETP,LCAT,STARD3,APOB, 
APOE,APOA1 ABCA1,APOA4,APOC3,APOC1 
Ingenuity 
LPS IL-1 mediated inhibition 
of RXR function 52 3 9 2.0x10-2 NR0B2 
ABCA1,SCARB1,LIPC,CETP, 
PLTP,APOE APOC2,NR1I2 
KEGG Neurotrophin signaling 116 6 16 2.1x10-2 
AKT1,GSK3
B SORT1 
RAC1,RPS6KA1,SH2B3,NFKB1, 
NTRK1,MAP2K7,RELA,PLCG2, 
PRKCD,PTPN11,MAP2K2,TP53, 
MAPK10 
Ingenuity PXR RXR activation 45 2 8 2.4x10-2 NR0B2 HNF4A 
RELA,NR1I2,ABCB9,GSTM1, 
INSR,CPT1A 
KEGG Adipocytokine signaling 63 3 11 2.5x10-2 AKT1   
AGRP,TRADD,SOCS3,ACSL5, 
NFKB1,RELA,PTPN11,CHUK, 
CPT1A,MAPK10 
GOTERM Triglyceride lipase activity 15 1 5 2.5x10-2 DAGLB LIPC,LIPG,LPL DAGLA 
Ingenuity NFKB signaling 39 2 7 2.9x10-2 GSK3B   
RELB,CD40,NFKB1,RELA, 
PLCG2,CHUK 
Ingenuity PPARaRXRa activation 50 3 8 3.4x10-2 NR0B2 ABCA1,LPL,APOA1 CKAP5,MED1,NCOA6,INSR 
GOTERM Enzyme binding 108 5 16 3.8x10-2 AKT1 
UBE2L3,SORT1,APOB, 
APOA1 
APOA5,RAC1,CSF3,CD40, 
PRKCD,PLAUR,DNM2,CBX1, 
TP53,MIZF,HMGA1 
GOTERM Phospholipid binding 47 2 9 4.2x10-2 CPS1 ABCA1,APOB,APOE,APOA1 
APOA5,LYPLA3,APOC3, 
MAP1LC3A 
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Supplementary Table S2.5-B: Pathways that Show Enrichment of Genes at Novel LDL Associated Loci by MAGENTA analysis 
Database Gene Set 
Effective 
Gene Set 
Size 
No. of 
Expected 
Genes 
(>95% 
Cutoff) 
No. of 
Observed 
Genes 
(>95% 
Cutoff) 
FDR  
P-value 
Genome-wide Significant Genes 
Novel Known Other Enriched Genes 
LDL Cholesterol 
GOTERM Cholesterol metabolic process 53 3 18 < 3.3x10-5 
NR0B2,INSIG2, 
VLDLR,CUBN 
ABCA1,CETP,PCSK9,APOB, 
LDLR,APOE,LDLRAP1,HNF1A, 
ANGPTL3,APOA1 APOC1,APOA4,APOC3,PPARD 
Ingenuity FXR RXR activation 54 3 16 < 3.3x10-5 
NR0B2,PPARA,
VLDLR, 
ABCB11 
HNF4A,APOB,APOE,CYP7A1,H
NF1A,APOA1 
PPARG,APOC2,ABCG5,ABCG8,APO
C3,MTTP 
GOTERM Lipoprotein metabolic process 15 1 7 1.7x10-4 PPARA PCSK9,NPC1L1 APOC1,APOA5,APOA4,APOC3 
GOTERM Lipid transport 61 3 14 1.6x10-3 VLDLR 
CETP,APOB,LPA,LDLR,APOE,A
POA1 
APOC1,APOC2,APOC4,COL4A3BP, 
APOA5,APOA4,APOC3 
Ingenuity 
LPS I-1 mediated inhibition of RXR 
function 53 3 11 2.2x10-3 
NR0B2,PPARA, 
ABCB11 ABCA1,CETP,APOE,CYP7A1 APOC2,ABCG5,ABCG8,LY96 
GOTERM 
Low-density lipoprotein receptor 
binding 11 1 5 2.9x10-3 LRPAP1 PCSK9,APOB,APOE APOA5 
GOTERM 
Negative regulation of macrophage 
derived foam cell differentiation 12 1 5 3.4x10-3 PPARA ABCA1,CETP ITGB3,PPARG 
Ingenuity Hepatic cholestasis 58 3 11 3.4x10-3 
NR0B2,PPARA, 
ABCB11 
CETP,HNF4A,CYP7A1, 
HNF1A TIRAP,MAP3K4,LY96,NR1H4 
GOTERM Steroid metabolic process 67 3 13 6.5x10-3 
INSIG2,VLDLR, 
CUBN 
ABCA1,CETP,PCSK9,APOB, 
OSBPL7,LDLR,LDLRAP1, 
NPC1L1,CYP7A1 SORL1 
Ingenuity PPAR Signaling 18 1 5 7.9x10-3 NR0B2,PPARA RAF1 PPARG,PPARD 
GOTERM Phosphatidylserine binding 10 1 4 1.3x10-2 ANXA9 SCARB1 CPNE1,TRIM72 
Ingenuity PXR RXR activation 46 2 8 1.7x10-2 
NR0B2,PPARA, 
ABCB11, 
UGT1A1 HNF4A,CYP7A1 GSTM1,UGT1A9 
GOTERM Lipoprotein transport 10 1 4 1.7x10-2 CUBN APOB PPARG,MTTP 
GOTERM Steroid hormone receptor activity 45 2 9 3.3x10-2 NR0B2,PPARA HNF4A 
PPARG,PPARD,NR1H4,RARB, 
NR4A3,THRA 
GOTERM Organ regeneration 24 1 6 3.5x10-2 APOH   PPARG,ATIC,GAS6,NR4A3,LIF 
GOTERM Receptor-mediated endocytosis 39 2 8 3.6x10-2 CUBN HFE,APOE 
IGF2R,ASGR1,M6PR,SORL1, 
ARHGAP27 
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Supplementary Table S2.5-C: Pathways that Show Enrichment of Genes at Novel Total Cholesterol Associated Loci by MAGENTA analysis 
Database Gene Set 
Effective 
Gene Set 
Size 
No. of 
Expected 
Genes 
(>95% 
Cutoff) 
No. of 
Observed 
Genes 
(>95% 
Cutoff) 
FDR  
P-value 
Genome-wide Significant Genes 
Novel Known Other Enriched Genes 
Total Cholesterol 
GOTERM Cholesterol metabolic process 52 3 18 < 3.3x10-5 
CUBN,INSIG2,VL
DLR 
ABCA1,CETP,LCAT,PCSK9, 
APOB,LDLR,APOE,LDLRAP1, 
HNF1A,ANGPTL3,APOA1 APOC1,APOA4,APOC3,PPARD 
Ingenuity FXR RXR activation 54 3 18 < 3.3x10-5 
ABCB11,PPARA,V
LDLR,NR0B2 
SCARB1,LIPC,HNF4A,APOB, 
APOE,CYP7A1,HNF1A,APOA1 
APOC2,ABCG5,ABCG8,APOC3, 
PPARG,SDC1 
Ingenuity 
LPS IL-1 Mediated Inhibition of 
RXR Function 53 3 14 6.7x10-5 
ABCB11,PPARA,
NR0B2 
ABCA1,SCARB1,LIPC,CETP, 
APOE,CYP7A1 
APOC2,ABCG5,ABCG8,LY96, 
ABCB9 
GOTERM 
Low-density lipoprotein receptor 
binding 11 1 6 1.6x10-4 LRPAP1 PCSK9,APOB,APOE APOA5,SNX17 
Ingenuity Hepatic cholestasis 56 3 12 7.5x10-4 
ABCB11,PPARA,
NR0B2 CETP,HNF4A,CYP7A1,HNF1A 
LY96,NR1I2,MAP3K4,NR1H4, 
HSD3B7 
Ingenuity PXR RXR activation 46 2 10 1.1x10-3 
ABCB11,PPARA,
UGT1A1,NR0B2 HNF4A,CYP7A1 GSTM1,UGT1A9,ABCB9,NR1I2 
GOTERM 
Negative regulation of macrophage-
derived foam cell differentiation 12 1 5 4.2x10-3 PPARA ABCA1,CETP PPARG,ITGB3 
Ingenuity PPAR signaling 18 1 5 7.7x10-3 PPARA,NR0B2 RAF1 PPARG,PPARD 
GOTERM Steroid metabolic process 68 3 13 9.8x10-3 
CUBN,INSIG2, 
VLDLR 
ABCA1,CETP,LCAT,PCSK9,APO
B,LDLR,LDLRAP1,NPC1L1 
,CYP7A1 NR1I2 
GOTERM Gamma-tubulin binding 10 1 4 1.6x10-2 BRCA2   SPATC1,MARK4,BLOC1S2 
GOTERM Phosphatidylserine binding 10 1 4 2.0x10-2 ANXA9 SCARB1 CPNE1,TRIM72 
Ingenuity 
NRF2-mediated oxidative stress 
Response 50 3 8 3.3x10-2 GSK3B SCARB1,RAF1 
HERPUD1,KEAP1,ERP29, 
HMOX1,FTH1 
Ingenuity Axonal guidance signaling 65 3 9 3.3x10-2 GSK3B RAF1 
SDCBP,VASP,PTPN11,CXCR4, 
ARHGEF15,GDF7,ERBB2 
Ingenuity Neuregulin signaling 25 1 5 3.4x10-2 DLG4 RAF1 
PTPN11,RPS6,GRB7 
Ingenuity Estrogen receptor signaling 30 2 5 4.4x10-2 NR0B2 RAF1 
SMARCA4,CARM1,PELP1 
Ingenuity PPARaRXRa activation 50 3 7 4.5x10-2 PPARA,NR0B2 ABCA1,RAF1,APOA1 
MED24,MED1 
GOTERM Receptor-mediated endocytosis 39 2 8 4.7x10-2 CUBN APOE 
IGF2R,ASGR1,M6PR,CXCL16, 
PLD2,SNX17 
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Supplementary Table S2.5-D: Pathways that Show Enrichment of Genes at Novel Triglyceride Associated Loci by MAGENTA analysis 
Database Gene Set 
Effectiv
e Gene 
Set Size 
No. of 
Expecte
d Genes 
(>95% 
Cutoff) 
No. of 
Observe
d Genes 
(>95% 
Cutoff) 
FDR  
P-value 
Genome-wide Significant Genes 
Novel Known Other Enriched Genes 
Triglycerides 
Ingenuity FXR RXR activation 54 3 15 < 3.3x10-5 NR0B2 
SCARB1,LIPC,PLTP,APOB, 
APOE,CYP7A1,MLXIPL 
,APOA1 
APOC2,APOC3,PPARG,CYP27
A1,NR1H3,SLCO1B1 
GOTERM 
Low-density lipoprotein receptor 
binding 11 1 5 2.3x10-3 LRPAP1 APOB,APOE SNX17,APOA5 
KEGG Primary bile acid biosynthesis 16 1 5 1.0x10-2 AKR1C4 CYP7A1 HSD3B7,CYP27A1,HSD17B4 
GOTERM Cholesterol metabolic process 52 3 11 1.2x10-2 NR0B2 
ABCA1,CETP,APOB, 
APOE,ANGPTL3,APOA1 
APOA4,APOC1,APOC3,CYP27
A1 
Ingenuity PPAR signaling 18 1 5 1.4x10-2 INSR,NR0B2 RAF1 PPARG,NR1H3 
GOTERM Cell surface 184 9 23 3.0x10-2 
VEGFA 
,LRPAP1,MPP3 SCARB1 
PVRL2,EDG4,BACE1,STX4,BC
AM,STRC,FLT3LG,MPP2,TME
M102,PCSK6,DSCAML1 
,HSPB1,CD6,C9orf127,BMPR2,
IGF2R ,ITGAL,SDC1,HFE2 
Ingenuity 
LPS IL-1 mediated inhibition of 
RXR function 51 3 8 5.0x10-2 NR0B2 
ABCA1,LIPC,CETP,PLTP, 
APOE,CYP7A1 APOC2 
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Supplementary Table S2.6: Overlap Between eQTL Loci and New Lipid Associated Loci 
 
Index SNP 
 
Position Transcript 
Index 
SNP 
P-value 
Expression 
Increasing 
Allele 
Top eQTL 
SNP 
Top 
eQTL 
SNP 
P-value 
r2 
Conditional 
P-value 
(Index 
SNP) 
Conditional 
P-value 
(Top eQTL 
SNP) 
           
 eQTLs in Loci Primarily Associated with HDL 
rs2013208  chr3 at 50.1Mb RBM5 in Omental Fat 3x10-30 T rs2353579 7x10-33 0.93 1.00 0.60 
rs2013208  chr3 at 50.1Mb RBM5 in Subcutaneous Fat 5x10-22 T rs4688758 2x10-23 0.93 0.93 0.63 
rs2602836  chr4 at 100.2Mb ADH5 in Omental Fat 7x10-27 G rs1800759 4x10-47 0.82 0.09 7x10-9 
rs2602836  chr4 at 100.2Mb ADH5 in Subcutaneous Fat 5x10-17 G rs1800759 7x10-31 0.80 0.20 6x10-4 
rs702485  chr7 at 6.4Mb DAGLB in Omental Fat 6x10-26 G rs13238780 3x10-27 0.94 0.99 0.79 
rs702485  chr7 at 6.4Mb DAGLB in Subcutaneous Fat 2x10-13 G rs836556 1x10-15 0.92 0.93 0.61 
rs17173637  chr7 at 150.2Mb TMEM176A in 
Subcutaneous Fat 
2x10-13 C Index SNP     
           
 eQTLs in Loci Primarily Associated with LDL 
rs364585  chr20 at 12.9Mb SPTLC3 in Liver 8x10-37 A rs168622 1x10-38 0.97 0.95 0.88 
           
 eQTLs in Loci Primarily Associated with Total Cholesterol 
rs13315871  chr3 at 58.4Mb PXK in Liver 7x10-17 A rs13066269 7x10-17 0.99 1.00 1.00 
rs1997243  chr7 at 1.1Mb GPR146 in Omental Fat 7x10-33 A Index SNP     
rs1997243  chr7 at 1.1Mb GPR146 in Subcutaneous 
Fat 
9x10-18 A rs2363286 9x10-18 1.00 1.00 1.00 
The table lists index SNPs for new lipid-associated loci that are also eQTLs (with P< 5x10-8) for a nearby transcript in liver, omentalfat, or subcutaneous fat. The top eQTL-
associated SNP in the region is also listed, together with its eQTL association P-value and linkage disequilibrium with the lipid-associated SNP. Conditional P-values for the index 
SNP are from an analysis that includes the top eQTL SNP as a covariate (and vice-versa). Only loci for which the r2 linkage disequilibrium coefficient between the index GWAS 
SNP and top eQTL SNP was >0.50 are listed. 
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Supplementary Table S2.7: Nonsynonymous Variants in Linkage Disequilibrium with Index SNPs at Novel Loci 
 
Lead SNP Chr 
hg19 
Position 
(Mb) 
Lead 
Trait 
Nonsynonymous 
SNP r
2
 
Gene with 
Nonsynonymous 
SNP 
Amino 
Acid 
Change 
PolyPhen-2 
Classifiera 
rs12748152 1 27.14 HDL rs17360994 1.00 C1orf172 Gln100Arg 0.20 
    rs7545442 .90 NUDC Thr68Met NA 
    rs6659176 1.00 NR0B2 Gly171Ala 0.99 
rs12145743 1 156.70 HDL rs4399146 1.00 HDGF Pro201Leu 0.00 
rs1047891 2 211.54 HDL rs1047891 -- CPS1 Thr1412Asn 0.01 
rs2290547 3 47.06 HDL rs2305637 .94 NBEAL2 Ser2054Phe 0.99 
rs2013208 3 50.13 HDL rs2230590 .89 MST1R Gln523Arg 0.00 
    rs1062633 .93 MST1R Arg1335Gly 0.00 
rs13326165 3 52.53 HDL rs887515 .85 NISCH Ala1056Val 0.00 
rs970548 10 46.01 HDL rs2291429 .95 MARCH8 Leu269Trp NA 
    rs2291428 .95 MARCH8 Phe277Leu NA 
rs11246602 11 55.20 HDL rs12419022 .97 OR5W2 His65Arg 0.01 
    rs11230983 .97 OR5D13 Arg124His 0.02 
    rs12224086 .94 OR5AS1 Arg122Leu 0.90 
rs267733 1 150.96 LDL rs267733 -- ANXA9 Asp166Gly 0.99 
rs10490626 2 118.84 LDL rs17512204 1.00 CCDC93 Pro228Leu 0.01 
rs1250229 2 216.30 LDL rs1250259 1.00 FN1 Gln15Leu 0.00 
rs7640978 3 32.53 LDL rs2303857 .91 DYNC1LI1 Gln277Arg 0.02 
rs17404153 3 132.16 LDL rs41272321 .85 ACAD11 Lys414Thr NA 
rs1801689 17 64.21 LDL rs1801689 -- APOH Cys325Gly 1.00 
rs2287623 2 169.83 TC rs2287622 1.00 ABCB11 Val444Ala 0.00 
rs1997243 7 1.08 TC rs11761941 1.00 GPR146 Gly11Glu NA 
rs138777 22 35.71 TC rs1053593 .92 HMGXB4 Gly165Val 0.01 
rs1832007 10 5.25 TG rs3829125 1.00 AKR1C4 Ser145Cys 0.00 
    rs17134592 1.00 AKR1C4 Leu311Val 0.00 
aThe PolyPhen-2 classifier estimates the probability that the amino-acid change is damaging to the encoded protein. For markers labeled NA, PolyPhen scores were not available 
from the PolyPhenwebservice at: http://genetics.bwh.harvard.edu/pph2/bgi.shtml 
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Supplementary Table S2.8: Overlap of SNPs at Known and Novel Lipid Loci with Chromatin 
States in 9 Different Cell Types 
 
Cell Type 
Observed Number of 
Chromatin States* Showing 
Excess Overlap with Lipid 
Loci  
(of 13 tested, P< 1x10-5) 
Chromatin States* Showing Excess Overlap 
with Lipid Loci (P< 1x10-5) 
H1 embryonic stem cells (H1 ES) 2 Transcription Transition (HMM9) P =4x10
-10
 
Transcription Elongation (HMM10) P =5x10-10 
B-lymphoblastoid cells (GM12878) 0  
Umbilical vein endothelial cells 
(HUVEC) 2 
Transcription Transition (HMM9) P =2x10-7 
Transcription Elongation (HMM10) P =6x10-7 
Skeletal muscle myoblasts (HSMM) 1 Transcription Elongation (HMM10) P =6x10-8 
Mammary epithelial cells (HMEC) 2 Transcription Transition (HMM9) P =6x10
-11
 
Transcription Elongation (HMM10) P =2x10-9 
Normal epidermal keratinocytes 
(NHEK) 2 
Transcription Elongation (HMM10) P =2x10-8 
Weak Transcription (HMM11) P =3x10-6 
Normal lung fibroblasts (NHLF) 2 Transcription Elongation (HMM10) P =2x10
-10
 
Transcription Transition (HMM9) P =8x10-8 
Erythrocyticleukaemia cells (K562) 3 
Weak Transcription (HMM11) P =1x10-11 
Weak Enhancer (HMM7) P =2x10-10 
Strong Enhancer (HMM5) P =4x10-8 
Hepatocellular carcinoma cells 
(HepG2) 8 
Strong Enhancer (HMM4) P =2x10-25 
Weak Enhancer (HMM7) P =4x10-14 
Weak Transcription (HMM11) P =2x10-11 
Strong Enhancer (HMM5) P =5x10-11 
Transcription Elongation (HMM10) P =3x10-10 
Weak Enhancer (HMM6) P =1x10-7 
Active Promoter (HMM1) P =4x10-7 
Weak Promoter (HMM2) P =7x10-7 
 
*Chromatin states were described previously (Ernst J et al. Nature 473, 43-9, 2011) based on 
hidden Markov models of histone methylation and acetylation marks from 9 cell types. SNPs in 
high linkage disequilibrium (r2> 0.8 in 1000 Genomes Project European ancestry samples) with 
known or novel lipid loci was compared to matched sets of HapMap SNPs (see Methods) 
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Supplementary Table S2.9: Overlap with Chromatin States, Histone Marks and Transcription Factor ChIP-
Seq in HepG2 Cells 
 
 Known and Novel Lipid Loci (N=157) Only Novel Lipid Loci (N=62) 
 
Observed 
Number of 
Loci with 
≥1 SNP in 
a 
Regulatory 
Region 
Expected 
Number of 
Loci 
P-value 
Observed 
Number of 
Loci with 
≥1 SNP in a 
Regulatory 
Region 
Expected 
Number of 
Loci 
P-value 
Overlap with Chromatin States from Ernst et al.* (13 tested) 
Strong Enhancer (HMM4) 49 13.7 2x10-25 20 6.2 9x10-10 
Weak Enhancer (HMM7) 60 26.9 4x10-14 25 11.9 3x10-5 
Weak Transcription 
(HMM11) 99 62.1 2x10
-11
 41 26.4 9x10-5 
Strong Enhancer (HMM5) 34 12.8 5x10-11 10 5.6 5x10-2 
Transcription Elongation 
(HMM10) 65 35.4 3x10
-10
 26 15.4 1x10-3 
Weak Enhancer (HMM6) 57 33.5 1x10-7 21 14.5 .013 
Active Promoter (HMM1) 39 20.3 4x10-7 14 8.8 .039 
Weak Promoter (HMM2) 45 24.8 7x10-7 15 10.6 .088 
Transcription Transition 
(HMM9) 37 18.7 3x10
-5
 18 8.0 4x10-4 
Overlap with Histone Marks (5 tested) 
H3K9ac 97 47.3 3x10-22 37 20.1 6x10-8 
H3K27ac 84 39.2 3x10-20 34 16.7 4x10-8 
H3K4me3 88 47.9 2x10-15 34 20.1 7x10-5 
H3K36me3 104 62.3 4x10-14 41 26.1 2x10-5 
H3K4me2 111 74.3 8x10-12 44 31.1 7x10-5 
Overlap with Open Chromatin (2 tested) 
FAIRE 51 26.5 5x10-9 19 11.3 8x10-3 
DNase hypersensitivity 33 18.3 2x10-4 12 8.1 .09 
Overlap with Transcription Factor ChIP-Seq (11 tested) 
HNF4Α 38 16.2 6x10-10 14 7.1 6x10-3 
CEBP/Β 40 20.4 1x10-5 16 9.1 .010 
CTCF 55 37.6 4x10-4 21 16.2 .055 
HSF1 9 2.6 1x10-3 4 1.1 .024 
*Chromatin states were described previously (Ernst J et al. Nature 473, 43-9, 2011) based on hidden Markov models 
of histone methylation and acetylation marks from 9 cell types. Data for histone marks, open chromatin, and 
transcription factor ChIP-seq were obtained from the ENCODE Project (ENCODE Project Consortium, PLoS Biol. 
9:e1001046, 2011).  SNPs in high linkage disequilibrium (r2> .8 in 1000 Genomes Project European ancestry 
samples) with known or novel lipid loci were compared to matched sets of HapMap SNPs (see Methods). The table 
lists only regulatory elements that exhibited a significant excess overlap (P< 1x10-3 to account for 31 HepG2 
regulatory elements tested). 
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Supplementary Table S2.10: Overlap of Regulatory Features and Associated SNPs at Novel Lipid Loci 
  Hidden Markov model-defined regulatory domains from histone methylation marks Histone methylation marks Markers of open 
chromatin 
Transcription factor binding (ChIP-Seq) 
Locus Lead SNP Strong 
Enhancer 
(HMM4) 
Weak 
Enhancer 
(HMM7) 
WeakTxn 
(HMM11) 
Strong 
Enhancer 
(HMM5) 
Txn 
Elongation 
(HMM10) 
Weak 
Enhancer 
(HMM6) 
Active 
Promoter 
(HMM1) 
Weak 
Promoter 
(HMM2) 
Txn 
Transition 
(HMM9) 
H3k9ac H3k27ac H3k4me3 H3k36me3 H3k4me2 FAIRE DNase 
 
Hnf4A 
(Forskolin) 
Cebpb 
(Forskolin) 
CTCF Hsf1 
Loci Primarily Associated with HDL Cholesterol 
PIGV- 
NR0B2 
rs12748152 
x x x x x x x x x x x x x x x x x x x x 
HDGF- 
PMVK 
rs12145743 
x  x x x x  x  x x x x x x x x x  x 
ANGPTL1 rs4650994 
x x x x x     x x x x x x x x x   
CPS1 rs1047891 
  x          x        
ATG7 rs2606736 
 x x  x  x   x  x x x x x x x x  
SETD2 rs2290547 
  x   x   x x x  x x       
RBM5 rs2013208 
 x x  x x x x x x x x x x x x   x  
STAB1 rs13326165 
     x       x        
GSK3B rs6805251 
 x x   x   x    x x   x  x  
C4orf52 rs10019888 
                  x  
FAM13A rs3822072 
x x x  x x x  x x x x x x x    x  
ADH5 rs2602836 
 x x     x  x x x x x x x x x   
RSPO3 rs1936800 
           x  x     x  
DAGLB rs702485 
  x   x   x x x  x x     x  
SNX13 rs4142995 
  x          x        
IKZF1 rs4917014 
                    
TMEM176A rs17173637 
x         x x x  x       
MARCH8- 
ALOX5 
rs970548 
 x x  x x    x x x x x       
OR4C46 rs11246602 
  x       x x x x x     x  
KAT5 rs12801636 
x  x   x x   x x x x x     x  
MOGAT2- 
DGAT2 
rs499974 
 x   x  x   x  x  x x   x   
ZBTB42- 
AKT1 
rs4983559 
  x           x       
FTO rs1121980 
x x x x x x    x x x x x  x     
HAS1 rs17695224 
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Supplementary Table S2.10 (continued) 
Loci Primarily Associated with LDL Cholesterol 
ANXA9- 
CERS2 
rs267733 
  x          x        
EHBP1 rs2710642 
x  x   x   x x X x x x   x    
INSIG2 rs10490626 
x  x x x x x x x x X x x x x  x x x  
LOC84931 rs2030746 
x x x  x  x   x X x  x     x  
FN1 rs1250229 
x x x  x  x x x x X x x x       
CMTM6 rs7640978 
 x x    x   x X x x x       
ACAD11 rs17404153 
 x x   x x x x x X x x x       
CSNK1G3 rs4530754 
  x     x  x X x x x x      
MIR148A rs4722551 
       x  x X x  x       
SOX17 rs10102164 
                    
BRCA2 rs4942486 
  x   x       x        
APOH- 
PRXCA 
rs1801689 
       x x x X x x x       
SPTLC3 rs364585 
x  x       x X x  x  x     
SNX5 rs2328223 
x         x X x  x   x x   
MTMR3 rs5763662 
x x x x x x   x x X x x x x  x  x  
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Supplementary Table S2.10 (continued) 
Loci Primarily Associated with Total Cholesterol 
ASAP3 rs1077514 
x x x x  x   x x X x x x       
ABCB11 rs2287623 
  x                  
FAM117B rs11694172 
 x x   x  x x x X x x x x  x    
UGT1A1 rs11563251 
                    
PXK rs13315871 
x x x  x x x x  x X x x x x  x x x  
KCNK17 rs2758886 
                    
HBS1L rs9376090 
                    
GPR146 rs1997243 
x x x x x x x x x x X x x x x x x x x x 
VLDLR rs3780181 
  x          x  x      
VIM-CUBN rs10904908 
                  x  
PHLDB1 rs11603023 
 x x  x x    x X  x x       
PHC1- 
A2ML1 
rs4883201 
            x        
DLG4 rs314253 
  x  x  x   x  x  x     x  
TOM1 rs138777 
x x x x  x x x x x X x x x x x  x   
PPARA rs4253772 
 x x  x x       x x       
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Supplementary Table S2.10 (continued) 
Loci Primarily Associated with Triglycerides 
LRPAP1 rs6831256 
    x         x    x x  
VEGFA rs998584 
             x   x    
MET rs38855 
  x   x       x        
AKR1C4 rs1832007 
 x x x      x X  x x x x   x  
PDXDC1 rs3198697 
     x       x        
MPP3 rs8077889 
x x x  x x   x x X x x x x  x x x  
INSR rs7248104 
        x    x x  x     
PEPD rs731839 
x x   x     x X x  x x  x x x x 
Supplementary Table S2.10 annotates overlap (denoted as x) between regulatory features and either the index SNP or a variant in high linkage disequilibrium (r2>0.8) with the 
index SNP.  Regulatory features were obtained from Ernst J et al. Nature 473, 43-9, 2011, and the ENCODE Project (ENCODE Project Consortium, PLoS Biol. 9:e1001046, 
2011). The corresponding BED file available on the UCSC Genome Browser for each regulatory feature is listed below. 
Strong Enhancer (HMM4): wgEncodeBroadHmmHepg2HMM.bed.4_Strong_Enhancer.bed 
Weak Enhancer (HMM7): wgEncodeBroadHmmHepg2HMM.bed.7_Weak_Enhancer.bed 
WeakTxn (HMM11): wgEncodeBroadHmmHepg2HMM.bed.11_Weak_Txn.bed 
Strong Enhancer (HMM5): wgEncodeBroadHmmHepg2HMM5_Strong_Enhancer.bed 
Txn Elongation (HMM10): wgEncodeBroadHmmHepg2HMM.bed.10_Txn_Elongation.bed 
Weak Enhancer (HMM6): wgEncodeBroadHmmHepg2HMM.bed.6_Weak_Enhancer.bed 
Active Promoter (HMM1): wgEncodeBroadHmmHepg2HMM1_Active_Promoter.bed 
Weak Promoter (HMM2): wgEncodeBroadHmmHepg2HMM.bed.2_Weak_Promoter.bed 
Txn Transition (HMM9): wgEncodeBroadHmmHepg2HMM.bed.9_Txn_Transition.bed 
H3k9ac: wgEncodeBroadChipSeqPeaksHepg2H3k9ac.bed 
H3k27ac: wgEncodeBroadChipSeqPeaksHepg2H3k27ac.bed 
H3k4me3: wgEncodeBroadChipSeqPeaksHepg2H3k4me3.bed 
H3k36me3: wgEncodeBroadChipSeqPeaksHepg2H3k36me3.bed 
H3k4me2: wgEncodeBroadChipSeqPeaksHepg2H3k4me2.bed 
FAIRE: wgEncodeUncFAIRESeqPeaksHepg2V3.bed 
DNase: wgEncodeUwDnaseSeqPeaksRep1Hepg2.bed 
Hnf4a-Forskln: wgEncodeYaleChIPseqPeaksHepg2Hnf4aForskln.narrowPeak 
Cebpb-Forskln: wgEncodeYaleChIPseqPeaksHepg2CebpbForskln.narrowPeak 
CTCF: wgEncodeBroadChipSeqPeaksHepg2Ctcf 
HSF1: wgEncodeYaleChIPseqPeaksHepg2Hsf1Forskln.narrowPeak  
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Supplementary Table S2.11: Fine-Mapping Results in Different Ancestries 
 
     
Estimates from GWAS Samples for 
Top GWAS SNP 
Estimates from Ancestry-specific 
Metabochip Samples for Top 
GWAS SNP 
  
  
Estimates from Ancestry-specific 
Metabochip Samples for Top MC 
SNP 
Chr 
Fine 
Mapping 
Interval 
(hg19 Mb) 
Locus Name 
Top 
GWAS 
SNP 
# LD 
Proxies 
in 
Europe 
P N % Var Freq P N 
% 
Var Freq 
Top 
Metabochip 
SNP 
# LD  
Proxie
s 
EUR 
r2 
with 
GWA 
SNP 
Other 
r2 
with 
GWA 
SNP 
P N % Var Freq 
HDL Cholesterol 
African 
16 56.98-57.02 CETP rs173539 12 9x10-370 92,820 2.48 0.34 3x10-3 2,738 0.37 0.38 rs17231520 
 
3 NA 0.11 2x10-16 4,420 3.03 0.08 
European 
2 165.5-165.73 COBLL1 rs12328675 9 1x10-10 94,311 0.06 0.86 2x10-6 92,781 0.03 0.88 rs355863 13 0.43 0.43 6x10-9 90,652 0.04 0.11 
11 46.33-47.35 LRP4 rs3136441 80 7x10-18 94,311 0.10 0.81 8x10-14 92,664 0.08 0.83 rs10838692 55 0.28 0.28 1x10-26 92,742 0.16 0.65 
17 37.39-38.07 MED1 (PPP1R1B) rs881844 55 3x10
-14
 92,820 0.06 0.34 3x10-5 92,574 0.02 0.37 rs10445306 270 0.44 0.44 2x10-10 92,699 0.05 0.24 
LDL Cholesterol 
African 
1 109.66-110.31 SORT1 rs629301 11 2x10-168 89,888 1.19 0.75 4x10-5 3,940 0.93 0.65 rs12740374 2 1 0.63 3x10-10 2,555 1.84 0.24 
19 11.18-11.26 LDLR rs6511720 43 3x10-115 87,565 1.05 0.13 8x10-6 2,652 0.89 0.13 rs115594766 17 0.97 0.6 9x10
-10
 2,636 1.73 0.81 
19 45.40-45.44 APOE-C1-C2-C4 rs4420638 6 1x10
-140
 77,643 1.52 0.81 0.697 2,628 0.01 0.81 rs7412 (2) 1 0.02 0.02 1x10-50 2,594 9.64 0.11 
European 
1 55.50-55.51 PCSK9 rs17111503 1 2x10-27 89,888 0.22 0.75 9x10-24 83,102 0.14 0.76 rs11591147 (R46L) 1 0 0 2x10
-136
 77,417 1.38 0.03 
6 160.47 - 160.58 IGF2R rs1564348 4 2x10
-16
 89,873 0.11 0.81 7x10-9 83,116 0.05 0.84 rs2297374 15 0.11 0.11 2x10-13 83,090 0.07 0.37 
7 44.37-44.68 NPC1L1 rs217406 6 6x10-11 86,806 0.12 0.79 2x10-5 82,799 0.03 0.73 rs2073547 5 0.39 0.39 1x10-12 83,083 0.08 0.76 
11 126.22 - 126.27 ST3GAL4 rs11220463 24 4x10
-15
 89,888 0.12 0.85 2x10-6 83,068 0.04 0.74 rs59379014 11 0.35 0.35 6x10-11 83,083 0.06 0.07 
19 45.40-45.44 APOE-C1-C2-C4 rs4420638 6 1x10
-140
 77,643 1.52 0.81 3x10-44 15,460 1.71 0.8 rs7412 (e2) 2 0.02 0.02 2x10-651 82,533 4.63 0.07 
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Supplementary Table S2.11 (continued) 
 
     
Estimates from GWAS Samples for 
Top GWAS SNP 
Estimates from Ancestry-specific 
Metabochip Samples for Top 
GWAS SNP 
  
  
Estimates from Ancestry-specific 
Metabochip Samples for Top MC 
SNP 
Chr 
Fine 
Mapping 
Interval 
(hg19 Mb) 
Locus Name 
Top 
GWAS 
SNP 
# LD 
Proxies 
in 
Europe 
P N % Var Freq P N 
% 
Var Freq 
Top 
Metabochip 
SNP 
# LD  
Proxie
s 
EUR 
r2 
with 
GWA 
SNP 
Other 
r2 
with 
GWA 
SNP 
P N % Var Freq 
Triglycerides 
East Asian 
11 116.53-116.67 APOA5-A4-C3-A1 rs2160669 20 3x10
-128
 91,013 0.96 0.9 3x10-27 8,743 1.37 0.79 rs651821 16 0.85 0.76 2x10-55 8,743 2.83 0.73 
 
Supplementary Table S2.11: Locus labels are from Teslovich et al. (2010).  # LD Proxies in Europe, the number of SNPs r2> 0.7 with GWAS SNP in 1000 Genomes European 
Ancestry samples; # Ancestry-Specific LD Proxies, number of SNPs r2> 0.7 with top Metabochip SNP in the relevant ancestry group; EUR r2, LD between top GWAS SNP and 
top Metabochip SNP in European ancestry samples; Other r2, LD between top GWAS SNP and top Metabochip SNP in the relevant ancestry group. 
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Supplementary Table S2.12: Novel and Known Lipid Loci Associated with BMI, CAD, DBP, SBP, Fasting Glucose, T2D, and 
WHR adj BMI 
 
In silico Association Results (P< .05) at Lipid Associated Loci for A. Body Mass Index (BMI), B. Coronary Artery Disease (CAD), C. 
Diastolic Blood Pressure (DBP), D. Systolic Blood Pressure (SBP), E. Fasting Glucose (FG), F. Type 2 Diabetes (T2D), and G. Waist-
Hip Ratio adjusted for BMI (WHRadjBMI) 
 
Supplementary Table S12.12-A: Novel and Known Lipid Loci with BMI P-value < 0.05 from GIANT* 
 
Locus SNP Chr hg19 Pos (Mb) Type Trait A1/A2 
Lipid 
Direction Lipid N 
Lipid 
P-value 
BMI 
Direction BMI N 
BMI 
P-value 
FTO rs1121980 16 53.81 novel HDL A/G - 185,524 6.8x10-9 + 123,845 1.8x10-57 
MC4R rs12967135 18 57.85 known HDL A/G - 153,533 3.6x10-8 + 123,864 5.3x10-22 
SLC39A8 rs13107325 4 103.19 known HDL T/C - 179,316 1.1x10-15 + 123,348 1.4x10-7 
ARL15 rs6450176 5 53.3 known HDL A/G - 187,132 6.9x10-10 - 123,861 7.7x10-5 
BRAP rs11065987 12 112.07 known TC A/G + 187,309 2.1x10-16 + 123,855 1.2x10-4 
HMGCR rs12916 5 74.66 known TC T/C - 182,530 4.6x10-74 + 123,863 1.5x10-4 
UBASH3B rs7941030 11 122.52 known TC T/C - 187,106 2.4x10-14 - 123,819 6.6x10-4 
JMJD1C rs10761731 10 65.03 known TG A/T + 91,013 8.4x10-12 + 123,863 9.9x10-4 
RBM5 rs2013208 3 50.13 novel HDL T/C + 169,708 8.9x10-12 - 123,864 1.4x10-3 
ZNF664 rs4765127 12 124.46 known HDL T/G + 94,198 7.8x10-10 + 123,737 1.7x10-3 
RAB3GAP1 rs7570971 2 135.84 known TC A/C + 184,956 1.2x10-13 - 123,850 3.3x10-3 
HPR rs2000999 16 72.11 known TC A/G + 185,692 6.8x10-41 + 123,673 4.9x10-3 
PDE3A rs7134375 12 20.47 known HDL A/C + 187,088 1.1x10-8 + 123,830 4.9x10-3 
PEPD rs731839 19 33.9 novel TG A/G - 176,161 2.7x10-9 + 123,854 5.2x10-3 
PGS1 rs4129767 17 76.4 known HDL A/G + 185,469 2.1x10-11 - 123,798 6.1x10-3 
IRS1 rs2972146 2 227.1 known HDL T/G - 184,044 1.9x10-17 - 123,855 7.2x10-3 
TOP1 rs6029526 20 39.67 known LDL A/T + 88,433 4.8x10-18 - 123,862 7.2x10-3 
FRMD5 rs2929282 15 44.25 known TG A/T - 83,616 2.0x10-9 + 122,284 1.1x10-2 
ZBTB42-AKT1 rs4983559 14 105.28 novel HDL A/G - 183,672 9.6x10-9 + 119,958 1.6x10-2 
KCNK17 rs2758886 6 39.25 novel TC A/G + 187,266 3.0x10-8 - 123,863 1.6x10-2 
LRP1 rs11613352 12 57.79 known TG T/C - 177,799 9.4x10-14 + 123,865 1.9x10-2 
EHBP1 rs2710642 2 63.15 novel LDL A/G + 172,994 6.1x10-9 + 123,853 2.1x10-2 
TRPS1 rs2293889 8 116.6 known HDL T/G - 180,102 4.3x10-17 + 123,863 2.1x10-2 
C6orf106 rs2814982 6 34.55 known TC T/C - 187,263 3.7x10-15 + 123,848 3.1x10-2 
VEGFA rs998584 6 43.76 novel TG A/C + 174,573 3.4x10-15 - 119,481 3.3x10-2 
COBLL1 rs12328675 2 165.54 known HDL T/C - 187,092 2.1x10-15 - 123,856 3.4x10-2 
CTF1 rs11649653 16 30.92 known TG C/G + 89,449 1.6x10-7 + 123,819 3.6x10-2 
PDXDC1 rs3198697 16 15.13 novel TG T/C - 175,934 2.2x10-8 + 123,669 3.7x10-2 
SETD2 rs2290547 3 47.06 novel HDL A/G - 187,142 3.7x10-9 - 118,647 3.8x10-2 
UBE2L3 rs181362 22 21.93 known HDL T/C - 178,283 4.3x10-18 + 123,910 4.7x10-2 
LRP4 rs3136441 11 46.74 known HDL T/C - 186,975 6.8x10-29 + 123,866 4.7x10-2 
FLJ36070 rs492602 19 49.21 known TC A/G - 184,180 1.1x10-16 + 120,451 4.9x10-2 
 
*Speliotes EK et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42, 937-948 
 
 
 
 
 
 
 
 64
Supplementary Table S12.12-B: Novel and Known Lipid Loci with CAD P-value < 0.05 from CARDIOGRAM+C4D Meta-analysis* 
 
Locus SNP Chr hg19 Pos (Mb) Type Trait A1/A2 
Lipid 
Direction Lipid N 
Lipid 
P-value 
CAD 
Direction CAD N 
CAD 
P-value 
APOA1 rs964184 11 116.65 known TG C/G - 90,991 6.6x10-224 - 110,492 4.8x10-11 
SORT1 rs629301 1 109.82 known LDL T/G + 142,643 5.4x10-241 + 82,222 6.1x10-10 
BRAP rs11065987 12 112.07 known TC A/G + 187,308 2.1x10-16 - 73,578 2.4x10-9 
LDLR rs6511720 19 11.2 known LDL T/G - 170,607 3.9x10-262 - 86,870 1.2x10-7 
ABCG5/8 rs4299376 2 44.07 known LDL T/G - 144,861 3.9x10-72 - 106,016 3.7x10-7 
HNF1A rs1169288 12 121.42 known TC A/C - 175,774 3.9x10-17 - 80,633 3.5x10-6 
NAT2 rs1495741 8 18.27 known TG A/G - 87,977 2.7x10-12 - 109,804 1.2x10-5 
TRIB1 rs2954029 8 126.49 known TG A/T + 177,729 1.0x10-107 + 81,977 2.8x10-5 
LPL rs12678919 8 19.84 known TG A/G + 177,749 1.8x10-199 + 111,065 4.7x10-5 
RBM5 rs2013208 3 50.13 novel HDL T/C + 169,708 8.9x10-12 - 82,470 7.0x10-5 
LPA rs1564348 6 160.58 known LDL T/C - 172,988 2.8x10-21 - 108,431 1.8x10-4 
APOE rs4420638 19 45.42 known LDL A/G - 93,103 1.5x10-178 - 36,066 2.1x10-4 
CILP2 rs10401969 19 19.41 known TC T/C + 185,666 4.1x10-77 + 81,644 2.4x10-4 
IRS1 rs2972146 2 227.1 known HDL T/G - 184,044 1.9x10-17 + 82,540 3.8x10-4 
CMTM6 rs7640978 3 32.53 novel LDL T/C - 172,227 9.8x10-9 - 81,843 4.1x10-4 
C6orf106 rs2814982 6 34.55 known TC T/C - 187,262 3.7x10-15 + 99,096 1.6x10-3 
 ACAD1 rs17404153 3 132.16 novel LDL T/G - 172,898 1.8x10-9 - 83,225 1.8x10-3 
CETP rs3764261 16 56.99 known HDL A/C + 177,533 1.4x10-769 - 83,626 2.2x10-3 
FRMD5 rs2929282 15 44.25 known TG A/T - 83,616 2.0x10-9 - 81,446 2.8x10-3 
MAP3K1 rs9686661 5 55.86 known TG T/C + 177,050 2.5x10-16 + 81,234 3.2x10-3 
KLF14 rs4731702 7 130.43 known HDL T/C + 187,085 4.8x10-17 - 99,195 3.2x10-3 
ZNF664 rs4765127 12 124.46 known HDL T/G + 94,198 7.8x10-10 - 83,532 3.6x10-3 
SPTY2D1 rs10128711 11 18.63 known TC T/C - 157,199 1.1x10-11 - 80,934 3.9x10-3 
CAPN3 rs2412710 15 42.68 known TG A/G + 153,909 1.7x10-11 + 79,267 5.3x10-3 
HMGCR rs12916 5 74.66 known TC T/C - 182,529 4.6x10-74 - 81,050 5.3x10-3 
CYP26A1 rs2068888 10 94.84 known TG A/G - 177,712 1.7x10-11 - 83,627 7.2x10-3 
ST3GAL4 rs11220462 11 126.24 known LDL A/G + 145,030 6.6x10-21 + 109,031 7.4x10-3 
VEGFA rs998584 6 43.76 novel TG A/C + 174,573 3.4x10-15 + 66,823 9.0x10-3 
PCSK9 rs2479409 1 55.5 known LDL A/G - 172,970 2.5x10-50 - 83,207 1.1x10-2 
PINX1 rs11776767 8 10.68 known TG C/G + 177,360 2.9x10-11 - 81,760 1.2x10-2 
CITED2 rs605066 6 139.83 known HDL T/C + 94,311 2.8x10-8 - 81,709 1.5x10-2 
ABCA8 rs4148008 17 66.88 known HDL C/G + 165,732 1.1x10-12 - 96,645 2.0x10-2 
HBS1L rs9376090 6 135.41 novel TC T/C + 187,263 2.6x10-9 + 81,664 2.1x10-2 
APOB rs1367117 2 21.26 known LDL A/G + 173,007 9.5x10-183 + 79,823 2.3x10-2 
IKZF1 rs4917014 7 50.31 novel HDL T/G - 186,868 1.0x10-8 + 111,434 3.4x10-2 
KAT5 rs12801636 11 65.39 novel HDL A/G + 187,099 3.2x10-8 - 74,817 3.8x10-2 
HPR rs2000999 16 72.11 known TC A/G + 185,692 6.8x10-41 + 97,651 4.1x10-2 
GALNT2 rs4846914 1 230.3 known HDL A/G + 186,995 3.5x10-41 - 84,068 4.1x10-2 
ASAP3 rs1077514 1 23.77 novel TC T/C + 184,079 6.4x10-9 + 84,078 4.4x10-2 
KLHL8 rs442177 4 88.03 known TG T/G + 177,798 1.3x10-18 + 82,034 4.6x10-2 
Supplementary Table S2.12B: 
*Schunkert H et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 
2011;43(4):333-8 
*Coronary Artery Disease (C4D) Genetics Consortium. A genome-wide association study in Europeans and South Asians identifies five 
new loci for coronary artery disease. Nat Genet. 2011; 43(4):339-44 
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Supplementary Table S2.12-C: Novel and Known Lipid Loci with DBP P-value < 0.05 from ICBP** 
 
Locus SNP Chr hg19 Pos (Mb) Type Trait A1/A2 
Lipid 
Direction Lipid N Lipid P-value 
DBP 
Direction DBP N DBP P-value 
BRAP rs11065987 12 112.07 known TC A/G + 187,309 2.1x10-16 - 62,481 3.4x10-12 
SLC39A8 rs13107325 4 103.19 known HDL T/C - 179,316 1.1x10-15 - 58,926 7.5x10-7 
VEGFA rs998584 6 43.76 novel TG A/C + 174,573 3.4x10-15 + 49,589 1.6x10-4 
HFE rs1800562 6 26.09 known LDL A/G - 171,209 8.3x10-14 + 65,399 3.2x10-4 
CITED2 rs605066 6 139.83 known HDL T/C + 94,311 2.8x10-8 - 68,145 9.9x10-4 
LACTB rs2652834 15 63.4 known HDL A/G - 185,613 3.6x10-11 + 61,977 1.4x10-3 
PABPC4 rs4660293 1 40.03 known HDL A/G + 187,027 2.9x10-18 - 69,815 1.8x10-3 
LOC55908 rs737337 19 11.35 known HDL T/C + 185,432 4.6x10-17 - 61,569 2.1x10-3 
PDE3A rs7134375 12 20.47 known HDL A/C + 187,088 1.1x10-8 - 63,231 2.3x10-3 
FAM13A rs3822072 4 89.74 novel HDL A/G - 187,115 4.1x10-12 + 66,600 2.8x10-3 
FADS1-2-3 rs174546 11 61.57 known TG T/C + 177,785 7.4x10-38 + 69,718 6.9x10-3 
RSPO3 rs1936800 6 127.44 novel HDL T/C - 187,111 3.1x10-10 - 67,494 7.3x10-3 
JMJD1C rs10761731 10 65.03 known TG A/T + 91,013 8.4x10-12 + 68,336 8.3x10-3 
PINX1 rs11776767 8 10.68 known TG C/G + 177,360 2.9x10-11 - 68,201 1.2x10-2 
TOM1 rs138777 22 35.71 novel TC A/G + 185,274 4.7x10-8 + 67,303 1.4x10-2 
 KAT5 rs12801636 11 65.39 novel HDL A/G + 187,099 3.2x10-8 - 62,171 1.7x10-2 
KCNK17 rs2758886 6 39.25 novel TC A/G + 187,266 3.0x10-8 + 69,242 1.9x10-2 
ABCA1 rs1883025 9 107.66 known HDL T/C - 186,365 1.5x10-65 + 61,161 1.9x10-2 
FTO rs1121980 16 53.81 novel HDL A/G - 185,524 6.8x10-9 - 67,121 2.7x10-2 
MAFB rs2902940 20 39.09 known TC A/G + 185,716 8.8x10-10 + 67,497 2.7x10-2 
SBNO1 rs4759375 12 123.8 known HDL T/C + 94,311 3.0x10-8 + 62,022 2.9x10-2 
APOE rs4420638 19 45.42 known LDL A/G - 93,103 1.5x10-178 + 43,118 3.2x10-2 
ARL15 rs6450176 5 53.3 known HDL A/G - 187,132 6.9x10-10 + 65,297 3.3x10-2 
KLF14 rs4731702 7 130.43 known HDL T/C + 187,085 4.8x10-17 - 68,636 3.5x10-2 
PEPD rs731839 19 33.9 novel TG A/G - 176,161 2.7x10-9 - 62,641 3.9x10-2 
CYP26A1 rs2068888 10 94.84 known TG A/G - 177,712 1.7x10-11 - 56,303 3.9x10-2 
MTMR3 rs5763662 22 30.38 novel LDL T/C + 162,777 1.2x10-8 + 58,243 4.4x10-2 
TYW1B rs13238203 7 72.13 known TG T/C - 101,951 3.1x10-6 - 34,202 4.6x10-2 
CMIP rs2925979 16 81.53 known HDL T/C - 185,553 1.3x10-19 + 65,526 4.7x10-2 
 
**International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB et al. Genetic variants in novel 
pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478(7367):103-9 
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Supplementary Table S2.12-D: Novel and Known Lipid Loci with SBP P-value < 0.05 from ICBP* 
 
Locus SNP Chr hg19 Pos (Mb) Type Trait A1/A2 
Lipid 
Direction Lipid N Lipid P-value 
SBP 
Direction SBP N SBP P-value 
BRAP rs11065987 12 112.07 known TC A/G + 187,309 2.1x10-16 - 62,444 2.1x10-8 
SLC39A8 rs13107325 4 103.19 known HDL T/C - 179,316 1.1x10-15 - 58,910 2.6x10-7 
VEGFA rs998584 6 43.76 novel TG A/C + 174,573 3.4x10-15 + 49,585 9.3x10-5 
CITED2 rs605066 6 139.83 known HDL T/C + 94,311 2.8x10-8 - 68,154 1.1x10-3 
LACTB rs2652834 15 63.4 known HDL A/G - 185,613 3.6x10-11 + 61,931 2.6x10-3 
KCNK17 rs2758886 6 39.25 novel TC A/G + 187,266 3.0x10-8 + 69,249 2.9x10-3 
PABPC4 rs4660293 1 40.03 known HDL A/G + 187,027 2.9x10-18 - 69,821 3.0x10-3 
 KAT5 rs12801636 11 65.39 novel HDL A/G + 187,099 3.2x10-8 - 62,173 3.7x10-3 
KLF14 rs4731702 7 130.43 known HDL T/C + 187,085 4.8x10-17 - 68,646 7.0x10-3 
MTMR3 rs5763662 22 30.38 novel LDL T/C + 162,777 1.2x10-8 + 58,275 1.8x10-2 
DAGLB rs702485 7 6.45 novel HDL A/G - 186,974 6.5x10-12 + 67,622 2.2x10-2 
RSPO3 rs1936800 6 127.44 novel HDL T/C - 187,111 3.1x10-10 - 67,485 2.5x10-2 
PLEC1 rs11136341 8 145.04 known LDL A/G - 82,810 7.1x10-12 + 45,602 2.7x10-2 
TOM1 rs138777 22 35.71 novel TC A/G + 185,274 4.7x10-8 + 67,285 3.0x10-2 
CSNK1G3 rs4530754 5 122.86 novel LDL A/G + 173,003 3.6x10-12 - 69,174 3.3x10-2 
HFE rs1800562 6 26.09 known LDL A/G - 171,209 8.3x10-14 + 65,402 3.3x10-2 
MVK rs7134594 12 110 known HDL T/C + 94,311 1.8x10-13 + 69,719 3.9x10-2 
PEPD rs731839 19 33.9 novel TG A/G - 176,161 2.7x10-9 - 62,643 4.1x10-2 
LOC55908 rs737337 19 11.35 known HDL T/C + 185,432 4.6x10-17 - 61,587 4.1x10-2 
PDE3A rs7134375 12 20.47 known HDL A/C + 187,088 1.1x10-8 - 63,215 4.3x10-2 
 
*International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB et al. Genetic variants in novel pathways 
influence blood pressure and cardiovascular disease risk. Nature. 2011;478(7367):103-9 
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Supplementary Table S2.12-E: Novel and Known Lipid Loci with Fasting Glucose P-value < 0.05 from MAGIC* 
 
Locus SNP Chr hg19 Pos (Mb) Type Trait A1/A2 Lipid Direction Lipid N 
Lipid 
P-value 
FG 
Effect 
FG 
P-value 
GCKR rs1260326 2 27.73 known TG T/C + 177,765 2.3x10-239 -0.027 4.3x10-13 
FADS1-2-3 rs174546 11 61.57 known TG T/C + 177,785 7.4x10-38 -0.021 2.7x10-8 
PPP1R3B rs9987289 8 9.18 known HDL A/G - 169,235 2.0x10-41 0.028 7.5x10-6 
HBS1L rs9376090 6 135.41 novel TC T/C + 187,263 2.6x10-9 0.014 1.1x10-3 
DNAH11 rs12670798 7 21.61 known TC T/C - 187,287 9.5x10-17 0.014 1.5x10-3 
TRPS1 rs2293889 8 116.6 known HDL T/G - 180,102 4.3x10-17 0.011 2.3x10-3 
TOM1 rs138777 22 35.71 novel TC A/G + 185,274 4.7x10-8 0.012 3.1x10-3 
LIPC rs1532085 15 58.68 known HDL A/G + 185,482 1.2x10-188 -0.011 4.9x10-3 
LRP1 rs11613352 12 57.79 known TG T/C - 177,799 9.4x10-14 -0.012 5.8x10-3 
INSR rs7248104 19 7.22 novel TG A/G - 176,083 5.1x10-10 0.0085 2.1x10-2 
NPC1L1 rs2072183 7 44.58 known TC C/G + 183,969 4.2x10-15 -0.012 2.1x10-2 
ABCA1 rs1883025 9 107.66 known HDL T/C - 186,365 1.5x10-65 0.01 2.2x10-2 
APOB rs1367117 2 21.26 known LDL A/G + 173,007 9.5x10-183 -0.009 2.8x10-2 
UGT1A1 rs11563251 2 234.68 novel TC T/C + 187,107 1.3x10-9 0.014 3.1x10-2 
STARD3 rs11869286 17 37.81 known HDL C/G + 177,918 2.7x10-17 -0.0078 4.1x10-2 
MVK rs7134594 12 110 known HDL T/C + 94,311 1.7x10-13 0.0075 4.4x10-2 
PABPC4 rs4660293 1 40.03 known HDL A/G + 187,027 2.9x10-18 -0.0087 4.5x10-2 
 
*Data on glycaemic traits have been contributed by MAGIC investigators and have been downloaded from 
www.magicinvestigators.org; Dupuis J et al. New genetic loci implicated in fasting glucose homeostasis and 
their impact on type 2 diabetes risk. Nat Genet. 2010;42:105-16 
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Supplementary Table S2.12-F: Novel and Known Lipid Loci with T2D P-value < 0.05 from DIAGRAM* 
 
Locus SNP chr hg19 Pos (Mb) Type Trait A1/A2 
Lipid 
Direction Lipid N 
Lipid 
P-value T2D N 
T2D OR 
(95% CI) 
T2D 
P-value 
FTO rs1121980 16 53.81 novel HDL A/G - 185,524 6.8x10-9 22,570 1.12 (1.07,1.26) 1.4x10-7 
KLF14 rs4731702 7 130.43 known HDL T/C + 187,085 4.8x10-17 22,570 -1.10 (-1.06,-1.15) 2.1x10-6 
APOE rs4420638 19 45.42 known LDL A/G - 93,103 1.5x10-178 18,352 1.15 (1.07,1.23) 5.4x10-5 
IRS1 rs2972146 2 227.1 known HDL T/G - 184,044 1.9x10-17 22,570 1.09 (1.04,1.13) 9.0x10-5 
ARL15 rs6450176 5 53.3 known HDL A/G - 187,132 6.9x10-10 22,570 1.09 (1.04,1.14) 4.0x10-4 
MAP3K1 rs9686661 5 55.86 known TG T/C + 177,050 2.5x10-16 22,570 1.09 (1.03,1.14) 1.7x10-3 
CILP2 rs10401969 19 19.41 known TC T/C + 185,667 4.1x10-77 22,570 -1.14 (-1.04,-1.24) 3.1x10-3 
HNF1A rs1169288 12 121.42 known TC A/C - 175,774 3.9x10-17 22,570 -1.06 (-1.02,-1.11) 4.7x10-3 
CMIP rs2925979 16 81.53 known HDL T/C - 185,553 1.3x10-19 21,198 1.07 (1.02,1.12) 4.9x10-3 
NPC1L1 rs2072183 7 44.58 known TC C/G + 183,969 4.2x10-15 17,302 -1.10 (-1.03,-1.18) 5.0x10-3 
COBLL1 rs12328675 2 165.54 known HDL T/C - 187,092 2.1x10-15 22,570 1.08 (1.02,1.16) 1.2x10-2 
ABO rs9411489 9 136.155 known LDL T/C + 119,312 1.8x10-41 21,520 1.07 (1.01,1.13) 1.5x10-2 
VEGFA rs998584 6 43.76 novel TG A/C + 174,573 3.4x10-15 17,302 1.07 (1.01,1.13) 1.8x10-2 
GPAM rs2255141 10 113.93 known TC A/G + 187,266 6.5x10-16 22,570 -1.05 (-1.01,-1.10) 2.1x10-2 
FADS1-2-3 rs174546 11 61.57 known TG T/C + 177,785 7.4x10-38 22,570 -1.04 (-1.01,-1.09) 2.6x10-2 
MC4R rs12967135 18 57.85 known HDL A/G - 153,533 3.6x10-8 22,570 1.05 (1.01,1.10) 2.9x10-2 
LIPC rs1532085 15 58.68 known HDL A/G + 185,482 1.2x10-188 22,570 -1.05 (-1.00,-1.09) 2.9x10-2 
HNF4A rs1800961 20 43.04 known HDL T/C - 157,871 1.6x10-34 13,971 1.14 (1.00,1.30) 4.7x10-2 
*Voight BF et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. 
Nat Genet. 2010;42:579–589 
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Supplementary Table S2.12-G: Novel and Known Lipid Loci with WHR adj BMI P-value < 0.05 from GIANT* 
 
Locus SNP Chr 
hg19 Pos 
(Mb) Type Trait A1/A2 
Lipid 
Direction Lipid N 
Lipid  
P-value 
WHR 
Direction WHR N 
WHR  
P-value 
RSPO3 rs1936800 6 127.44 novel HDL T/C - 187,111 3.1x10-10 + 77,164 5.0x10-14 
VEGFA rs998584 6 43.76 novel TG A/C + 174,573 3.4x10-15 + 72,804 3.2x10-9 
ZNF664 rs4765127 12 124.46 known HDL T/G + 94,198 7.8x10-10 - 77,048 1.8x10-5 
COBLL1 rs12328675 2 165.54 known HDL T/C - 187,092 2.1x10-15 + 77,160 2.8x10-5 
C4orf52 rs10019888 4 26.06 novel HDL A/G + 187,077 4.9x10-8 - 77,165 5.1x10-5 
MAP3K1 rs9686661 5 55.86 known TG T/C + 177,050 2.5x10-16 + 77,164 8.0x10-5 
CITED2 rs605066 6 139.83 known HDL T/C + 94,311 2.8x10-8 - 77,164 1.3x10-4 
TOM1 rs138777 22 35.71 novel TC A/G + 185,274 4.7x10-8 + 77,218 2.8x10-4 
GCKR rs1260326 2 27.73 known TG T/C + 177,765 2.3x10-239 + 77,128 3.4x10-4 
FAM13A rs3822072 4 89.74 novel HDL A/G - 187,115 4.1x10-12 + 77,163 3.5x10-4 
FN1 rs1250229 2 216.3 novel LDL T/C - 173,032 3.1x10-8 + 77,155 6.6x10-4 
APOE rs4420638 19 45.42 known LDL A/G - 93,103 1.5x10-178 + 69,832 8.5x10-4 
STAB1 rs13326165 3 52.53 novel HDL A/G + 187,134 9.0x10-11 - 77,168 1.0x10-3 
CILP2 rs10401969 19 19.41 known TC T/C + 185,666 4.1x10-77 - 77,160 2.5x10-3 
ERGIC3 rs2277862 20 34.15 known TC T/C - 185,738 5.3x10-11 - 77,165 9.9x10-3 
TOP1 rs6029526 20 39.67 known LDL A/T + 88,433 4.8x10-18 + 77,165 1.0x10-2 
KCNK17 rs2758886 6 39.25 novel TC A/G + 187,266 3.0x10-8 + 77,167 1.2x10-2 
CMIP rs2925979 16 81.53 known HDL T/C - 185,553 1.3x10-19 + 77,164 1.5x10-2 
ARL15 rs6450176 5 53.3 known HDL A/G - 187,131 6.9x10-10 - 77,165 1.8x10-2 
ACAD1 rs17404153 3 132.16 novel LDL T/G - 172,898 1.8x10-9 - 77,166 1.9x10-2 
PPP1R3B rs9987289 8 9.18 known HDL A/G - 169,234 1.9x10-41 + 77,170 2.0x10-2 
MYLIP rs3757354 6 16.13 known LDL T/C - 172,986 2.1x10-17 - 72,863 2.6x10-2 
HBS1L rs9376090 6 135.41 novel TC T/C + 187,263 2.6x10-9 - 77,165 3.3x10-2 
ANXA9-CERS2 rs267733 1 150.96 novel LDL A/G + 164,562 5.3x10-9 - 77,162 4.1x10-2 
 LRPAP1 rs6831256 4 3.47 novel TG A/G - 177,494 1.6x10-12 - 77,141 4.1x10-2 
NAT2 rs1495741 8 18.27 known TG A/G - 87,977 2.7x10-12 + 77,166 4.6x10-2 
TTC39B rs581080 9 15.31 known HDL C/G + 186,937 1.0x10-19 + 77,165 4.9x10-2 
*Heid IM et al. Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of 
fat distribution. Nat Genet 2010;42, 949-960. 
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Supplementary Table S2.13: Overlap of Lipid Subfractions in Framingham with Novel and Known Lipid Associated Loci 
(P<1.4x10-5) 
Locus SNP Lipid Subfraction Trait* A1/A2 N MAF Beta P-value 
Novel 
Lipid 
Locus 
Lipid P-
value 
Overlap of Lipid Subfractions with HDL Loci 
LIPC rs1532085 HDL2 cholesterol subfraction A/G 2,900 0.38 0.13 2x10-06 N 1x10-188 
LIPC rs1532085 HDL size A/G 2,742 0.38 0.17 4x10-09 N 1x10-188 
LIPC rs1532085 Large particles of HDL A/G 2,742 0.38 0.16 6x10-08 N 1x10-188 
CETP rs3764261 Intermediate density lipoprotein A/C 2,742 0.31 -0.16 9x10-08 N 1x10-769 
CETP rs3764261 HDL2 cholesterol subfraction A/C 2,900 0.31 0.18 1x10-09 N 1x10-769 
CETP rs3764261 LDL size A/C 2,742 0.31 0.17 7x10-08 N 1x10-769 
CETP rs3764261 Large particles of LDL A/C 2,742 0.31 0.14 9x10-06 N 1x10-769 
CETP rs3764261 HDL size A/C 2,742 0.31 0.19 6x10-10 N 1x10-769 
CETP rs3764261 Large particles of HDL A/C 2,742 0.31 0.22 4x10-13 N 1x10-769 
CETP rs3764261 HDL3 cholesterol subfraction A/C 2,900 0.31 0.23 1x10-14 N 1x10-769 
CETP rs3764261 Apoliprotein AI concentration A/C 2,885 0.31 0.19 4x10-10 N 1x10-769 
LIPG rs7241918 Apoliprotein AI concentration G/T 2,885 0.17 -0.19 2x10-07 N 1x10-44 
PLTP rs6065906 Large particles of HDL C/T 2,742 0.18 -0.18 1x10-06 N 5x10-40 
PLTP rs6065906 Medium particles of HDL C/T 2,742 0.18 0.35 1x10-21 N 5x10-40 
Overlap of Lipid Subfractions with LDL Loci 
SORT1 rs629301 Apolipoprotein B concentration G/T 2,821 0.21 -0.19 2x10-08 N 5x10-241 
ApoE rs4420638 ApoE concentration G/A 2,260 0.16 -0.62 9x10-10 N 2x10-178 
Overlap of Lipid Subfractions with Triglyceride Loci 
GCKR rs1260326 Apolipoprotein CIII concentration T/C 2,484 0.45 0.18 2x10-10 N 2x10-239 
LPL rs12678919 Apoliprotein AI concentration G/A 2,885 0.1 0.2 1x10-05 N 2x10-199 
APOA1 rs964184 Medium particles of VLDL G/C 2,742 0.14 0.26 2x10-10 N 7x10-224 
APOA1 rs964184 Remnant like particles expressed as triglycerides G/C 2,385 0.14 0.2 5x10-06 N 7x10-224 
APOA1 rs964184 Remnant like particles expressed as cholesterol G/C 2,468 0.14 0.19 7x10-06 N 7x10-224 
APOA1 rs964184 Apolipoprotein B concentration G/C 2,821 0.14 0.23 4x10-09 N 7x10-224 
 
*LDL=low density lipoprotein, HDL=high density lipoprotein, VLDL=very low density lipoprotein 
 
 
The threshold used for significance is1.4x10-5. This corresponds to a Bonferroni correction for 23 subfractions and 151 
SNPs found in the lipid subfraction dataset (0.05/(23*151)). 
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Supplementary Figures 
Supplementary Figure S2.1: Study Design 
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Supplementary Figure S2.2: QQ Plots of Metabochip Meta-Analysis P-value Distributions 
Quantile-quantile plots of metabochip meta-analysis observed association –log10 p-values plotted against expected –
log10 p-values.  Points in blue represent the p-value distribution after removing ± 1MB of previously known lipid loci.  
There is reduced inflation of p-values after removing ± 1MB of all genome-wide significant loci (shown in green). 
Lambda values for all Metabochip SNPs were between 1.19 (triglyceride levels) and 1.28 (HDL cholesterol) and reflect 
the enrichment of associated SNPs in the genotyping array.  After removing SNPs within 1 Megabase of previously 
reported associated variants, the lambda values ranged from 1.00 (LDL cholesterol) to 1.10 (HDL cholesterol).  After 
removing SNPs in newly genome-wide significant loci, lambda values reached 1.00 for two traits (LDL cholesterol and 
triglyceride levels) but were at 1.05 for total cholesterol and 1.07 for HDL cholesterol.  The interpretation of genomic 
control values from this experiment is complex because MetaboChip SNPs are heavily concentrated on regions associated 
with lipids and other cardiovascular traits.  The initial genomic control values likely reflect this enrichment; the modestly 
high genomic control value after excluding confirmed regions of association could reflect a combination of polygenic 
effects, additional loci to discover, or population stratification. 
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Supplementary Figure S2.3: Manhattan Plots of Lipid-specific Association Results 
Manhattan plots highlight significant SNP associations for each trait (P< 5x10-8).  Trait-specific novel loci are shown in 
red.  Association results for known markers previously reported to be associated with lipid traits are shown in dark blue 
(when primary trait is the same trait) and light blue (when primary trait is a different lipid trait). 
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Supplementary Figure S2.4: Effect Size vs. Allele Frequency at Lipid Associated Loci 
Lipid effect sizes of SNPs in the GWAS + Metabochip meta-analysis are shown in red (novel lipid loci) in comparison to 
SNPs discovered by previous GWAS efforts (shown in blue and green).  Dotted lines represent power curves for the 
minimum effect sizes that could be identified for a given effect-allele frequency with 10%, 50%, and 90% power, 
assuming sample size 200,000 and alpha level 5x10-8. 
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Supplementary Figure S2.5: Direct Protein-Protein Interactions from Dapple Analysis 
Direct protein-protein interactions for A. HDL-C (8 interactions, P = .002), B. LDL-C (10 interactions, P = .0002), C. 
total cholesterol (6 interactions, P = .017), and D. triglycerides (2 interactions, P = .27) show connections between novel 
and known genes in the same pathways. We tested genes near previously known and new loci. 
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Supplementary Figure S2.6: Lipid vs. CAD Effect Sizes 
Plots show coronary artery disease (CAD) effect sizes against lipid effect sizes for SNPs showing primary 
association with each lipid trait. All effect sizes were oriented to the lipid trait-increasing (or trait-
decreasing for HDL) allele.  Diagonal lines represent regressions of predictor lipid effect sizes by 
outcome CAD effect sizes for SNPs that show primary association with each trait including both 
previously known and newly reported index SNPs. LDL effect sizes were strongly associated with CAD 
effect sizes (Pearson r= 0.74, P =7x10-6).  The correlation between CAD effect size and triglyceride effect 
size (Pearson r= 0.46, P =0.02) was higher than that observed for HDL (Pearson r=-9x10-4, P =0.99).  
Lipid effect sizes were transformed into SD units. 
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Supplementary Figure S2.7: Association with Lipid Subfractions 
Heatmaps show effect sizes for association (P < 0.10) with 23 lipid subfractions in Framingham offspring 
with respect to the trait-decreasing allele of (A) HDL-C and trait-increasing allele of (B) LDL-C, (C) TC, 
and (D) TG.  Significant association (P < 0.05) of lipid-associated SNPs with coronary artery disease 
(CAD) is annotated on the y-axis at both known and novel genetic loci primarily associated with each 
trait.  Dendrogram clustering of loci (y-axis) and lipid subfraction phenotypes (x-axis) based on the effect 
sizes (beta) are also shown. (E) shows a heatmap of correlations for the 23 lipid subfractions in 
Framingham.  F-I show results from Women’s Genome Health Study1.  (J) shows a heatmap of lipid 
subfraction correlations in WGHS. 
 
A. 
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B. 
 
*The beta for the strongest association observed, rs4420638 at the APOE locus and Lapoeser5apc (beta = 
-0.62), is displayed as the minimum (-0.3) so that the color scale for the heatmap is more comparable to 
the heatmaps from the other 3 lipid traits. 
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C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 82
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E. 
 
HDLLG: Large particles of high density lipoprotein concentrations determined by NMR, Exam 4 
HDLSM: Small particles of high density lipoprotein concentrations determined by NMR, Exam 4 
HDLSZ: Weighted average for HDL size based on measurements of HDLP1 through HDLP6, Exam 4 
Lapoeser5*: ApoE concentrations in mg/dL using immunochemical technique by Servia, Exam 5 
LCHYLO*: Chylomicron particles size >220 nm (expressed as TG concentrations in mg/dl) and determined using 
NMR, Exam 4 
LDLINT: Medium particles of low density lipoprotein determined by NMR, Exam 4 
LDLLG: Large particles of low density lipoprotein determined by NMR, Exam 4 
LDLSZ: Weighted average for LDL size based on measurements of LDLP1 through LDLP6 determined by NMR, 
Exam 4 
Lhdl25*: HDL2 cholesterol subfractions after chemical precipitation 
LIDLP*: Intermediate density lipoprotein determined by NMR, Exam 4 
LLDLSM*: Small particles of low density lipoprotein determined by NMR, Exam 4 
Llpaconc*: Lipoprotein(a) concentration, Exam 3 
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LRLP_C*: Remnant like particles measured using selective immunoseparation of lipoproteins using the Otsuka kit. 
Expressed as cholesterol in mg/dL, Exam 4 
LRLP_tg*: Remnant like particles measured using selective immunoseparation of lipoproteins using the Otsuka kit. 
Expressed as triglycerides in mg/dL, Exam 4 
LVLDLINT*: Medium particles of very low density lipoprotein determined by NMR, Exam 4 
LVLDLLG*: Large particles of very low density lipoprotein determined by NMR, Exam 4 
VLDLSM: Small particles of very low density lipoprotein determined by NMR, Exam 4 
VLDLSZ: Weighted average for VLDL size based on measurements of VLDLP1 through VLDLP6 determined by 
NMR, Exam 4 
 
*log transformed 
All models were adjusted for age, sex and PCs. Low-, high-, intermediate- and very low-density lipoprotein particle 
concentrations were measured by nuclear magnetic resonance. 
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llp: LDL large  hmp: HDL medium   vsp: VLDL small 
lsp: LDL small  ln.hmp: ln [HDL medium]  vz: VLDL mean size 
ln.lsp: ln [LDL small] hsp: HDL small    ntg: TG by NMR 
lz: LDL mean size hz: HDL mean size   ln.ntg: ln [TG by NMR] 
idlp: IDL total  nhc: HDL-C by NMR   TGGB: TG assay 
ln.idlp: ln [IDL total] HDL: HDL-C assay   ln.TGGB: ln[TG assay] 
ldlp: LDL total  vldlcp: VLDL total   CHOL: Total Cholesterol 
ln.ldlp: ln [LDL total] vlcp: VLDL large 
LDL: LDL-C assay ln.vlcp: ln [VLDL large] 
hdlp: HDL total  vmp: VLDL medium 
hlp: HDL large  ln.vmp: ln [VLDL medium] 
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Supplementary Note: Candidate Genes at Novel Loci 
The list of notable genes in newly identified loci, below, is meant to provide an overview of the 
diverse set of loci associated with blood lipids in our study. Although the list can provide a 
starting point for exploration of these loci and help motivate follow-up studies and/or 
hypotheses, the list should not be considered exhaustive.  
 
ABCB11 (ATP-binding cassette, sub-family B, member 11) is involved in the ATP-dependent 
secretion of bile salts (MIM 603201). Hepatic overexpression of Abcb11 in mice increased 
absorption of cholesterol and promoted diet-induced obesity and hypercholesterolemia (Henkel 
et al. 2011). G6PC2 encodes a glucose-6-phosphatase catalytic subunit (MIM 608058).  Variants 
at this locus have been implicated in liver enzyme and fasting glucose levels (Chambers et al. 
2011; Chen et al. 2008). 
 
ACAD11 (acyl-CoA dehydrogenase family, member 11) is involved in the β-oxidation of 
long-chain fatty acids in muscle and heart (MIM 614288).  
 
ADH5 (alcohol dehydrogenase 5 (class III), chi polypeptide) encodes a protein involved in 
oxidation of long-chain primary alcohols and which catalyzes a step in the elimination of 
formaldehyde (MIM 103710). 
 
AKR1C4 (aldo-keto reductase family 1, member C4) encodes a protein that produces 
intermediates in bile acid biosynthesis and inactivates circulating steroid hormones (MIM 
600451). AKR1C4 is expressed exclusively in the liver and is transcriptionally regulated by 
LXRA. 
ANGPTL1 (angiopoietin-like 1 gene) is a member of the angiopoietin family involved in 
angiogenesis, and widely expressed in highly vascularized tissues (MIM 603874).  
 
ANXA9 (annexin A9) and CERS2 (ceramide synthase 2). ANXA9 is a calcium-dependent 
phospholipid-binding protein (MIM 603319). CERS2 is involved in regulation of long acyl chain 
and sphingolipid metabolism (MIM 606920). 
 
APOH (Apolipoprotein H, also known as beta-2 glycoprotein I) and PRKCA (protein kinase 
C, alpha) APOH is a glycoprotein that is involved in the activation of lipoprotein lipase and 
which neutralizes negatively charged phospholipids (MIM 138700). PRKCA is activated by 
APOA1 and diacylglycerol during cholesterol mobilization (MIM 176960) (Ito et al. 2004). 
 
ASAP3 (ArfGAP with SH3 domain, ankyrin repeat and PH domain 3)is a GTPase-activating 
protein that promotes cell differentiation and migration and has been implicated in cancer cell 
invasion (Ha et al. 2008).  
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ATG7 (autophagy related 7) encodes a protein that is part of the autophagy machinery (MIM 
608760). Dysfunction in autophagy canimpact systems related to intracellular energy utilization 
andpromote apoptotic cell death.  
 
BRCA2 (breast cancer 2, early onset) is involved in maintenance of genome stability, 
specifically the homologous recombination pathway for repair of double stranded DNA.  
Variants in the region can increase risk of breast and other types of cancer (MIM 600185). 
 
C4orf52 (chromosome 4 open reading frame 52). The nearest gene to the lead signal is an 
uncharacterized gene with unknown function, and there are no other obvious candidate genes in 
the locus. 
 
CMTM6 (CKLF-like MARVEL). This gene belongs to the chemokine-like factor gene 
superfamily, but the exact function of the encoded protein is unknown (MIM 607889).  
 
CPS1 (carbamoyl-phosphate synthase 1, mitochondrial) encodes a mitochondrial enzyme that 
catalyzes the first committed step of the urea cycle (MIM 608307).  The lead variant encodes a 
threonine to asparagine substitution previously associated with levels of homocysteine and 
fibrinogen (Pare et al. 2009; Danik et al. 2009). 
 
CSNK1G3 (casein kinase 1, gamma 3) encodes a serine/threonine-protein kinase that is 
involved in a number of cellular processes including DNA repair, cell division, nuclear 
localization and membrane transport (MIM 604253). 
 
DAGLB (diacylglycerol lipase, beta) catalyzes the hydrolysis of diacylglycerol (DAG) to 2-
arachidonoyl-glycerol, an abundant endocannabinoid (MIM 614016). Endocannabinoids 
function signaling molecules, regulate axonal growth, and drive adult neurogenesis (Bisogno et 
al. 2003). 
 
DLG4 (discs, large homolog 4) encodes a membrane-associated guanylate kinase and may 
function at postsynaptic sites (MIM 602887).  Nearby, DVL2 may also play a role in signal 
transduction (MIM 602151) and CTDNEP1 is involved in a phosphatase cascade regulating 
nuclear membrane biogenesis (MIM 610684) (Kim et al. 2007). SLC2A4 is an insulin-regulated 
glucose transporter (MIM 138190). The variant identified here was previously associated with 
alkaline phosphatase levels in plasma (Chambers et al. 2011). 
 
EHBP1 (EH domain binding protein 1) The mouse homologue of EHBP1 was down-regulated 
in a transgenic Pcsk9 mouse model and up-regulated in a Pcsk9 knockout mouse (Denis et al. 
2011). 
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FAM13A (family with sequence similarity 13, member A). FAM13A has a putative role in 
signal transduction, and gene expression has been shown to be increased in response to hypoxia 
in cell lines from several tissues (MIM 613299).  
 
FAM117B (family with sequence similarity 117, member B) is an uncharacterized protein. 
Nearby, BMPR2 encodes a bone morphogenetic protein receptor (MIM 600799). Defects in 
BMPR2 cause primary pulmonary hypertension.   
 
FN1 (fibronectin 1) is a glycoprotein involved in cell adhesion and migration processes 
including embryogenesis, wound healing, blood coagulation, host defense, and metastasis (MIM 
135600). Fibronectin is one of the first extracellular matrix proteins deposited at atherosclerosis-
prone sites, and is central in the formation of atherosclerotic lesions (Rohwedder et al. 2012). 
 
FTO (fat mass and obesity associated) contributes to the regulation of the global metabolic 
rate, energy expenditure and energy homeostasis (MIM 610966). Variants in this gene have been 
repeatedly associated with obesity-related phenotypes, and it may act through hypothalamic 
regulation of food intake (Frayling et al. 2007; Fischer et al. 2009). 
 
GPR146 (G protein-coupled receptor 146) is an orphan G protein-coupled receptor. While no 
ligand has yet been identified, knockout mice exhibit reduced cholesterol levels (U. S. Patent 
Filing 20090036394). The adjacent gene, GPER encodes the intracellular G protein-coupled 
estrogen receptor 1 (MIM 601805).   
 
GSK3B (glycogen synthase kinase 3 beta) encodes a kinase involved in energy metabolism, 
neuronal cell development, and body pattern formation (MIM 605004). In mice, Gsk3b activity 
regulates pancreatic islet beta cell growth (Liu et al. 2010). Nearby, NR1I2 encodes a nuclear 
receptor that can form a heterodimer with retinoic acid receptor RXR and involved with 
homeostasis of numerous metabolites, including lipids (MIM 603065). 
 
HAS1 (hyaluronan synthase 1) is one of three isozymes that synthesize hyaluronic acid, 
produced during wound healing and tissue repair to provide a framework for growth of blood 
vessels and fibroblasts (MIM 601463). The nearest gene, FPR3 (formyl peptide receptor 3) is 
involved in host defense and inflammation (MIM 136539). 
 
HBS1L (HBS1-like, S. cerevisiae) encodes a member of the GTP-binding elongation factor 
family (MIM 612450) (Wallrapp et al. 1998). Variants at this locus regulate persistence of fetal 
hemoglobinin adults and other haematological traits (Uda et al. 2008; Soranzo et al. 2009). 
 
HDGF (hepatoma derived growth factor) and PMVK (phosphomevalonate kinase).HDGFis 
a growth factor that may be involved in cell proliferation and differentiation (MIM 600339). 
 93
PMVK catalyzes the fifth reaction of the cholesterol biosynthetic pathway (MIM 607622). 
Nearby, CRABP2 (cellular retinoic acid binding protein 2) encodes a cytosol-to-nuclear shuttling 
protein involved in the retinoid signaling pathway (MIM 180231) (Majumdar et al. 2011). 
 
IKZF1 (IKAROS family zinc finger 1) is a transcription factor that regulates the low-density 
lipoprotein receptor in certain cell types (Loeper et al. 2008). 
 
INSIG2 (insulin induced gene 2). INSIG2 influences cholesterol metabolism, lipogenesis, and 
glucose homeostasis in diverse tissues (MIM 608660).   
 
INSR (insulin receptor) is a transmembrane tyrosine kinase receptor that binds insulin and 
stimulates glucose uptake (MIM 147670). The receptor activates several downstream pathways. 
 
LOC84931 (uncharacterized gene). The nearest gene to the lead signal is an uncharacterized 
gene with unknown function, and there are no obvious candidate genes in the region. 
 
LRPAP1 (low density lipoprotein receptor-related protein associated protein 1) encodes a 
chaperone for the lipoprotein receptor-related proteins (MIM 104225).  Lrpap1 knockout mice 
exhibit impaired export of LRP2 and VLDL receptors from the endoplasmic reticulum.   
 
KAT5 (K(lysine) acetyltransferase 5). KAT5 is a positive regulator of PPARG transcription 
involved in adipogenesis (can Beekum et al. 2008).  
 
KCNK17 (potassium channel, subfamily K, member 17) passes outward current under 
physiological potassium concentrations (MIM 607370).  Variants ~50 kb away at KCNK16 have 
been implicated in type 2 diabetes (Cho et al. 2012).   
 
MARCH8 (membrane-associated ring finger (C3HC4) 8, E3 ubiquitin protein ligase) and 
ALOX5 (arachidonate 5-lipoxygenase) MARCH8 induces the internalization of several 
membrane glycoproteins (MIM 613335). ALOX5 is a lipid metabolism enzyme that catalyzes 
the conversion of arachidonic acid to leukotrienes, inflammatory mediators implicated in 
atherosclerosis and several cancers (MIM 152390).  
 
MET (met proto-oncogene (hepatocyte growth factor receptor))encodes a receptor tyrosine 
kinase that regulates hepatocytecell proliferation, migration and survival (MIM 164860) (Yu et 
al. 2010; Zou et al. 2007). 
 
MIR148A (microRNA 148a). MicroRNAs are short non-coding RNAs involved in post-
transcriptional regulation of gene expression. miR-148a has been implicated in several cancers 
(MIM 613786) (Zhou et al. 2012; Zheng et al. 2011).  
 94
 
MOGAT2 (monoacylglycerol O-acyltransferase 2) and DGAT2 (diacylglycerol O-
acyltransferase 2). MOGAT2 plays a central role in absorption of dietary fat in the small 
intestine (Cao et al. 2004). DGAT2 encodes one of two enzymes that catalyze the final reaction 
in the synthesis of triglycerides, in which diacylglycerol is covalently bound to long chain fatty 
acyl-CoA (MIM 606983). 
 
MPP3 (membrane protein, palmitoylated 3) is a membrane-associated guanylate kinase that 
regulates trafficking and processing of cell-cell adhesion molecule nectin-1α (MIM 601114).  
 
MTMR3 (myotubularin related protein 3) encodes a phosphatase that binds to 
phosphoinositide lipids (MIM 603558). 
 
OR4C46 (olfactory receptor, family 4, subfamily C, member 46). This signal is located in a 
cluster of G-protein-coupled olfactory receptors, including OR5W2, OR5D13, and OR5AS1 
(MIM 614273).  
 
PDXDC1 (pyridoxal-dependent decarboxylase domain containing 1). Little is known about 
this decarboxylase (MIM 614244). Variants at this locus have been shown previously to be 
associated with circulating sphingolipid levels (Demirkan et al. 2012). About 300 kb away, 
PLA2G10 encodes a protein that releases arachidonic acid from cell membrane phospholipids 
(MIM 603603). 
 
PEPD (peptidase D) encodesan enzyme that hydrolyzes peptides with C-terminal proline or 
hydroxyproline residues and helps recycle proline (MIM 613230). Also at this locus are the 
genes encoding transcription factors CCAAT/enhancer binding protein alpha and gamma 
(CEBPA (MIM 116897), CEBPG (MIM 138972)), involved in adipogenesis. Variants in this 
locus are associated with adiponectin levels and type 2 diabetes in East Asians (Cho et al. 2012; 
Dastani et al. 2012). 
 
PHC1 (polyhomeotic homolog 1) and A2ML1 (alpha-2-macroglobulin-like 1) is required to 
maintain the transcriptionally repressed state of many genes (MIM 602978). A2ML1 is an 
inhibitor for several proteases and binds to low density lipoprotein receptor-related protein 1 
(MIM 610627) (Galliano et al. 2008). 
 
PHLDB1 (pleckstrin homology-like domain, family B, member 1). PHLDB1 is an insulin-
responsive protein that enhances Akt activation, and PHLDB1 expression is increased during 
adipocyte differentiation (MIM 612834) (Zhou et al. 2010). 
 
PIGV (phosphatidylinositol glycan anchor biosynthesis, class V) and NR0B2 (nuclear 
 95
receptor subfamily 0, group B, member 2).  PIGV is a mannosyl transferase that plays a role in 
multiple cellular processes, including protein sorting and signal transduction (MIM 610274). 
NR0B2 is a transcriptional regulator involved in cholesterol, bile acid, and fatty acid metabolism 
and glucose-energy homeostasis.  
 
PPARA (peroxisome proliferator activated receptor alpha) encodes a nuclear transcription 
factor that regulates fatty acid synthesis, and oxidation and gluconeogenesis (MIM 170998). 
PPARA regulates the expression of lipoprotein receptors and cholesterol transporters involved in 
the reverse cholesterol transport pathway. 
 
PXK (PX domain containing serine/threonine kinase) plays a critical role in epidermal growth 
factor receptor trafficking by modulating ubiquitination of the receptor (MIM 611450) (Takeuchi 
et al. 2010).  
 
RBM5 (RNA binding motif protein 5) is a hypothetical tumour suppressor gene encoding a 
nuclear RNA binding protein involved in the induction of cell cycle arrest and apoptosis (MIM 
606884). Nearby, MST1R encodes macrophage stimulating 1 receptor and is involved in host 
defense (MIM 600168). 
 
RSPO3 (R-spondin 3). RSPO3 encodes a protein that regulates beta-catenin signaling, promotes 
angiogenesis and vascular development (MIM 610574). In mouse, Rspo3 is required for Vegf 
expression and endothelial cell proliferation (Kazanskaya et al. 2008). Variants in this locus are 
associated with waist-hip ratio (Heid et al. 2010), bone mineral density (Duncan et al. 2011) and 
renal traits (Kim et al. 2011). 
 
SETD2 (SET domain containing 2) encodes a histone methyltransferase specific for lysine-36 
of histone H3, a mark associated with active chromatin (MIM 612778). Nearby, NBEAL2 
encodes neurobeachin-like 2, which may play a role in megakaryocyte alpha-granule biogenesis 
(MIM 614169). 
 
SNX5 (sorting nexin 5) encodes a protein that binds to phosphatidylinositol 4,5-bisphosphate 
and is involved in intracellular transport of cargo receptors from endosomes to the trans-Golgi 
network (MIM 605937) (Koharudin et al. 2009). 
 
SNX13 (sorting nexin 13). This gene belongs to the sorting nexin (SNX) family and the 
regulator of G protein signaling (RGS) family (MIM 606589). It may be involved in several 
stages of intracellular trafficking. 
 
SOX17 (SRY (sex determining region Y)-box 17) encodes a transcription regulator that plays a 
key role in the regulation of embryonic development and is required for normal looping of the 
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embryonic heart tube (MIM 610928).  
 
SPTLC3 (serine palmitoyltransferase, long chain base subunit 3). SPTLC3 catalyzes the rate-
limiting step of the de novo synthesis of sphingolipids (MIM 611120).  Variants at this locus are 
associated with circulating sphingolipid levels (Hicks et al. 2009). 
 
STAB1 (stabilin 1) encodes a large, transmembrane receptor involved in angiogenesis, 
lymphocyte homing, cell adhesion, and receptor scavenging (MIM 608560). STAB1 mediates 
endocytosis of various ligands, including low-density lipoprotein (Li et al. 2011). Variants at this 
locus have been associated with waist-hip ratio (Heid et al. 2010). 
 
TMEM176A (transmembrane protein 176A) is a transmembrane protein (MIM 610334).  
TOM1 (target of myb1). TOM1 shares its N-terminal domain in common with proteins 
associated with vesicular trafficking at the endosomes (MIM 604700). Nearby, HMOX1 encodes 
an essential enzyme in heme catabolism (MIM 141250). Hmox1 knockout mice have low plasma 
triglycerides and altered composition of HDL (Ishikawa et al. 2012). 
 
UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1). This complex locus 
encodes several glycosyltransferases that transform small lipophilic molecules, such as steroids, 
bilirubin, hormones, and drugs, into water-soluble excretable metabolites (MIM 191740). 
Variants at this locus are associated with serum bilirubin levels. 
 
VEGFA (vascular endothelial growth factor A) encodes a growth factor active in angiogenesis 
and endothelial cell growth, promoting cell migration, and inhibiting apoptosis (MIM 192240). 
Variants in this locus are associated with waist-hip ratio (Heid et al. 2010). 
 
VIM (vimentin) and CUBN (cubilin, intrinsic factor-cobalamin receptor).VIM is an 
intermediate filament that controls the transport of LDL-derived cholesterol from a lysosome to 
the site of esterification (MIM 193060) (Sarria et al. 1992). CUBN is a receptor for high-density 
lipoproteins/apolipoprotein A-I, intrinsic factor-vitamin B12, and albumin (MIM 602997). 
 
VLDLR (very low density lipoprotein receptor) binds VLDL and other lipoproteins and 
transports them into cells (MIM 192977). VLDLR is expressed on the capillary endothelium of 
skeletal muscle, heart, and adipose tissue (Wyne et al. 1996). 
 
ZBTB42 (zinc finger and BTB domain containing 42) and AKT1 (v-akt murine thymoma 
viral oncogene homolog 1) ZBTB42is a DNA-binding transcriptional repressor (MIM 613915). 
AKT1 is a serine-threonine protein kinase that is activated by platelet-derived growth factor 
(MIM 164730). The Akt signaling pathway controls multiple cellular functions in the 
cardiovascular system, and murine Akt1 has an atheroprotective role (Ding et al. 2012). 
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Chapter 3: Prioritizing Functional Variants in Genetic Association Studies 
 
Introduction 
Genome-wide association studies, which examine millions of genetic variants across 
thousands of individuals, have identified many complex trait associated loci. Most of these loci 
include many strongly associated variants in linkage disequilibrium with each other and 
exhibiting similar evidence for association. The large number of variants showing evidence for 
association in each locus makes it challenging to prioritize likely functional variants.  
Information regarding biological plausibility can help prioritize SNPs for follow-up 
(Minelli et al. 2013). SNPs where annotation suggests a functional role are significantly enriched 
in loci associated with human diseases (Schaub et al. 2012). Importantly, the SNP most strongly 
supported by experimental evidence is often not the SNP where association peaks but another 
nearby SNP in linkage disequilibrium (Schaub et al. 2012). Several types of biological 
information have been shown to be useful, including impact on coding sequence (Hindorff et al 
2009; Schork et al. 2013), impact on gene expression (Nicolae et al. 2010; Lappalainen et al. 
2013), and impact on transcription factor binding motifs (Maurano et al. 2012; Trynka and 
Raychaudhuri 2013).  Some of the earliest searches for overlap between association signals and 
functional annotation focused on eQTLs, which are extremely plentiful (Nicolae et al. 2010). 
Early enrichment analyses demonstrated strong enrichment of eQTLs near transcription factor 
binding sites, particularly near transcription start and end sites (Veyrieras et al. 2008). There is 
also strong enrichment of eQTLs in open chromatin regions and we now know that regulatory 
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annotation can help prioritize SNPs most likely to drive gene expression variation (Gaffney et al. 
2012). Over time, these analyses have become increasingly sophisticated, extending from eQTLs 
to more complex traits and examining functional annotations specific to individual cell types or 
tissues (Global Lipids Genetics Consortium 2013; ENCODE Project Consortium 2012). 
We define “causal” variants as the functional genetic variants that influence the risk for 
disease and explain the observed association. Overall, it is now well accepted that the search for 
causal variants for any trait may be aided by systematically modeling the features they share. For 
example, causal variants for lipid traits might preferentially overlap transcription factor binding 
sites active in liver, where important steps in lipid metabolism take place (Ernst et al. 2011). 
Intuitively, when choosing among two nearby lipid GWAS variants with similar association 
signals, we expect the one which overlaps a liver transcription factor binding site is more likely 
to be causal. Here, we set out to develop a method that quantifies the enrichment of particular 
annotations among the associated variants in a GWAS that is computationally efficient and 
reliably convergent so as to become a part of routine post GWAS analysis. In this way, we hope 
to prioritize variants for follow-up in a systematic and quantitative manner. 
We propose two methods to study enrichment for GWAS: (i) a simpler approach that 
seeks causal variants in loci with genome-wide significant evidence for association and (ii) a 
Bayesian approach that allows for causal variants to reside in loci that do not reach genomewide 
significance. Our methods work with summary level data (effect sizes and standard errors, or p-
values) and thus can be applied conveniently to large samples, including those derived through 
meta-analysis. Using the enrichment analysis results, our method computes a credible set of 
likely causal variants (Maller et al. 2012), narrowing the list of variants to be followed-up. Using 
simulations, we show that our method appropriately controls type I error rates and has 
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comparable or better power than the published method fGWAS (Pickrell 2014).  We demonstrate 
real data applications of our method using publicly available datasets for lipids (Global Lipids 
Genetics Consortium 2013) and schizophrenia (Schizophrenia Working Group of the Psychiatric 
Genomics Consortium 2014). We explore the enrichment of different genomic features such as 
coding variation, overlap with complement genes, and CADD score (Kircher et al. 2014) in 
association data for age-related macular degeneration. We use the UK Biobank dataset (Sudlow 
et al. 2015, Bycroft et al. 2017) to explore the enrichment of eQTL and coding variation among 
GWAS associated variants and find eQTLs to be significantly enriched in 37 of 45 traits while 
nonsynonymous variants are significantly enriched in 19 of 45 traits.  
Methods 
We set out to quantify the relationship between the causal variants for a trait and a 
genomic feature of interest. When there is a set of similarly associated variants, our method aims 
to identify the features that would most effectively at separate out truly causal variants. More 
generally, our method aims to combine association summary statistics and biological feature 
annotation to prioritize variants for follow-up.  
Consider the following contingency table: 
Table 3.1: Example of a Contingency Table if Causal Variants are Known 
 
 Annotated Not Annotated 
Causal a b 
Non-causal c d 
 
If we knew exactly which variants were causal, an odds ratio derived from this table 
would represent how likely a variant with annotation is to be causal relative to a variant without 
the annotation. Unfortunately, we do not know which variants are causal and, instead, expect that 
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in addition to each causal variant many nearby variants in linkage disequilibrium will show 
evidence for association in each locus. Thus, we use an iterative model to estimate expected cell 
counts and make inferences about the importance of a candidate biological feature. 
We begin by dividing the variants into loci assuming each locus has at most one causal 
variant. We then use an initial estimate of the odds ratio to estimate the expected cell counts of 
the table. Next, we use these expected counts to update our odds ratio estimate and repeat the 
process until the estimates converge. This iterative algorithm is computationally efficient and can 
be implemented with only summary level data from single SNP association analysis, namely 
either effect sizes and standard errors or p-values. 
To implement this method, we need to model the multi-SNP association with the trait, 
link annotation to the model and compute the conditional expected values of the cells given 
association summary statistics. 
Modeling the Association 
We begin with observed data from an association study. Let  be the sample size,  the 
trait vector denoting the trait values for each individual under study and  the  ×  genotype 
matrix where  is the total number of SNPs in the study. Let there be  causal loci and let  be 
the number of variants in the  locus and  be the corresponding genotype matrix. 
We model the trait as follows: 
 = 	 +	() +  !"#  
 
where  ∼ %(&, ()*)10 and  is the indicator vector for the  locus denoting which variant is 
causal.  
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To make estimating this model more tractable, we make two simplifying assumptions. 
First, we assume that there is exactly one causal variant in each causal locus. In practice, there 
may be loci with multiple signals in which case we use a conditional analysis approach 
(described later) to model more than one causal variant. Second, we assume that variants from 
different loci are not in linkage disequilibrium and, thus, that causal variants are not in linkage 
disequilibrium with each other. These assumptions allow us to conveniently process loci one at a 
time and derive an approximate solution to the variable selection problem.  Since we expect most 
of the uncertainty about the identity of causal variants to be local, and caused by linkage 
disequilibrium, we expect this approximation captures and tackles the most interesting features 
of the data.  
Note that our simplifying assumption ensures that each  has exactly one entry as 1 and 
the rest as 0. The estimates from the summary level data are for single SNP analysis but we can 
use those to approximate the above multi-SNP model as described in the Supplementary 
Methods. 
Linking the Annotations 
Let +, denote whether the - variant in the  locus has the feature or not, and let . be 
an underlying parameter used to quantify the enrichment of variants with the feature among 
causal variants according to the following model: 
(, = 1	|+,, .) = 	 exp(3 + .45)1 + exp(3 + .45) 
which is a prior imposed on the missing data  which denotes whether a variant is causal or not. 
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. is our principal parameter of interest and represents how much more likely a variant with the 
feature is to be causal compared to the other variants in the locus. We estimate this . defined as 
the log odds ratio from the contingency table (Table 3.1). 
Conditional Expectation 
Assuming exactly one causal variant per locus, for each SNP in a causal locus, the 
probability of being causal incorporating the prior based on annotations conditional on . 
becomes: 
(, = 1	|	, , +, .) = 	 (	|	, +, ., , = 1)	(, = 	|	+, .)	∑ (	|	, +, ., 7 = 1)	87 = 1	9	+, .):;<"#  
Note that since  takes values 0 or 1, the above conditional probability is also the conditional 
expectation of  which denotes the number of causal variants. We use these expected values to 
fill the cells of the contingency table (Table 3.1).  
EM Algorithm 
To implement this method, we begin by defining loci as described below. We start with 
an initial estimate of . and calculate the expected cell counts of the table, which we use to 
estimate an updated value of .. We repeat this process till our estimates converge 
(Supplementary Methods). Note that if any of the cell counts in the contingency table (Table 
3.1) is small, the estimates may fail to converge. This generally occurs if there are too few 
annotated variants with significant p-values in the associated loci, so we report a failure to 
converge and expect that there is no enrichment in such cases. 
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Defining Loci and Modifying the Prior 
Having described a simple strategy for calculating the probability that each variant is 
causal (within a locus) and for estimating our enrichment parameter ., we now proceed to 
outline two approaches for dividing the genome into loci and interpreting the evidence for 
association.  
Simpler Approach: Focusing on Loci that Reach Genome-wide Significance 
In our first approach, we classify loci into two discrete groups at the beginning of our 
analysis. One group consists of trait associated loci, the other includes the remaining non-
associated loci. We begin with the single-SNP analysis results and divide the genome into loci. 
Associated loci are regions near SNPs that are significantly associated with the trait (e.g., 
typically those with p-value < 5	 × 10). We assume that each associated locus has exactly one 
causal variant and that background variants not in the associated loci are never causal. This 
simplification greatly improves computational efficiency, since it allows us to track only a 
simple count of variants in each category outside associated loci. We make further simplifying 
assumptions that the average chi-square for the background variants is 1. Suppose that there are 
>#and > background variants with and without the annotation respectively, and  associated 
loci, we assign the background variants to the associated loci, so that the prior for a variant at 
each locus becomes 
(, = 1	|	+, .) = 	 	exp(.45)> + ># exp(.) + ∑ 	exp8.4<?:;<"#  
This ensures that the background variants are accounted for when estimating the 
enrichment parameter without having to iterate through the association results for the whole 
genome. 
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Proceeding one locus at a time, and using the assumption that there is exactly one causal 
variant per locus, we approximate (Supplementary Methods) 
(	|	, +, ., ) = 	(	|	, +, ., , = 1) ≈ expA12 C5)se8C5?)E	 
where : , = 1, 7 = 0		∀H ≠ -. 
Hence, 
(, = 1	|	, , +, .) ≈ 	
expA12 C5)se8C5?)E 	exp(.45)
∑ expA12 C<
)
se8C<	?)E 	exp8.4<? + J> + ># exp(.)K exp L12M 	:;<"#
 
Here we assumed that the N) test statistic O5 is  
O5 = J C5PQ	8C5?K
)
 
 
and thus, we can approximate 
O5 ≈	CHIDIST#(5,	df = 1) 
where 5 is the p-value for the - marker in the  locus and CHIDIST returns the one-tailed 
probability of the N) distribution function. We can therefore invert the p-values to get the 
corresponding N) test statistic, and implement our method even if the effect sizes and standard 
errors are not available. 
The likelihood contribution of one locus 	is 
Z(.) ≈ 		 (	|	, +, ., , = 1)5 (, = 1	|	+, .)
+ exp [12\ A> + ># exp(.)E 1> + ># exp(.) + ∑ 	exp8.4<?:;<"#  
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= ] expA12 C5
)
se8C5?)E 	exp(.45)
:;
5"#
+ exp [12\A> + ># exp(.)E^	 1> + ># exp(.) + ∑ 	exp8.4<?:;<"#  
We assume that the loci are independent and approximate the joint likelihood by taking a product 
across loci as 
Z(.) ≈ 	_Z(.)  
 
 
An Alternative Bayesian Approach: 
For the Bayesian approach, we divide the variants across the whole genome into loci 
based on LD patterns (Berisa and Pickrell 2016; Pickrell 2014), and assume that each locus  has 
 variants and a probability ` of being causal. We assume that the loci are defined such that 
they contain at most one causal variant. Then,  
` = 	1 −_ 11 + 	exp	(3 + .45)
:;
5"#  
which is obtained by calculating the probability – based on the parameters 3 and  . –  that none 
of the variants in a locus is causal, and then taking the complement of that. For this approach, we 
iterate through the association results for the whole genome to estimate both . and 3. 
The corresponding conditional probability is (Supplementary Methods): 
(, = 1	|, , +, .) = 	 a ∑ exp	(3 + .4b)		cd<b1 + ∑ exp	(3 + .4b)		cdbb e a exp	(.45)	cd5∑ exp	(.4b)cdbb e 
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where cd5< represents the Bayes Factor for the H SNP at the - locus and can be computed 
using summary level data based on single-SNP association analysis (Wen 2014): 
cd5 =	A1 + f)se8C5?)E
#/) 	exp	 h12 f)se8C5?) Lse8C5?) +	f)Mi	C5
)
 
where we assume a %(0, f)) prior on 5 and in practice, average over a range of values of f). 
The joint likelihood then becomes (Supplementary Methods): 
(	|	, +, 3, .) ∝_` ]cd5 	exp	(3 + .45) + 15 ^∈!l  
 
Prioritizing Variants for Follow-up 
We use a Likelihood Ratio to test whether the enrichment parameter . is significantly 
different from null (Supplementary Methods). For each method, we use the estimated . and the 
corresponding log likelihoods to get the test statistic 
Λ = 2(ZZn8.C? − ZZn(0)) 
which follows a N)distribution with 1 degree of freedom. 
If significant (p < 0.05), we use the estimated value of . to calculate the posterior 
probability that each SNP in an associated locus is causal. The 95% credible set for a locus is the 
smallest set of variants in that locus whose posterior probabilities sum up to ≥ 95% (Maller et 
al. 2012).  Thus, we calculate the 95% Bayesian credible set for each locus to get a list of 
variants most likely to be causal. These credible sets can be used to prioritize variants for follow-
up. 
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Loci with Multiple Causal Variants 
The method described thus far assumes that each causal locus has exactly one true causal 
variant and that variants from different loci are not in linkage disequilibrium. In practice, 
conditional analyses of GWAS results often demonstrate that there are multiple causal variants in 
a locus (Hormozdiari et al. 2014). To enable us to prioritize causal variants when there are 
overlapping loci, we use conditional analysis. Specifically, when there are multiple nearby 
independent signals, we first define a super-locus including all variants near these signals. Then, 
we define a series of pseudo-loci by conditioning association statistics in turn on all but one of 
the top independent signals in the region. For example, if conditional analysis indicates 3 distinct 
association signals in one locus, we define 3 pseudo-loci for that locus. Each pseudo locus 
corresponds to one of the distinct association signals and uses association results obtained after 
conditioning on the top variants from the other two signals. This is, admittedly, a rather ad-hoc 
approach to approximate the multi-SNP association model that would be required. Observe that 
in such a scenario, summary level data based on single-SNP analysis can still be used when a 
method such as GCTA (Yang et al. 2011) is used to carry out approximate conditional analyses 
and define the pseudo-loci.  
Application to Multiple Traits 
Phenome-wide Association Studies (PheWAS) involve evaluating the association of a 
single genetic marker with multiple phenotypes (Ye et al. 2015). Decreases in genotyping costs 
have led to large biobanks genotyping all participants making it feasible to conduct PheWAS on 
a genome-wide scale (Bush et al. 2016). Electronic Health Records (EHR) and survey 
questionnaires are leveraged to construct thousands of phenotypes. For example, in the Michigan 
Genomics Initiative (Schmidt et al. 2017), International Classification of Diseases (ICD) codes 
 108
(https://www.cdc.gov/nchs/icd/icd9.htm) are used to track 8,940 phenotypes derived from 
distinct ICD-9 codes in the data. In an initial analysis of 21,241 individuals, Schmidt et al (2017) 
report 145 associated loci across 131 traits. We reason that some genomic features may be 
enriched in causal loci for all traits and thus applied our approach for across traits. To 
accommodate multiple traits, we defined 41 causal loci associated with at least one of the 
phenotypes under study. When causal loci for two or more phenotypes overlapped, we kept the 
phenotype with the more significant association. The rest of the algorithm works as described 
above. 
Simulation 
We use simulations based on real genotype data from a study on age-related macular 
degeneration (AMD) (Fritsche et al. 2016) to validate our method by ensuring that Type I error is 
controlled and investigate the power to detect different values of the enrichment parameter. The 
original study includes 17,832 European controls genotyped at 439,350 variants. To generate 
simulated GWAS datasets, we sampled 5,000 European ancestry individuals and a set of 3,000 
loci, each with 100 variants. The 3,000 loci are selected so that they are at least10 Mb apart, so 
that a pair of variants from two different loci is not likely to be in linkage disequilibrium with 
each other.  
For the baseline model, we assume that variants possess a feature of interest with 
probability 0.1 and that the value of . used to determine the causal variant is 2.5 (odds ratio = 
12.2). We use the parametric model 
(, = 1	|+,, .) = 	 exp	(3 + .+,)1 + exp	(3 + .+,) 
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to determine which variants are causal, using 3 = 	−8 which generates approximately 100 causal 
loci under the null.  
We vary the parameters to observe the behavior of our method under different scenarios. 
We also use the simulated data to compare our method with the published method fGWAS 
(Pickrell 2014). 
Real Data Application 
Age-related Macular Degeneration 
We apply our method on sequencing data based on case-control study of age-related 
macular degeneration (AMD) with a sample size of 4,787 individuals with 2,394 cases and 2,393 
controls. Studies have shown that up 70% of AMD risk can be attributed to genetic variation 
(Seddon et al. 2005). Previous association studies have found up to 52 signals in 34 different loci 
(Fritsche et al. 2016). The sequencing study samples were matched based on age and sex and 
restricted to European ancestry using LASER (Wang et al. 2015). The sequencing study involved 
45.4 million variants most of which were intergenic and very rare, and led to the detection of 9 
signals in 4 distinct loci CFH, C2/CFB/SK1V2L, C3 and ARMS2/HTRA1. Most notably, the CFH 
locus has multiple signals as well as variants with very high odds ratios. We construct 9 pseudo-
loci using conditional analysis results from Firth-adjusted logistic regression analysis. We use 
our method to do enrichment analysis on these data considering different genomic annotations –  
whether a variant is (i) non-synonymous, (ii) non-synonymous or frameshift, (iii) overlaps with a 
complement gene, or (iv) has a CADD score greater than 20 (Kircher et al. 2014). 
 110
Publicly Available GWAS Datasets: Lipids and Schizophrenia 
We also implement our method on publicly available data-sets for a variety of traits 
including lipids (Global Lipids Genetics Consortium 2013) and schizophrenia (Schizophrenia 
Working Group of the Psychiatric Genomics Consortium 2014). We use the published lists of 
associated variants to define our associated loci to investigate the enrichment of non-
synonymous variants. 
Michigan Genomics Initiative 
The Michigan Genomics Initiative (MGI) (https://www.michigangenomics.org/) is a 
large data repository where phenotype information is collected using both Electronic Health 
Records and questionnaires (Schmidt et al. 2017). Based on the February 2016 data freeze, 1,448 
traits based on PheWAS codes (Supplementary Figure S3.1) are analyzed for a sample size of 
21,241 participants.  
We defined significant loci based on the GWAS signals for all PheWAS traits. We 
defined 1Mb loci (500kb on either side) from the top signals (p-value < 5x10 -9 to adjust for 
multiple testing as we considered multiple traits simultaneously), resulting in 41 significant loci. 
A handful of overlapping loci were merged as required, with the more significant trait’s statistics 
being used.  
The saddlepoint approximation (Dey et al. 2017) test calculates only the association p-
values for each variant, which were inverted to approximate the N) test statistics. We tested for 
enrichment of nonsynonymous variants in the trait associated loci. 
We obtained eQTL data from 44 human tissues collected by GTEx 
(http://www.gtexportal.org/home/), and ranked the eGenes by first q-value and then effect size 
(GTEx Consortium 2015). Considering the top 5,000 eGenes for each of the 44 tissues, we 
 111
annotated whether variants were one of the eQTL SNPs on the GTEx list. We then used these to 
estimate the enrichment parameter and the posterior probabilities. Then we used these posterior 
probabilities to compute 95% credible sets at each locus (Supplementary Figure S3.2).  
UK Biobank  
We estimated enrichment of non-synonymous variants in GWAS results from UK 
Biobank data (Sudlow et al. 2015, Bycroft et al. 2017) of 408,961 white British European 
ancestry samples. Association results for 989 ICD-10 derived phenotypes were obtained using 
SAIGE (Zhou et al. 2017) and used to find genome-wide significant loci. 45 traits were found 
with at least 9 genome-wide significant loci. Non-synonymous variants were annotated using 
VEP (McLaren et al. 2016) and tested for enrichment in these traits with at least 9 genome-wide 
significant loci. Additionally, we investigated enrichment of eQTL SNPs for 44 tissues obtained 
from GTEx (GTEx Consortium 2015; http://www.gtexportal.org/home/) in the associated loci for 
the 45 traits.  
Results 
Simulation 
Simulation results show that power to detect enrichment increases with sample size as 
well as with number of associated loci (Figure 3.1). As number of associated loci increases, we 
get a more accurate estimate of the enrichment parameter when combining information across 
many loci. With smaller sample sizes, small effect sizes are difficult to detect leading to fewer 
causal loci being detected and wider bounds on . estimates. 
Additionally, stronger enrichments are easier to detect and hence, the higher the true 
value of ., the greater the power (Figure 3.2). For example, with sample size 5,000, as 
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simulating . increases from 1 to 2 (odds ratio increases from 2.7 to 7.4), empirical power 
increases from 45.5% to 97.8% in the simpler approach and from 61.6% to 100% in the Bayesian 
approach. For simulation purposes, we do not consider the scenario where . is less than zero as 
significant depletion of a rare annotation among associated variants is extremely difficult to 
detect (consider, for example, that if ~1% of the variants are coding, detecting a deficit of coding 
variants among disease associated loci might require 100s or 1000s of independent association 
signals).  
We observe that the Bayesian approach has slightly greater power than the simpler binary 
classification approach. However, for large datasets we recommend using the binary approach as 
it is much faster. While the simpler approach controls the Type I error at 0.05, the Bayesian 
approach is over-conservative near the null (Type I error = 0.01) due to the approximations made 
when estimating 3. 
Considering the estimation aspect of our method, observe that a theoretical lower bound 
of the standard error of the estimate can be calculated from the contingency table set-up. The 
standard error of the true log-odds from the contingency table is: 
se(log	OR)	 = 	v1w + 1> + 1x + 1y 
which is dominated by the term #z as we expect the first cell of the contingency table 
(Table 3.1) to have the smallest cell count. Thus, if we assume that there are fewer than 100 
causal loci, the standard error of the log-odds is greater than 0.1, which puts a minimum bound 
on the confidence interval length. Since we do not know the actual cell values of the table, the 
estimate we use is more uncertain and has a wider confidence interval than the true log-odds 
ratio. Thus, increasing sample size or varying other parameters does not allow us to improve the 
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standard error beyond this limit.  Simulations show that our estimated confidence intervals are 
very similar to those obtained when the true causal variants are known, although they are slightly 
larger as expected (Table 3.2) due to the uncertainty involved in identifying associated loci. 
As expected, the confidence interval length decreases as the value of the true underlying 
enrichment parameter increases (e.g. confidence interval length decreases from 1.40 to 0.61 as . 
increases from 0 to 2.5 (Table 3.2)).  
We calculate the coverage probability of our estimate, that is, the proportion of times the 
simulation . lies in the confidence interval of the estimate and observe that in our method it lies 
in the 95% confidence interval at least 95% of the time (range 95% - 99%) (Figure 3.3). We 
observe that the confidence interval also always contains the true observed log-odds ratio, that is, 
the log-odds ratio calculated based on the causal variants used in simulation.  
We compute credible sets of the causal variants. In the simpler approach, we calculate the 
posterior probability of being causal for each variant in the associated loci. Then, for each 
associated locus, the 95% credible set of variants is the minimal set whose posterior probabilities 
sum up to be equal to or more than 0.95. In the Bayesian approach, we do the same for every 
locus after removing loci where the total posterior probabilities are small . 
We compute credible sets using both a flat prior and our method, and observe how the 
credible set size decreases when taking enrichment due to genomic features into account (Table 
3.3). Note that in our simple simulation scenario, we get consistently smaller credible sets than 
under the null (that is, assuming no enrichment), and, as expected, the decrease in credible set 
size increases as enrichment increases (credible set size decrease of 12.7% for . = 2.5). 
We compare our method with the published method fGWAS and observe that our method 
tends to be more stable when . values are very high or very close to 0. It is difficult to compare 
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estimates directly since the fGWAS approach gives estimates at two levels – a variant level 
enrichment parameter and a locus level enrichment parameter – but at the more extreme values 
of . our method generates more reasonable confidence intervals than fGWAS. The power of the 
simpler approach is very similar to fGWAS, with the Bayesian approach having slightly more 
power (Figure 3.4).  
Real Data Application 
Age-Related Macular Degeneration 
We use our method to analyze AMD sequencing data with a sample of 4,806 individuals. 
We construct 9 pseudo-loci based on conditional analysis as well as single SNP analysis results. 
For a locus with multiple signals, we obtain the pseudo loci by conditioning in turn by all top 
independent signals but one. For example, in a locus with 3 independent signals, we obtain 3 
pseudo loci where all the variants in the locus are analyzed after conditioning on each pair of the 
3 signals. 
We expect annotating non-synonymous variants (estimated log-odds ratio = 3.05; odds 
ratio = 21.1) to lead to a high enrichment parameter, but observe that dichotomized CADD score 
(estimated log odds ratio = 5.54; odds ratio = 254.7), overlap with complement gene (estimated 
log odds ratio = 5.17; odds ratio = 175.9) or frameshift variations along with nonsynonymous 
variants (estimated log odds ratio = 5.14; odds ratio = 170.7) are estimated to be more enriched 
in the associated loci (Table 3.4).  
We construct 95% credible sets at each locus based on the different enrichment 
parameters, and compare them to credible sets constructed assuming no enrichment (Table 3.5). 
Observe that while most of the credible sets are reduced in size to some extent compared to the 
no enrichment scenario, there are 5 loci where the credible set is reduced to exactly 1 variant for 
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at least one of the four annotations considered. We observe that the credible sets are reduced for 
at least seven of the nine loci for all four traits (Table 3.5). While there is considerable reduction 
in credible set size (for example, total credible set size across all 9 loci reduces from 13,669 to 
640 when considering annotation with CADD score (Table 3.5)), it is mostly driven by one or 
two loci with hundreds or thousands of variants in the null credible set. We highlight some of the 
variants that are in these reduced sets (Table 3.6) which have at least 95% posterior probability 
for one of the four annotations considered, and note that all of them are present in credible sets 
for at least 2 kinds of annotations. 
To illustrate our method, we focus on loci 8 and 9 in particular, which are pseudo-loci 
obtained using conditional analysis on chromosome 19 (Figure 3.5). There are several variants 
in high linkage disequilibrium with the top SNP, but considering the annotations, 3 variants stand 
out. Note that without using conditional analysis results, the variant chr19:6718146 would not be 
in any credible set as the credible sets would be dominated by the signal in locus 8 .  
Publicly Available GWAS Datasets: Lipids and Schizophrenia 
We do similar analyses for association results from lipids and schizophrenia to test for 
enrichment of non-synonymous variants (Table 3.7). While non-synonymous variants are found 
significantly enriched for HDL-cholesterol, LDL-cholesterol and triglycerides, the enrichment is 
not statistically significant for total cholesterol or schizophrenia. Using the estimated enrichment 
parameter to compute 95% credible sets leads to a reduction in the number of variants to 
potentially follow-up on. For example for HDL-cholesterol, there is a 16% reduction in credible 
set size as number of variants in 95% credible sets across all loci reduces from 547 to 452 when 
the estimated enrichment parameter is used (Table 3.7). 
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Michigan Genomics Initiative 
We defined 41 loci based on association results from 38 traits. Nonsynonymous variants 
were found to be significantly enriched in trait-associated loci with an estimated enrichment 
parameter of 3.68 (odds ratio = 39.6; p-value = 2 x 10-7). We computed the 95% credible set at 
each locus, and found that the credible sets at most loci were very similar to the 95% null 
credible sets computed assuming no enrichment of nonsynonymous variants. We observed that 
21 of the loci had fewer than 5 variants in the credible sets in both cases. 
We tested for enrichment in overlap with eQTL SNPs across all traits and obtained an 
estimated enrichment parameter of 4.41 (odds ratio = 82.3; p-value = 3 x 10-8). We observed that 
24 of the 41 loci had 5 or fewer variants in their 95% credible sets and 9 of those loci had exactly 
one variant in their 95% credible sets. We note that, for a pair of loci, using the estimated 
enrichment parameter decreases the credible sets from 46 variants to 1 variant and from 23 
variants to 11 variants respectively. 
Table 3.8 shows the annotated variants which have a posterior probability of ≥ 10% and 
are present in the 95% credible sets for the 41 associated loci. We observed some biologically-
plausible connections such as a variant in the credible set for ‘disorders of lipid metabolism’ 
annotated in liver, and a variant in the credible set for ‘Skin cancer’ annotated for ‘skin - sun 
exposed lower leg’. However, not all the connections were obvious to us, so we considered 
estimating the enrichment for each eQTL tissue separately. However, since there are only 3,551 
annotated variants for all 44 tissues in the 41 loci, considering only one tissue dropped this 
number to less than 150, and we often end up with fewer than 5 annotated variants in the credible 
sets. This leads to unstable estimates and inflated standard errors. 
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UK Biobank 
We used association results from SAIGE (Zhou et al. 2017) to find trait-associated loci 
for 989 traits. We found 45 traits with at least 9 distinct genome-wide significant loci where loci 
were defined using both physical distance (100kb on either side) and p-value cut-off (p < 5x10-8) 
so that loci extend 100kb on either side of the peaks. Nonsynonymous variants were found to be 
significantly enriched in 19 traits as detailed in Table 3.9. Additionally, we found nominally 
significant enrichment of eQTL SNPs in 37 of the 45 traits (Table 3.10).  
Discussion 
Recent work from various consortia (ENCODE Project Consortium 2012, Bernstein et al. 
2010) has led to detailed mappings of the genomic regulatory regions and the functional 
properties therein. We attempt to integrate this knowledge with GWAS study results to provide a 
deeper insight into potentially causal variants. Our method works with summary level data, 
namely effect sizes and standard errors or p-values, and thus can be used with already published 
GWAS data. 
There are some existing methods which have similar aims(Pickrell 2014; Kichaev et al. 
2014). However, our method uses a multi-SNP model based on single-SNP analysis results and 
provides an easy to interpret enrichment parameter estimate. Simulations show that our method 
is more stable than existing methods when the true values are near zero. The algorithm is fast and 
efficient as it takes advantage of the fact that most SNPs in the genome are not associated with 
the trait of interest. We then use the estimated enrichment parameter to construct credible sets of 
SNPs prioritized for follow-up.  
The summary statistics from any association study are sufficient to implement our 
method. This makes it easy to apply our method to previously published GWAS to compare how 
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different genomic features affect various traits. Another advantage is that we can easily use our 
method for meta-analysis data. Meta-analysis is a popular method to increase sample size by 
combining studies to get improved power. We can study enrichment easily in this combined 
sample as individual level data is not required. 
Our method helps us interpret GWAS results in a systematic manner. We construct 
credible sets for each locus which narrows down the set of potential causal variants there. For 
example, in the AMD data, the total number of variants in credible sets for all the loci goes down 
from 13,669 to 640 when considering annotation with CADD score (Table 3.5). However, note 
that this decrease is mainly driven by one locus where the credible set sizes decreases from 
13,425 to 591 and there is much smaller reduction in credible set sizes for the other loci.  
Loci can be defined based on linkage disequilibrium or distance from top associated 
SNPs. Loci based on distance is simpler to implement but loci based on linkage disequilibrium 
may be better for refining the signals as they can allow for unequal sized loci. For loci with 
multiple signals, we recommend using conditional analysis results to define them as multiple 
pseudo-loci. This enables us to get credible sets for each independent signal which are not 
dominated by stronger signals nearby. 
We recommend using the simpler binary classification approach in most cases for faster 
results as most GWAS have a large number of variants and comparatively fewer associated loci. 
However, for better power the Bayesian approach is preferred in situations where the sample size 
or the number of associated variants is relatively low. 
We have shown that our method works well to estimate the enrichment parameter. 
However, our method does not work well in situations where the SNPs annotated with the 
feature of interest are likely to be depleted in the causal loci. This is because the features of 
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interest tend to be rare, and in case of depletion, we may end up with too few annotated variants 
in the associated loci to get stable estimates. Our method also requires either a sufficient number 
of causal loci (ideally >25), or loci with high effect sizes to achieve sufficient power.  
While both methods described are easy to implement and quite effective, there are several 
directions in which it can be extended. We may wish to consider quantitative annotations, or 
categorical annotations with more than 2 levels. In our analysis, we dichotomized the CADD 
score, but using all the different levels available may lead to more informative results. Another 
option is to consider multiple genomic annotations simultaneously, which may or may not be 
correlated. We hope that our method can form the basis to develop tools which help us 
statistically quantify the relation between genomic features and phenotypes, and lead to a better 
understanding of the biological mechanisms behind complex genetic traits. 
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Table 3.2:  Estimated Confidence Interval Lengths for the Enrichment Parameter 
 
Simulating 
λ 
Mean estimated CI 
length 
SD of estimated CI 
length 
Actual 
observed CI 
length 
SD of actual 
observed CI 
length 
0 1.40 0.17 1.36 0.25 
0.5 1.18 0.10 1.07 0.12 
1 1.00 0.08 0.87 0.07 
1.5 0.84 0.05 0.72 0.04 
2 0.71 0.03 0.62 0.02 
2.5 0.61 0.02   
Confidence intervals reported are calculated using the Bayesian approach. Mean and SD 
calculated empirically based on 500 simulations for each parameter. Actual observed CI refers 
to CI based on using the known causal variants used in simulation. 
 
 
 
 
Table 3.3: Decrease in Credible Set Size using Enrichment Parameter 
 
Simulation { 
 
Mean Credible Set 
Size with Estimate 
Mean Credible Set Size 
under Null 
Mean Decrease in Credible 
Set Size (SD) 
0 1099.59 1109.87 10.28 (15.42) 
0.5 1128.34 1139.62 11.28 (13.06) 
1 1132.18 1154.08 21.90 (18.73) 
1.5 1129.53 1178.23 48.70 (30.11) 
2 1113.07 1202.94 89.86 (44.31) 
2.5 1012.76 1159.78 147.02 (61.98) 
95% credible sets are calculated using the enrichment parameter estimated. Results are shown 
based on enrichment parameter for simpler approach, but Bayesian approach results similar. 
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Table 3.4: Estimated enrichment parameter in AMD data for different genomic features 
 
Annotation Estimated λ Odds Ratio P-value 
Nonsynonymous 3.05 21.1 1 x 10-3 
Nonsyn + Frameshift 5.14 170.7 4 x 10-5 
CADD score 5.54 254.7 1 x 10-4 
Complement Genes 5.17 175.9 2 x 10-4 
Enrichment parameters estimated for different genomic features based on 9 associated ‘pseudo-
loci’ in association results for age-related macular degeneration. Odds ratio = exp(.). 
 
 
 
Table 3.5: Credible Set Sizes Based on Different Genomic Features for AMD Data 
 
Top SNP at Locus Null Nonsyn NFS CADD Complement 
chr1:196684392 20 19 20 19 19 
chr1:196661505 90 53 62 9 88 
chr1:196024122 13,425 4,537 7,483 591 1,402 
chr1:196358288 6 5 30 1 67 
chr6:31894355 2 2 2 1 1 
chr6:32609038 111 27 111 11 27 
chr10:124214600 11 8 2 1 11 
chr19:6718387 2 1 1 1 2 
chr19:6718146 2 1 1 6 1 
 
Credible sets constructed based on estimated enrichment parameter at 9 ‘pseudo-loci’ for AMD 
sequencing data. Null denotes credible sets constructed assuming no enrichment. Annotations 
are: Nonsyn = nonsynonymous; NFS = nonsynonymous or frameshift; CADD = CADD score > 
20; Complement = nearest gene is a complement gene. 
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Table 3.6: Some Highlighted Variants in the Associated Loci for AMD Data 
 
Locus Top SNP Annotated Credible Set Posterior Probability 
    Nonsyn NFS CADD Compl. 
4 chr1:196407807 CADD All 4 0.16 0.15 0.97 0.04 
5 chr6:31930462 CADD Nonsyn, NFS, Compl. 0.79 1 0.99 0.02 
5 chr6:31894355 Compl. Nonsyn, NFS, Compl. 0.21 0.2 0.001 0.98 
7 chr10:124214600 CADD All 4 0.11 0.02 0.99 0.28 
7 chr10:124214448 Nonsyn, NFS Nonsyn, NFS, Compl. 0.65 0.94 0.001 0.08 
8 chr19:6718387 Nonsyn, NFS, Compl. Nonsyn, NFS, Compl. 0.99 0.99 0.04 0.90 
8 chr19:6717655 CADD, Compl. CADD, Compl. 0.004 0.0005 0.95 0.08 
9 chr19:6718146 Nonsyn, NFS, Compl. All 4 0.99 0.99 0.51 0.99 
 
Highlighted variants selected such that posterior probability >95% for at least one annotation. Annotated denotes what features the 
top variant has; Credible Set denotes which credible sets the variant is present in; Posterior Probability is the estimated posterior 
probability each enrichment parameter; Nonsyn = nonsynonymous; NFS = nonsynonymous or frameshift; CADD = CADD score > 
20; Compl. = nearest gene is a complement gene 
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Table 3.7: Estimated Enrichment Parameter for Nonsynonymous Variants in Publicly Available Datasets 
 
Trait Estimated { Odds Ratio P-value Credible set size Null credible set 
HDL 2.67 14.4 1.2 x 10-9 452 547 
LDL 2.85 17.3 2.0 x 10-5 132 289 
TC 1.50 4.5 0.53 - 788 
TG 2.04 7.7 0.03 271 312 
SCZ2 0.72 2.1 0.42 - 1,707 
 
Lipid traits High Density Lipoprotein cholesterol (HDL), Low Density Lipoprotein Cholesterol (LDL), Total Cholesterol (TC) and 
Triglycerides (TG) data taken from published meta-analysis (Global Lipids Genetics Consortium 2013). Schizophrenia (SCZ2) data 
taken from Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014). Nonsynonymous variants annotated using 
VEP (McLaren et al. 2016). 
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Table 3.8: Highlighted Variants in the Enrichment Analysis for eQTL SNPs in MGI Data 
 
Trait SNP 
Credible 
Set Size 
Posterior 
Probability 
Annotation 
Rhesus isoimmunization in 
pregnancy 
1:25561667 2 0.33 23 tissues* 
Rhesus isoimmunization in 
pregnancy 
1:25583610 2 0.62 33 tissues* 
Disorders of lipoid metabolism 1:109817192 5 0.25 Liver, Muscle Skeletal 
Disorders of lipoid metabolism 1:109817590 5 0.26 Esophagus Mucosa, Pancreas 
Disorders of lipoid metabolism 1:109818306 5 0.42 
Brain Cortex, Skin-Not Sun Exposed Suprapubic, 
Whole Blood 
Gout 4:89045331 6 0.86 Vagina 
Skin Cancer 6:396321 1 1.00 
Cells EBV-transformed lymphocytes, Small 
Intestine Terminal Ileum, Whole Blood 
Fracture of pelvis 9:116113396 1 0.97 Whole Blood 
Other venous embolism and 
thrombosis 
9:136137065 11 0.33 Adrenal Gland 
Other venous embolism and 
thrombosis 
9:136149229 11 0.58 Colon Sigmoid, Pituitary, Uterus, Vagina 
Skin Cancer 16:90024202 13 0.28 Spleen 
Arrhythmia (cardiac) NOS 17:65200303 29 0.56 Brain Cortex 
Skin Cancer 20:32665748 1 0.96 Skin-Sun Exposed Lower leg 
Annotated variants in 95% credible sets that have at least 10% posterior probability of being causal are listed, along with the eQTL 
tissues they’re annotated for. Credible Set Size denotes the number of variants present in the credible set for that locus.  
*Some variants annotated for more than 20 eQTL tissues
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Table 3.9: Traits where Nonsynonymous Variants are found to be Significantly Enriched in 
UK Biobank Data 
 
Trait No. of Loci 
Enrichment 
Estimate 
Odds 
Ratio P-value 
Cholelithiasis and cholecystitis 30 4.38 79.85 5 x 10
-08
 
Disorders of lipoid metabolism 47 3.48 32.33 1 x 10
-07
 
Hypercholesterolemia 43 3.57 35.37 3 x 10
-07
 
Skin cancer 46 3.40 29.97 7 x 10
-07
 
Other non-epithelial cancer of skin 48 3.45 31.44 1 x 10
-06
 
Coronary atherosclerosis 51 3.54 34.31 4 x 10
-06
 
Hypothyroidism 49 3.46 31.81 2 x 10
-05
 
Diabetes mellitus 56 2.97 19.40 5 x 10
-04
 
Disorders of mineral metabolism 9 3.99 53.94 2 x 10
-03
 
Cataract 21 3.29 26.91 2 x 10
-03
 
Gout 11 4.24 69.14 0.02 
Phlebitis and thrombophlebitis 11 3.43 30.86 0.03 
Ischemic Heart Disease 29 2.57 13.04 0.03 
Other chronic ischemic heart disease, 
unspecified 
20 3.00 20.11 0.03 
Other arthropathies 9 3.54 34.58 0.03 
Phlebitis and thrombophlebitis of lower 
extremities 
12 3.11 22.39 0.04 
Inflammatory bowel disease and other 
gastroenteritis and colitis 
20 3.29 26.80 0.04 
Circulatory disease NEC 9 3.09 21.98 0.04 
Other disorders of circulatory system 10 3.04 20.95 0.04 
 
Traits where nonsynonymous variants were found to be significantly enriched in associated loci. 
Analysis done on 44 traits found to have at least 9 significantly associated loci. No. of loci 
denotes the number of distinct regions found to be genome-wide significant; Enrichment 
Estimate the estimated enrichment parameter and P-value the corresponding P-value. 
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Table 3.10: Traits where eQTL SNPs are found to be Significantly Enriched in UK Biobank Data 
 
Trait No. of Loci 
Enrichment 
Estimate 
Odds 
Ratio P-value 
Varicose veins 31 5.53 252.87 4 x 10
-15
 
Coronary atherosclerosis 51 4.93 138.93 2 x 10
-14
 
Disorders of lipoid metabolism 47 4.71 111.41 1 x 10
-12
 
Varicose veins of lower extremity 33 5.14 171.19 2 x 10
-12
 
Cardiac dysrhythmias 25 5.62 275.70 2 x 10
-12
 
Hypercholesterolemia 43 4.67 106.86 7 x 10
-12
 
Other chronic ischemic heart disease, unspecified 20 5.42 225.92 5 x 10
-11
 
Angina pectoris 22 5.41 223.47 7 x 10
-11
 
Ischemic Heart Disease 29 4.80 121.18 2 x 10
-10
 
Osteoarthrosis 22 5.55 256.69 3 x 10
-10
 
Diabetes mellitus 56 4.54 94.15 4 x 10
-10
 
Myocardial infarction 23 5.17 175.98 2 x 10
-09
 
Skin cancer 46 4.16 63.88 7 x 10
-09
 
Asthma 43 4.38 80.01 1 x 10
-08
 
Cholelithiasis and cholecystitis 30 4.64 103.85 2 x 10
-08
 
Overweight, obesity and other hyperalimentation 10 5.36 212.12 7 x 10
-07
 
Hypothyroidism 49 4.04 56.89 9 x 10
-07
 
Disorders of muscle, ligament, and fascia 28 4.39 80.59 1 x 10
-06
 
Abdominal hernia 16 5.29 199.16 2 x 10
-06
 
Other non-epithelial cancer of skin 48 3.75 42.36 2 x 10
-06
 
Inflammatory bowel disease and other gastroenteritis and colitis 20 4.81 123.29 3 x 10
-06
 
Diverticulosis and diverticulitis 38 4.33 76.31 4 x 10
-06
 
Nasal polyps 25 4.62 101.24 8 x 10
-06
 
Benign neoplasm of colon 28 4.38 79.84 2 x 10
-05
 
Ulcerative colitis 13 4.96 143.16 1 x 10
-04
 
Diffuse diseases of connective tissue 13 5.54 254.23 1 x 10
-04
 
Lupus (localized and systemic) 9 6.28 532.10 2 x 10
-04
 
Benign neoplasm of uterus 18 4.23 69.02 7 x 10
 -04
 
Glaucoma 15 4.44 84.46 8 x 10
-04
 
Phlebitis and thrombophlebitis 11 4.85 127.34 9 x 10
-04
 
Pulmonary heart disease 16 3.98 53.75 0.01 
Circulatory disease NEC 9 4.10 60.64 0.01 
Other disorders of circulatory system 10 4.04 56.73 0.01 
Urinary calculus 10 3.58 35.82 0.03 
Gout 11 4.38 79.76 0.03 
Psoriasis and related disorders 9 3.55 34.82 0.03 
Cataract 21 3.72 41.27 0.05 
 
Traits where eQTL SNPs obtained from GTEx (http://www.gtexportal.org/home/) are enriched in the associated loci 
for UK Biobank Data. Analysis done on 44 traits found to have at least 9 significantly associated loci. 
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Figure 3.1: Power Curves for Different Sample Sizes 
 
As expected the power improves with increasing sample size, and the Bayesian method has 
slightly better power than the binary classification method. 
 
Figure 3.2: Empirical Mean and SD of Enrichment Parameter Estimate 
 
 
Estimated . with standard errors when we vary . values for (a) Simpler approach and (b) 
Bayesian approach show that as the true value of . increases, the standard errors decrease as 
we have better power for estimation. 
 
 
(a) Simpler Approach (b) Bayesian Approach 
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Figure 3.3: Coverage Probability 
 
The black line denotes the coverage probability of our estimate which is >95% for all the values 
of . simulated.  
 
Figure 3.4: Power Comparison with fGWAS 
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Figure 3.5: Locuszoom plot for region around chr19:6718387 for AMD 
 
Locuszoom plot for region around chr19:6718387 highlighting annotated variants in credible 
sets from single-SNP analysis as well as conditional analysis results Credible sets for ‘pseudo 
loci’ 8 and 9 leads to 3 variants for follow-up. 
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Supplementary Methods 
Algorithm 
We wish to quantify the enrichment of variants annotated with a particular feature among causal 
variants. Now suppose the causal variants were known. Consider the following contingency 
table: 
 Has Annotation No Annotation 
Causal a b 
Non-causal c d 
 
The log odds ratio of this table estimates the parameter . from the logistic model 
log (| = 1	|4)(| = 0	|4) = 3 + .4 
and thus, is an enrichment parameter as required. However, we do not observe the table in 
practice. We begin with some initial estimates of 3 and ., and compute the expected cell counts 
of the table and the corresponding log odds ratio under our model assumptions. We continue 
estimating in an iterative process till the estimates converge. 
Modeling the Association  
We begin with observed data from an association study. Let  be the sample size and  the trait 
vector,  the genotype matrix. 
We model the phenotype-genotype associations using a standard multiple linear regression 
model: 
 =  +5},~5"# + , 
where }, indicates the - column of the matrix .  
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Simpler Approach: Focusing on Loci that Reach Genome-wide Significance 
In this approach, we assume that each associated locus has exactly one causal variant and that the 
background variants not in the associated loci are not causal. We make further simplifying 
assumptions that the average chi-square for the background variants is 1. 
Prior 
Suppose that there are >#and > background variants with and without the annotation 
respectively, and  associated loci, we assign the background variants to the associated loci, so 
that the prior for a variant at each locus becomes 
(, = 1	|	+, .) = 	 	exp(.45)> + ># exp(.) + ∑ 	exp8.4<?:;<"#  
Association Results 
Note that the N) test statistics from the single-SNP association results can be used to 
approximate the likelihood as follows: 
O5 = 2	log J(	|, , = 1)(	|	) 	K	 
where O5 = (	C5/se8C5?)) is the N) test statistic associated with the - variant of the  locus, 
and  is the null case where the trait is not associated with any of the variants, and thus can be 
considered as a constant x independent of the genotypes. 
Hence, 
(	|, , = 1) ∝ exp	 [O52 \ 
Thus, for variants in the causal loci, we get 
(	|	, +, ., , = 1) ≈ expA12J C5se8C5?K
)E	 
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Likelihood 
The likelihood contribution of one locus 	is 
Z(.) ≈ 		 (	|	, +, ., , = 1)5 (, = 1	|	+, .)
+ exp [12\ A> + ># exp(.)E 1> + ># exp(.) + ∑ 	exp8.4<?:;<"#  
= ] expA12 
)
se8?)E 	exp(.45)
:;
5"#
+ exp [12\A> + ># exp(.)E^	 1> + ># exp(.) + ∑ 	exp8.4<?:;<"#  
We assume that the loci are independent so that the joint log-likelihood becomes 
ZZn(.) = 	log	(Z(.))  
Testing 
 The Likelihood ratio test is 
Λ = 2(ZZn8.C? − ZZn(0)) 
which follows a N)distribution with 1 degree of freedom.   
Posterior Probability 
Although we assign the background variants to the associated loci, they are spread across the 
genome. To calculate the posterior probability for the variants actually present in the loci, we get  
(, = 1	|	, , +, .) ≈ 	
exp A12 C5)se8C5?)E 	exp(.45)
]∑ expA12 C<
)
se8C<?)E 	exp8.4<? + exp L12M J> + ># exp(.)K:;<"# ^
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However, this formula still takes the background variants into account so that the posterior 
probabilities of variants actually present in an associated locus sum to <1. To compute the 
credible sets, we use the modified posterior probabilities: 
(, = 1	|	, , +, .) ≈ 	
exp A12 C5)se8C5?)E 	exp(.45)
]∑ expA12 C<
)
se8C<?)E 	exp8.4<?:;<"# ^
 
An Alternative Bayesian Approach 
Association Results 
The phenotype-genotype association is modeled using a standard multiple linear regression 
model: 
 =  +5},~5"# + , 
where }, indicates the - column of the matrix .  
In the GWAS context, we expect most of the SNPs in the genome to not be associated with the 
trait and thus, only a small proportion of the 5s is non-zero. However, we do not know which 
SNPs are causal and a large number of SNPs are in linkage disequilibrium with one another. Let 
 be a latent indicator variable denoting the causal SNPs. We assume that our genotype data is 
divided into  smaller segments or loci and that the vector  can be split correspondingly into 
vectors as follows:  
 =  ⊕ ⊕…⊕Z 
Let ,7 be the indicator variable corresponding to the H SNP in the - locus and +,7 be an 
indicator variable denoting whether the SNP has the feature of interest.  
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Prior 
We assume that the prior probability of a SNP being causal depends on whether it has the feature 
or not as follows: 
P( = 1) = exp(3 + .+,7)1 + exp(3 + .+,7) 
where . is the parameter of interest which quantifies the enrichment of SNPs with feature among 
the causal variants. 
Likelihood 
Now, the likelihood of the observed data can be obtained by summing over all possible values of 
the latent variable  as follows: 
(	|, 3, .) = 	(	| , )	(	|3, .) 
= (|)(	|, )(	|) (	|3, .)  
where  is the case where the trait is not associated with any of the variants, and thus can be 
considered as a constant x independent of the genotypes. Thus, 
(	|, 3, .) = x	cd()( = 	|	3, .)	  
where cd() indicates the Bayes Factor for the selected . 
Bayes Factor 
Here,  
cd5< =	J1 +	f)5<K
#/) 	exp	 A12
)
5< f
)5< +	f)E 
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with   and 5< being the estimated association effect size and variance for the H variant in the 
- locus respectively. The prior imposed on this effect size is  ∼ %(0, f)) and we average 
over a range of possible values of f (Wen 2014). 
Now, note that the Bayes Factor can be approximated as  
cd() = 	_cd(,)5∈!  
where cd(,) represents the Bayes Factor for the selected vector , at locus -. 
Simplification of Likelihood 
From the prior imposed on a variant being causal, we get 
(	|	3, .) = _8,79	3, .)5,<  
= _(,	|	3, .)5∈!  
Thus, 
(	|	, 3, .) ∝_cd(,)( = 	|	3, .)5∈!  
=  _cd(,)(, = ,	|	3, .)5∈!,,…	Z  
=	_hcd(,)(, = ,	|	3, .), i5∈!  
 
To iterate over all possible combinations of  is not computationally feasible. In order to make 
the inference procedure computationally tractable, we make some simplifying assumptions. 
Suppose that we can partition  into the set of loci without a causal variant () and the set of 
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loci with at least one causal variant (#) such that  =  ∪ #. In practice, we use association 
results based on single SNP analysis to approximate the partition. Observe that for a non-causal 
locus -, cd(,) = 1, and hence,  
cd(,)(, = ,	|	3, .) = 	(, = ,	|	3, .) = 1,,  
⇒ (	|	, 3, .) ∝ 	_hcd(,)(, = ,	|	3,, .)i5∈!l  
 
For the associated loci, we assume that the locus is defined to be small enough to contain a single 
causal variant. Then for such a locus -, 
cd(,)(, = ,	|	3, .) → 0			for	, ∶ 		,7 > 1<  
This means that there is at most one underlying causal variant in the locus, and terms involving 
indicator variables with more than one causal variant are negligible. 
Let 5 = {	, ∶ 	∑ ,7 = 1}< , that is, the set with exactly one causal variant in the locus.  
⇒cd(,)(, = ,	|	3, .) = 	  cd(,)(, = ,	|	3, .) + cd(&)(, = &	|	3, .),∈,,  
 
Note that for ,∗ ∈ 5 ∶ 	 ,7∗ = 1, cd(,∗) = cd(,7) and cd(&) = 1. 
⇒cd(,)(, = ,	|	3, .),
=	cd5<8,7 = 1, , = 0		∀	 ≠ H	9	3, .) + (, = 0	|	3, .)	<  
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= hcd5<	8,7 = 1	9	3, .)	_(, = 0	|3, .)b< i< + (, = &		|	3, .) 
 
= hcd5< exp	(3 + .45<)1 + 	exp	(3 + .45<)	_ 11 + exp	(3 + .45b)b< i< + (, = &	|	3, .) 
= `5 hcd5< 	exp	(3 + .45<)< + 1i 
 
where cd5< is the Bayes Factor corresponding to the H variant in the - locus and `5 is the 
locus specific probability that there is no causal variant in the - locus.  
Let the - locus have 5 variants. Then, 
`5 =	_ 11 + 	exp	(3 + .45<)
:
<"#  
 
⇒ (	|	, 3, .) ∝_`5 cd5< 	exp	83 + .45<? + 1< 5∈!l  
Testing 
Thus, the Likelihood Ratio Test is: 
Λ = 	2	log J (	|	, 3̂, .C)(	|	, 3, . = 0)K 
where  3 is the estimated value of 3 under the model assumption that . = 0 and Λ	follows N) 
with 1 degree of freedom. 
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Posterior Probabilities 
Note that as ,7 takes values 0 and 1, the posterior expectation of ,7 is simply the posterior 
probability that ,7 = 1. 
8,7 = 1	9	, , 3, .) = 8, ,7 = 1	9	, 3, .)(	|	, 3, .)  
Hence, 
8,7 = 1	9	, , 3, .) = 	  exp	83 + .45<?¡	`5	cd5<∑  exp	83 + .45<?¡`5cd5b +	`5 	b  
=	 ∑ exp	(3 + .45b)		cd5bb1 + ∑ exp	(3 + .45b)		cd5bb a exp	83 + .45<?	cd5<∑ exp	(3 + .45b)	cd5bb e 
=	 ∑ exp	(3 + .45b)		cd5bb1 + ∑ exp	(3 + .45b)		cd5bb a exp	8.45<?	cd5<∑ exp	(.45b)cd5bb e 
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Supplementary Figure S3.1: Phenotypes for MGI Data
 
Phenotype data for MGI was based on ICD-9 codes. 8,940 ICD-9 codes were aggregated into 
1,815 PheWAS Codes, out of which 1,448 had case count ≥ 20. 
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Supplementary Figure S3.2: Outline of Method to Estimate Enrichment of eQTL’s in MGI Data 
 
 
Δ : eQTL variant 
Ο : non-eQTL variant 
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Chapter 4: Correcting for Sample Overlap in GWAS Meta-Analysis Using Summary 
Statistics 
 
Introduction 
Meta-analysis is a practical method to increase sample size and power of genome-wide 
association studies, enabling discovery of novel signals and refinement of discovered loci. Many 
consortia have been formed to investigate the genetic underpinnings of different traits (Sullivan 
2010; Global Lipids Genetics Consortium 2013; The Coronary Artery Disease (C4D) 
Consortium 2010; International Consortium for Blood Pressure Genome-Wide Association 
Studies 2011), and often make their summary statistics publicly available. Newer studies may 
take advantage of these published statistics as a starting point for their own meta-analysis, further 
increasing sample sizes and increasing power to detect novel signals.  
In these successive meta-analyses, an important issue to consider is the potential overlap 
in the set of participants among successive studies. Any overlap can lead to inflated type I error 
and false signals. The overlap can have many sources. For example, in some analyses publicly 
available controls are shared among different studies (Burton et al. 2007). Additionally, same 
cohorts may contribute to different meta-analysis efforts. For example, for type 2 diabetes, data 
from FUSION was used in both GoT2D GWAS (Fuchsberger et al. 2016) and 70KforT2D 
GWAS (Bonàs-Guarch et al. 2017). 
Methods exist that account for overlap when individual-level data are available, or the 
number of participants contributing to both studies is known (Lin and Sullivan 2009). In this 
paper, we consider a different scenario in which only summary statistics (Z-score and sample 
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size at each marker) are available from potentially overlapping studies. Assuming that the 
samples belong to the same ancestry, we propose a method to identify overlap between pairs of 
studies using GWAS summary statistics, estimate the degree of overlap, and meta-analyze the 
studies appropriately accounting for the overlaps. 
We test the accuracy of our method by constructing overlapping samples based on real 
GWAS datasets to construct artificial overlapping datasets to illustrate our method. The results 
indicate that our method works well to estimate and correct for the overlap and obtain well-
calibrated summary statistics (Z-scores). 
 
Material and Methods 
Standard Meta-Analysis Method 
A common approach in meta-analysis is to sum the Z-scores across studies, weighting 
them appropriately using the sample sizes (Stouffer et al. 1949). Suppose we have ¢ studies, 
with |b,  = 1, …¢, being the Z-score from the  study and %b the corresponding sample 
size. A standard meta-analysis uses weights £b,  = 1, …¢, to combine the estimates as 
follows: 
| = 	£b	|b¤b"# 																										… Equation	(1) 
The |b’s are assumed to be have standard normal distribution under the null hypothesis 
of no association between trait and genetic marker. Hence, the variance of the combined Z-score 
is: 
Var(|) = 	£b)¤b"# 																					… Equation	(2) 
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The weights are usually chosen based on per-study sample size so that larger studies have 
more weight (eg.	£b = ¬­®¬∑ ­;; ). When the Z-scores are independent, these weights ensure that the 
combined Z-score is distributed as %(0,1) under the null. However, when the studies have 
overlapping samples, the variance (2) becomes: 
Var(|) = 	£b)¤b"# + 2	  £b£ Cov
¤
"b¯# (|b, |) 
¤
b"# 														… Equation	(3) 
where the covariance terms Cov(|b, |) depend on overlap between each pair of studies. 
Thus, using standard weights no longer leads to a %(0,1) test statistic under the null. To account 
for this, we estimate this covariance and adjust the weights accordingly. The optimal weights can 
be shown to be (Lin and Sullivan 2009): 
±£#, …£¤² = Q³Ω# Q³Ω#Q⁄ 																									… Equation	(4) 
where Q is a ¢	x	1 vector of 1’s and Ω is the estimated covariance matrix of (|#, … |¤).  
The covariance matrix Ω can be calculated easily if individual-level data are available, or 
if the exact number of overlapping samples between each pair of studies is known. We consider 
the more general case where the number of overlapping samples is not known and use the pair-
wise correlation between Z-scores to estimate the overlap and adjust the weights as in (4).  
Meta-Analysis Correcting for Sample Overlap 
We develop a method to estimate the sample overlap and correct for it (Figure 4.1) using 
the correlation between Z-scores from each pair of studies. First, we stratify the Z-scores 
according to sample size at each marker because differences in the number of typed samples at 
each site could reflect success – or lack thereof – in genotyping across different studies. Second, 
we truncate the Z-scores using a cutoff value x (|Z| < c) to remove the effect of strongly 
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associated loci. Finally, we estimate the correlation from these stratified truncated observations, 
and used to estimate the covariance matrix in (4) and meta-analyze using the modified weights. 
Correcting for Overlap in Meta-Analysis 
Suppose there are ¢ studies in a meta-analysis, and the Z-scores are combined in a 
weighted sum where £b is the weight for the  study. If we can estimate the covariance 
between Z-scores of each pair of studies in the meta-analysis, we can meta-analyze using 
modified weights as in (4) as follows: 
|C = 	 1¬∑ £b)b + ∑ ∑ £b£·̂bbb 	£b|b
¤
b"# 																						… Equation	(5) 
where ·̂b is the estimated correlation between the Z-scores of the  and  studies under the 
null. Note that the Z-scores are assumed to have standard normal distribution under the null, and 
hence, covariance and correlation can be interchanged. 
Using Truncated Z-scores to Estimate Covariance 
We assume that (a) effect sizes at trait associated loci do not vary from study to study, a 
condition that should be approximately true given our assumption that all studies are of the same 
ancestry and (b) the degree of overlap is uniform across markers after accounting for sample size 
stratification. Furthermore, we assume that the Z-scores for a pair of studies have a bivariate 
normal distribution. Suppose that the trait under consideration is independent of genetic effects. 
Then the Z-scores are standard normally distributed for each study, and sample correlation of 
paired Z-scores can be used to estimate the correlation parameter of the bivariate normal 
distribution. 
J|5|<K ∼ % A[00\ , J1 ¸5<¸5< 1KE																						… Equation	(6) 
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However, Z-scores at trait associated loci are expected to show positive correlation even 
in independent samples as trait associated loci are expected to have same direction of effect, and 
using the sample correlation between observed Z-scores would lead to an over-estimation of the 
correlation. We also expect most traits for GWAS to be complex polygenic traits where there 
may be many variants with small effect sizes.  
To exclude potentially causal loci, we use a cutoff x, and use markers with Z-scores in 
the interval (−x, x) to estimate the correlation. For example, using x = 1 uses about 68% of the 
markers while excluding the more significant loci. We assume a truncated normal distribution on 
the Z-scores to estimate the maximum likelihood estimate of correlation, and use this to estimate 
the overlap. The likelihood of the observed Z-scores between studies - and H is: 
 =_ f8,º, 7º9	¸5<)8|,º| < x, 97º9 < x	9	¸5<)» 																						… Equation	(7) 
where ½ ranges over all the markers present in both studies, and the Z-scores are assumed to 
follow a bivariate normal distribution with mean 0, variance 1 and correlation ¸5<. 
The estimated correlation obtained from (7) is then used in (5) to correctly meta-analyze 
the studies by modifying the weights to for overlap. 
Stratification Based on Sample Size of Marker 
For a pair of studies, if all markers are present in both studies, the overlap number is the 
same for each marker. However, it may happen that sample size varies across markers as some 
markers may be present only in a sub-cohort of a study. For example, Figure 4.2 describes a 
simple scenario where two studies have a cohort overlapping (cohort 2). Markers absent in this 
overlapping cohort 2 would have an overlap of 0, and so they should be meta-analyzed without 
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correcting for overlap. However, markers present in the overlapping cohort should be meta-
analyzed after correcting for an overlap the size of cohort 2. 
Two problems arise if the overlapping number varies by marker. First, the estimated total 
covariance is biased downward by the markers where there is no overlap and we may apply an 
insufficient adjustment at many markers, leading to false signals. Secondly, when applying a 
constant correction for overlap, we may over-correct at markers with no overlap and lose power. 
 Ideally, clustering methods such as k-means clustering can be used to stratify the total 
sample size at each marker and works well when comparing a pair of studies. When many 
studies are included in a meta-analysis there may be a broad range of sample sizes(Figure 4.3) 
and using less refined clustering improves computational efficiency. Thus, we use markers that 
have at least 50% of total sample size, and bin them using relatively broad bin sizes. Then we 
estimate the correlation at each stratified level using (7) to estimate the overlap for that group of 
markers, and then correctly meta-analyze using (5). 
If sample size per marker is not available, we can use the total sample size to estimate 
and correct for overlap. In this case, we omit the stratification step. However, if all markers are 
not present in all studies, we expect this to lead to errors in the final meta-analysis as some effect 
sizes may be over-corrected while others remain under-corrected. 
Using Pair-wise Correlation of Z-scores to Estimate Effective Overlap Size 
Consider a pair of studies with sample sizes # and ), and suppose that the trait under 
investigation is independent of genetic effects. Then, we expect the Z-scores to be distributed as 
%(0,1) for both studies. Let #) be the number of samples overlapping between the two studies. 
Now, the Z-scores for each study can be considered as a weighted sum of the Z-scores for the 
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overlapping and non-overlapping parts. Assuming the weights are proportional to the sample size 
as follows: 
|# = ¬(1 − #)|¾ + ¬#|¿ 																					… Equation	(8) 
|) = ¬(1 − ))|¾ +¬)|¿ 																						… Equation	(9) 
where the weights used are # = #)/# and ) = #)/), that is, the overlap proportions in 
each study and |¾, |À, |¿ are standard normal variables. Then, 
Cov(|#, |)) = Â(|#|)) = 	¬#) 																								… Equation	(10) 
Thus, as the Z-scores have variance 1, 
Cor(|#, |)) = 	¬#) = #)/¬#) 																								… Equation	(11) 
Hence, the effective overlapping number can be estimated using the sample correlation ·#) 
between the Z-scores of the 2 studies as follows: 
Ã#) =	¬#)·#) 																												… Equation	(12) 
In case of GWAS where the trait is not independent of genetic effects, the estimated 
correlation from (7) can be used in (12) to get an estimate of the effective sample size.   
Observe that (12) estimates the effective sample overlap which may be different from the 
actual sample overlap. For example, for two case-control studies  and , the estimated 
correlation corresponds to: 
Cor(|b, |) ≈ [bÄ
b##b + b#Äbb##\¬b 							… Equation	(13) 
 
where 1 refers to cases and 0 to controls (Lin and Sullivan 2009). 
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Hence, the estimated effective overlap sample size (Ãb =	¬b·̂b) may correspond to 
a range of actual overlap numbers. We can readily derive two extreme possibilities. First, when 
the overlap is restricted to the cases, Ä:®l:;l:®Å:®l Ãb is a point estimate of the number of overlapping 
samples. Second, when the overlap is restricted to the controls, Ä:®Å:;Å:®l:;l Ãb is an alternative point 
estimate of the overlap. 
Similar issues may arise in GWAS for quantitative traits if overlap proportions vary by 
phenotype values. For example, if overlap is concentrated in participants with extremely high 
phenotype, the estimated effective overlap may be an over-estimate. Note that while the 
estimated correlation may correspond to a range of overlap proportions, the adjustments to the 
weights in (5) are still valid. 
Meta-Analysis of Multiple Studies 
Multiple studies can be meta-analyzed sequentially, that is, each new study can be meta-
analyzed with the result from meta-analyzing the previous studies. For each marker for a pair of 
studies - and H, we meta-analyze them as described above and calculated the following 
quantities: 
Total Weight Æ = Ä£5) + £<) + 2 ∗ £5£<·5< 
Effective Sample Size % = 5 + < − 5< 
| = 1Æ (£5|5 + £<|<) 
Observe that this ensures that the order the studies are analyzed in doesn’t affect the results. 
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Simulation Set-up 
We used actual genotypes from 5,000 GWAS individuals from a European population 
(Fritsche et al. 2016) to simulate a series of overlapping studies with phenotype independent of 
the genotypes. We simulated the phenotype as normal with mean zero and variance 1 and used 
300,000 markers across the genome to run single marker tests for the overlapping studies. We 
then attempted to estimate sample overlap using GWAS summary statistics and to conduct a 
meta-analysis that accounted for this estimated overlap. 
Artificially Creating Overlapping Datasets based on GWAS Data 
We created another series of overlapping GWAS studies using actual lipids and type 2 
diabetes) data. We first considered a quantitative trait and used real data from GWAS of HDL-
cholesterol (Teslovich et al. 2010).  We used 3 studies that contributed to the meta-analysis to 
artificially create a pair of overlapping studies. We used 2 studies with sample sizes 7,841 and 
5,253 respectively, and meta-analyzed a study with sample size 2,485 with each of them to create 
2 datasets with an overlap of 2,485. We then meta-analyzed these overlapping together using 
both the standard meta-analysis as well as our method correcting for overlap. We compared the 
results with the target results obtained when meta-analyzing the initial three studies directly 
without overlap. 
We carried out a similar procedure for a case-control study using data for type 2 diabetes 
(Morris et al. 2012). We used 2 studies with sample sizes 6,528 and 16,503 respectively, and 
meta-analyzed a study with sample size 2,209 with each of them to create 2 datasets with an 
overlap of 2,209. We then meta-analyzed the overlapping datasets were meta-analyzed 
correcting for overlap and compared the Z-scores obtained to the target Z-scores obtained by 
meta-analyzing the studies without overlap. 
 150
Results 
Simulation Results 
Simulation results based on 300,000 markers from 5,000 individuals of European 
ancestry show that our method provides an accurate estimate of sample overlap (Table 4.1). For 
example, when GWAS studies overlapped by 17% of samples, we estimate overlapping 
proportions as 17.9% ± 0.8%.  We then meta-analyzed GWAS summary statistics accounting for 
estimated overlap and observed that the mean genomic control was 1.01 as compared to 1.22 
when meta-analyzed without considering overlap. 
Artificially Created Overlapping Datasets: Quantitative Trait 
We created overlapping datasets with sample sizes 10,326 and 7,738 where the overlap 
number is 2,485 using GWAS datasets for HDL-cholesterol (as per the scheme described in 
Supplementary Figure S4.1). We estimated the overlap proportion of 13.7% to be 14.1% when 
the Z-scores are truncated at the cutoff value x = 1 (Table 4.2), and meta-analyzed the data to 
obtain well-calibrated statistics (Figure 4.4). 
We varied the cut-off value c and observed that as the cut-off value decreases, the length 
of our confidence interval for the effective overlap sample size generally increases (e.g. In the 
maximum sample size category where observed total sample size is 18,064, when cut-off is 
changed from 1 to 0.5, the confidence interval size increases from 134 to 581). This happens 
because the number of markers with Z-score within the cut-off limit decreases as the value of the 
cutoff becomes smaller. However, as the cut-off value increases, we do not observe any 
systematic pattern to the bias (Table 4.2). One exception is the category where there is no actual 
overlap (observed N = 13,094), where estimated effective overlap increases as the cut-off value 
increases. Thus, while a more stringent cut-off may be better in terms of truncating trait 
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associated variants with very small effect sizes, the reduction in the total number of markers 
decreases the accuracy of the estimate. Based on the datasets investigated, a cut-off value of c=1 
appears to work well. 
We compared the Z-scores of the corrected meta-analysis with the Z-scores obtained 
from meta-analyzing the studies without overlap (Figures 4.4 and 4.5) and found 100 markers 
(0.004%) with corrected p-values differing from the target p-values by >=2 on the log10 scale. 
We examined these outliers and found that these occurred when the overlapping study 
had a different effect size compared to the non-overlapping studies. For example, a marker which 
had a Z-score of 8.9 in the overlapping sample and Z-scores of 5.0 and 2.3 in the non-
overlapping samples leads to a corrected Z-score of 9.3 instead of the target value of 8.1 as the 
correction does not account for the additional deviation from null in the overlapping sample. 
Similarly, a marker with a Z-score of -1.2 in the overlapping sample and Z-scores of -6.7 and -
5.0 in the non-overlapping samples leads to a corrected Z-score of -7.0 instead of the target value 
of -8.1 as there is overcorrection because of the overlapping Z-score being closer to the null than 
the others. Thus, population structure in the overlap affects the correction of the meta-analysis Z-
scores. We observe that our method improves on the naïve meta-analysis for 11% of the outliers 
on the log10 scale and for 49% of the outliers on the loge scale.  
Artificially Created Overlapping Datasets: Case-Control Study 
We created overlapping datasets with sample sizes 8,737 and 18,712 where the overlap 
number is 2,209 using GWAS datasets for type 2 diabetes (as per the scheme described in 
Supplementary Figure S4.2). We estimated the overlap proportion of 8.1% to be 8.5% (Table 
4.3) when cutoff value for truncating Z-scores was 1, and meta-analyzed the data to obtain well-
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calibrated statistics (Figure 4.6). A closer examination of the markers with p-value >10) 
shows that most markers have corrected Z-scores close to the target Z-scores (Figure 4.7). 
Varying the cut-off value allows for similar estimates with the confidence interval sizes 
varying accordingly (Table 4.3). We observe that for makers with no actual overlap (sample size 
= 23,031), increasing the cut-off value increases the estimated overlap as in the quantitative case. 
We expect this is because variants with small effect sizes may get included as we increase the 
cut-off value. Thus, for this example, a more stringent cut-off appears to work better. 
Discussion 
We describe a simple method to identify sample overlap based on GWAS summary 
statistics, to estimate the overlap, and to adjust for that overlap appropriately. Our method 
requires Z-scores and sample size at each marker for each study, which are usually available in 
published GWAS, and hence, can be used to meta-analyze publicly available GWAS data with 
newer datasets to increase sample size while accounting for any overlap. Not accounting for 
overlap generally leads to an inflation in type I error, potentially leading to false positive signals. 
Hence, our method helps to increase the power to detect weaker signals by aggregating sample 
size, while controlling type I error. 
We recommend using our method only if all the samples are of the same ancestry. If the 
overlapping samples have significantly different effect sizes than the non-overlapping samples, 
the assumption of homogeneity of effect sizes is more likely to be violated and our method may 
actually perform worse than a naïve meta-analysis by over-correcting.  
We assumed that the degree of overlap is uniform across markers after accounting for 
sample size stratification. Violation of this assumption leads to mis-calibration in correcting for 
overlap. For example, for a variant that is specific to a particular population (say, Finland) the 
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effect of overlap would be stronger than average if all the overlapping samples are drawn from 
that population (Finland). 
While our method only requires the summary statistics, we do need the sample size for 
each marker to accurately estimate the overlap. Overlap can vary by marker, and hence, not 
stratifying by sample size can lead to mis-calibration of the summary statistics. For example, 
Supplementary Figure S4.3 shows the comparison of corrected meta-analysis p-values when 
markers are not stratified by sample size with the target and we identify a significant variant not 
present in the overlapping sample. Not stratifying by sample size leads to an over-correction at 
this variant leading to a decrease in significance. 
We recommend using a more stringent cut-off value for traits known to be highly 
polygenic to ensure that variants with small effect sizes are not included when estimating 
correlation. We note that this may lead to fewer variants based on which correlation is estimated, 
and so may lead to a loss in power.  
We have implemented our method for a simple meta-analysis which uses every study 
available. It assumes there is no heterogeneity of effect sizes which is a rather stringent 
assumption. There exist newer meta-analysis approaches that modify the weighted Z-score to 
work under less stringent assumptions, e.g. meta-analysis using a subset based approach 
(Bhattacharjee et al 2012). Since our method works by estimating the covariance for Z-scores 
between a pair of studies, a direction for future research might be to extend our method to these 
approaches.  
In conclusion, our proposed method is a simple yet effective way to adjust for sample 
overlap in GWAS in homogeneous populations while working with the constraints of summary 
level data.  
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Table 4.1: Overlap estimate and confidence interval when trait is independent of genotypes 
 
N1 N2 Overlap Overlap Proportion Estimated Overlap Proportion (SD) 
 2,500 2,500 0 0.00 0 (-) 
2,550 2,550 100 0.02 0.02 (0.0056) 
2,750 2,750 500 0.09 0.09 (0.0066) 
3,000 3,000 1,000 0.17 0.17 (0.0079) 
5,000 5,000 5,000 1.00 1.00 (0.00) 
3,000 2,100 100 0.02 0.02 (0.0051) 
3,000 2,500 500 0.09 0.09 (0.0048) 
Estimated overlap when phenotype is simulated independent of genotypes using real genotypes 
from 5,000 European samples across 300,000 markers. N1 and N2 denote the sample sizes of the 
observed overlapping samples, and Overlap the true overlap number. Overlap proportion is 
defined as Overlap / (N1 + N2). 
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Table 4.2: Estimated Sample Overlap for Artificially Created Overlapping Studies for HDL-cholesterol  
 
 
Sample 
Size 
Cutoff = 0.5 Cutoff = 0.75 Cutoff = 1 Cutoff = 1.5 Cutoff = 2 
 
Estimate CI Estimate CI Estimate CI Estimate CI Estimate CI 
4,970 2,485 (2,473, 2,485) 2,485 (2,473, 2,485) 2,485 (2,478, 2,485) 2,485 (2,473, 2,485) 2,485 (2,473, 2,485) 
10,223 2,691 (2,280, 2,982) 2,390 (2,214, 2,543) 2,409 (2,324, 2500) 2,463 (2,412, 2,521) 2,463 (2,412, 2,499) 
12,811 2,091 (557, 2,887) 2,662 (2,381, 2,887) 2,448 (2,305, 2583) 2,476 (2,406, 2,558) 2,518 (2,457, 2,583) 
13,094 - (-2,792, -706) - (-674, -353) - (-546, -6) - (-128, 96) 40 (-32, 128) 
18,064 2,941 (2,637, 3,218) 2,616 (2,503, 2,716) 2,546 (2,458, 2,592) 2,538 (2,503, 2,592) 2,581 (2,548, 2,637) 
 
Three European GWAS datasets for HDL-cholesterol (Teslovich et al. 2010) are used to create two overlapping datasets. Datasets 1 
and 2 are meta-analyzed together, and datasets 2 and 3 are meta-analyzed together to generate a pair of overlapping datasets whose 
overlap number equals the sample size of dataset 2 (2,485). The sample size column denotes the total observed sample size for the 
markers. For sample size = 13,094, the true overlap is 0, and for all other categories, the true overlap is 2,485. The cutoff value is 
used to truncate the Z-scores used to estimate the correlation and overlap (markers with abs(Z)<cutoff used in the estimation). 
Estimates <0 are not reported. 
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Table 4.3:  Estimated Sample Overlap for Artificially Created Overlapping Studies for Type 2 Diabetes 
 
Sample 
Size 
Cutoff = 0.5 Cutoff = 0.75 Cutoff =1 Cutoff = 1.5 Cutoff = 2 
 Estimate CI Estimate CI Estimate CI Estimate CI Estimate CI 
4,418 2,209 (2,187, 2,209) 2,209 (2,187, 2,209) 2,209 (2,187, 2,209) 2,209 (2,187, 2,209) 2,209 (2,187, 2,209) 
10,946 2,061 (1,779, 2,284)  2,118 (2,021, 2,197) 2,225 (2,175, 2,262) 2,303 (2,284, 2,328) 2,310 (2,284, 2,328) 
20,921 1,696 (1,029, 2,282) 2,316 (2,122, 2,507) 2,656 (2,540, 2,765) 2,517 (2,443, 2,572) 2,372 (2,315, 2,411) 
23,031 0 (-882, 207) 200 (0, 415) 176 (52, 311) 287 (208, 363) 397 (363, 467) 
27,449 2,916 (2,685, 3,132) 2,391 (2,302, 2,493) 2,326 (2,238, 2,365) 2,335 (2,302, 2,365) 2,330 (2,302, 2,365) 
 
Three European GWAS datasets for type 2 diabetes (Morris et al. 2012) are used to create two overlapping datasets. Datasets 1 and 2 
are meta-analyzed together, and datasets 2 and 3 are meta-analyzed together to generate a pair of overlapping datasets whose 
overlap number equals the sample size of dataset 2 (2,2095). The sample size column denotes the total observed sample size for the 
markers. For sample size = 23,031, the true overlap is 0, and for all other categories, the true overlap is 2,209. The cutoff value is 
used to truncate the Z-scores used to estimate the correlation and overlap (markers with abs(Z)<cutoff used in the estimation).  
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Figure 4.1: Outline of procedure to meta-analyze correcting for overlap 
 
 
To correctly meta-analyze adjusting for potential overlap, the markers are first stratified by total 
observed sample size, and then the Z-scores truncated based on a pre-determined cutoff value 
and used to estimate the correlation between the paired Z-scores. Finally, the estimated 
correlation is used to adjust the weights in the meta-analysis so that covariance due to overlap is 
adjusted for. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Read Data
Stratify Markers by N
Estimate Covariance using Truncated Z-score
Meta-analyze and Output Results
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Figure 4.2: Example Illustrating the Need for Stratification Based on Sample Size 
The above diagram shows a simple scenario where 2 overlapping studies Study A and Study B 
share one cohort Cohort 2. Thus the actual number of overlapping samples is the sample size of 
cohort 2 (n2). However, if a marker is not present (that is, not genotyped or imputed) in cohort 2, 
the overlap number for it is 0. The diagram shows possible combinations for a marker, and why 
it is important to stratify based on observed sample size.  
 
Figure 4.3 : Example of Sample Size Distribution in a Large Meta-Analysis 
 
Sample size distribution of a meta-analysis for HDL cholesterol (Teslovich et al. 2010) for all 
markers with 73,588 unique values of sample size. This demonstrates that markers are not 
present in all samples as well as the fact that stratifying based on every possible sample size 
combination is not feasible in large-scale meta-analyses. 
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Figure 4.4: Performance of Meta-Analysis Correcting for Overlap in HDL-Cholesterol 
Comparison of target -log10 p-values obtained when meta-analyzing the 3 original non-
overlapping studies for HDL-cholesterol together with (a) -log10 p-values obtained when naively 
meta-analyzing the overlapping studies; and (b) -log10 p-values obtained when meta-analyzing 
after adjusting for overlap. 
 
Figure 4.5: Outliers in Meta-Analysis Correcting for Overlap in HDL-Cholesterol 
 
Investigating the markers that are outliers, we observe that zooming in on the markers with 
target –log10 p-value <20, the corrected meta-analysis p-values tend to be biased downward as 
expected since for most of the markers, the overlap is over-estimated slightly. 
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Figure 4.6: Performance of Meta-Analysis Correcting for Overlap in Type 2 Diabetes 
 
Comparison of target -log10 p-values obtained when meta-analyzing the 3 original non-
overlapping studies for type 2 diabetes together with (a) -log10 p-values obtained when naively 
meta-analyzing the overlapping studies; and (b) -log10 p-values obtained when meta-analyzing 
after adjusting for overlap 
 
Figure 4.7: Outliers in Meta-Analysis Correcting for Overlap in Type 2 Diabetes 
 
Markers with –log10 p-value< 20 for type 2 diabetes seem to be well calibrated: the color 
denotes the density at each point while the dots denote the outliers. 
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Supplementary Figure S4.1: Creating Overlapping Datasets for HDL-Cholesterol 
 
We artificially create an overlapping dataset for HDL-cholesterol using GWAS data (Teslovich 
et al. 2010). Study B is meta-analyzed with studies A and C respectively to create a pair of 
overlapping datasets. Studies A, B and C are meta-analyzed directly to get the target results 
without overlap. 
 
Supplementary Figure S4.2: Creating Overlapping Datasets for Type 2 Diabetes 
 
We artificially create an overlapping dataset for Type 2 Diabetes using GWAS data (Morris et 
al. 2012). Study B is meta-analyzed with studies A and C respectively to create a pair of 
overlapping datasets. Studies A, B and C are meta-analyzed directly to get the target results 
without overlap. 
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Supplementary Figure S4.3: Effect of Not Stratifying by Sample Size 
 
The target p-value denotes the p-values obtained by meta-analyzing the samples without the 
overlap, and thus are the gold standard for our analysis. The meta-analysis p-value denotes the 
p-values obtained using our method to meta-analyze correcting for potential sample overlap. 
Overlapping samples were created using HDL-cholesterol GWAS data (Teslovich et al. 2010). 
When the markers are not stratified by sample size before estimating covariance and correcting 
for overlap, we may lose some signals. Markers such as the one circled in red in the figure are 
not present in the overlapping sample. Thus, correcting for overlap leads to a decrease in power 
for these markers. 
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Chapter 5: Conclusion 
 
Meta-analysis is a powerful tool to jointly analyze genetic association results from 
multiple genome-wide association studies when individual level data is not available. 
Aggregating data across studies to increase sample size and power facilitates the discovery of 
trait-associated variants with modest effect sizes, and provides an opportunity to increase our 
understanding of genetic susceptibility. However, meta-analysis results may produce a large 
number of variants significantly associated with the trait of interest. The association findings 
from GWAS provide an initial guide for the development of medical treatments by pointing to a 
genomic region of interest and thus it is important to refine the lists of associated variants for 
further investigation. In this thesis, I have advanced our understanding of lipid genetics through a 
large scale meta-analysis, demonstrated the challenges in interpreting meta-analysis results, and 
provided a framework to integrate functional data to prioritize variants for follow-up. 
Additionally, I have developed a method to meta-analyze studies that may have overlapping 
samples.Chapter 2 described the largest genetic association study of blood lipid levels to date, 
where data on 94,595 individuals from the initial GWAS (Teslovich et al. 2010) were meta-
analyzed with a follow-up study of 93,982 individuals genotyped on the Metabochip (Voight et 
al. 2012). In the manuscript Global Lipids Genetics Consortium et al. (2013), we discovered 62 
novel genetic loci associated with lipids to contribute to the existing list of 95 known associated 
loci. Discovery efforts were followed by several downstream analyses to prioritize variants for 
follow-up such as literature review, pathway analysis, and investigation of regulation of mRNA 
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expression. However, the different sources of prioritization sometimes disagreed, establishing 
the difficulty in interpreting GWAS results and understanding causality. Fine mapping in 65 
lipid-associated loci in different ancestries facilitated separation of the strongest signal from the 
prior GWAS signal in 12 regions. Based on our downstream analyses, we suggested a list of 70 
genes from 44 of the novel loci that might be the focus of the first round of functional studies. 
However, the role of the remaining loci is unknown, leaving opportunities for future genetic 
studies to study their functional impact. 
In Chapter 3, I have described a method to systematically incorporate functional 
information about the genome to prioritize variants for follow-up analyses. Summary statistics 
(effect sizes and standard errors or p-values) are weighted using genomic annotation to produce 
credible sets constituting a list of potentially causal variants. I have proposed two methods: one 
which uses association results across the whole genome and is more computationally intensive, 
and one which approximates the association results for variants not in the associated loci to 
increase computational efficiency. Simulation studies demonstrated the accuracy of our estimates 
and compared their power with fGWAS (Pickrell 2014). Real data applications to MGI 
(https://www.michigangenomics.org/) and UK Biobank data (Sudlow et al. 2015, Bycroft et al. 
2017), which have hundreds of phenotypes, established the advantages of such a systematic 
approach. To sort through the large volumes of data, I aggregated data across related traits with 
few signals in the MGI data, which generated credible sets at associated loci. Applications to 
Age-related Macular Degeneration association data exhibited how using different genomic 
annotations can lead to different variants being prioritized. However, consolidating a unique list 
of potentially causal variants based on different genomic annotations remains a challenge. 
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As different studies and consortia make their summary statistics publicly available, it is 
challenging to consolidate their findings into one “bottom-line” p-value, which can be used as a 
guide to investigate and understand their genetic architecture. A major challenge in meta-
analyzing these data together is the potential for sample overlap. In Chapter 4, I have described a 
meta-analysis approach that identifies and corrects for this overlap and accurately meta-analyzes 
potentially overlapping studies. This method works with summary statistics (Z-score and sample 
size) and thus, can be used on publicly available data. A caveat is that my method assumes that 
overlap does not vary by ancestry, which may not always be the case. 
Prioritizing Variants for Follow-up Studies 
 Currently, integration of varying types of data is an emerging area of inquiry, as large 
volumes of data from both association studies as well as functional studies are being made 
publicly available. Investigators collaborate in large-scale consortia to generate association 
results for huge sample sizes, while large repositories of high-throughput genomics and 
epigenomic data are being built to enable functional annotation. For example, the systems 
genetics approach, or Genome Wide Network Study as coined by Björkegren et al. (2015), 
emphasizes combining data from intermediate phenotypes such as RNA, proteins, metabolites, 
and epigenetics in multiple disease-relevant tissues. 
As demonstrated in the downstream analyses in Chapter 2 and the method developed in 
Chapter 3, coupling of GWAS findings with functional genomics data can potentially advance 
our understanding of disease etiology. The method described in Chapter 3 currently works only 
for binary genomic annotations; thus, in the examples described, I dichotomized non-binary 
annotations such as CADD scores. However, using the complete range of CADD score values 
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may lead to better estimates. Additionally, comparing multiple genomic annotations at a time 
may be of interest, which this model does not yet support. 
A simplifying assumption I have used is that there is at most one causal variant per locus, 
which may not be realistic. An ad-hoc approach to adjust for violation of this assumption is 
described in the analysis of the AMD data, where conditional association results are used as 
“pseudo-loci.” In such a scenario, summary statistics are no longer adequate and additional 
conditional analyses are required. Additionally, selection of the variants that the conditional 
analysis is based on may prove difficult.  Multi-SNP models allowing for multiple causal variant 
per locus require individual level data (Kichaev et al. 2014) and hence, using summary statistics 
to model that remains difficult. 
A key challenge is selection of functional data to use, and to consolidate results from 
diverse functional annotations in a systematic manner. Future work in this direction may involve 
extending the model to incorporate non-binary or multiple annotations. While the large volumes 
of genomics and epigenomics data from sources such as ENCODE (ENCODE Project 
Consortium 2012) and Roadmap Epigenomics Consortium (Bernstein et al. 2010) make it 
enticing to test all possible annotations for enrichment, multiple testing issues should be kept in 
mind since it is possible that some annotations would be found significantly enriched by chance. 
Thus, a rigorous framework to integrate functional data and association results is required to take 
advantage of the diverse functional annotations available. 
Meta-Analysis of Studies with Sample Overlap 
With decreasing genotyping and sequencing costs, there are more and more available sets 
of genotyped or sequenced controls that can be used in multiple studies. Other sources of overlap 
may include participants belonging to multiple studies, or the same study contributing to multiple 
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meta-analysis efforts. We aimed to meta-analyze data for the same trait while correcting for 
overlap to generate a consolidated list of associated variants. An ongoing project for the type 2 
diabetes portal (www.type2diabetesgenetics.org/) is to generate a “bottom-line” p-value 
combining information across multiple potentially overlapping studies, that is, for each variant a 
single p-value combining information across all studies for type 2 diabetes should be reported. 
When overlap numbers are not known, and individual level data is not available, a method to 
meta-analyze correcting for overlap using summary statistics is required. 
A limitation of the method described in Chapter 4 is that we essentially assume a fixed 
effects model and that allele frequencies and effect sizes do not vary with overlap. This 
assumption may work if we limit our attention to European populations, which have been studied 
extensively. However, currently available GWAS data from non-Europeans tend to have smaller 
sample sizes and thus it may be desirable to meta-analyze them with data from other ancestries to 
increase power. In such scenarios, as effect sizes and allele frequencies may vary by ancestry, 
correction for overlap becomes challenging. Future work in this direction may involve using 
publicly available allele frequencies (1000 Genomes Project Consortium 2010) to approximate 
the population structure in the corrected meta-analysis. 
An additional question to consider is what happens when there is sample overlap between 
a pair of studies, but the overlap is between cases of one study and controls of another. 
Depending on how the phenotype is defined in each study, participants with borderline values of 
the trait may be categorized differently. For example, in the UK Biobank data (Sudlow et al. 
2015; Bycroft et al. 2017), several phenotypes are recorded that are highly correlated such as 
“disorders of lipoid metabolism”, “hyperlipidemia” and “hypercholesterolemia”. However, cases 
for one trait may be controls for the other, depending on the attending physician’s definition of 
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the trait in question, rather than inherent misclassification. Our method currently assumes that 
the studies have uniform definition of phenotypes, which is a realistic assumption in well-
designed meta-analyses. However, this is an important issue to keep in mind when using 
previously published results.  
In Summary 
In this dissertation, I have discussed various methods to interpret results obtained from 
genome-wide association studies. I have focused my research on the use of summary statistics to 
take advantage of the growing repositories of publicly available data. I have described a large-
scale meta-analysis for blood lipid levels, leading to new insights into lipid biology. 
Additionally, I have developed a method to integrate functional annotation of the genome with 
association results to prioritize lists of potential causal variants, as well as a method to meta-
analyze studies with potentially overlapping variants by estimating and correcting for the 
overlap. It is my hope that the methods and tools developed can lead to advances in our 
understanding of the genetics of various complex traits and diseases. 
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